UC Berkeley

UC Berkeley Electronic Theses and Dissertations

Title

Enantioselective Functionalizations of Alkenes Using Chiral Phosphoric Acids

Permalink

https://escholarship.org/uc/item/2mn5j1tp

Author

Wu, Jeffrey

Publication Date 2013

Peer reviewed|Thesis/dissertation

Enantioselective Functionalizations of Alkenes Using Chiral Phosphoric Acids

By

Jeffrey Wu

A dissertation submitted in partial satisfaction of the

requirements for the degree of

Doctor of Philosophy

in

Chemistry

in the

Graduate Division

of the

University of California, Berkeley.

Committee in charge: Professor F. Dean Toste, Chair Professor Peter Vollhardt

Professor Ben de Lumen

Fall 2013

Enantioselective Functionalizations of Alkenes Using Chiral Phosphoric Acids

© 2013

Jeffrey Wu

Abstract

Enantioselective Functionalizations of Alkenes Using Chiral Phosphoric Acids

By

Jeffrey Wu

Doctor of Philosophy in Chemistry University of California, Berkeley Professor F. Dean Toste, Chair

New organocatalytic enantioselective reactions were developed, focusing on using new modes of reactivity with chiral phosphoric acids. Prochiral alkenes and styrenes were explored as substrates for various transformations, including enyne cycloisomerization, hydroamination, halocyclization, and fluorination. The enantioenriched chiral products generated by these methods include heterocycles and allylic fluorides.

Table of Contents

ACKNOWLEDGEMENTS	i
PREFACE	ii

CHAPTER 1: DESIGN OF NEW CHIRAL PHOSPHORIC ACIDS FOR PALLADIUM CATALYZED 1,6-ENYNE CYCLOISOMERIZATION

Abstract	1
INTRODUCTION	2
RESULTS AND DISCUSSION	5
REFERENCES	12
SUPPORTING INFORMATION	13

CHAPTER 2: HYDROAMINATION AND HYDROARYLATION CATALYZED BY A DITHIOPHOSPHORIC ACID

ABSTRACT	4
INTRODUCTION	5
RESULTS AND DISCUSSION	7
REFERENCES	2
SUPPORTING INFORMATION	3

CHAPTER 3: NEW HALOGENATION REAGENTS DESIGNED FOR CHIRAL ANION PHASE-TRANSFER CATALYSIS: HALOCYCLIZATION

Abstract	127
INTRODUCTION	128
RESULTS AND DISCUSSION	129
REFERENCES	134
SUPPORTING INFORMATION	136

CHAPTER 4: COMBINATION OF CHIRAL ANION PHASE-TRANSFER CATALYSIS AND DIRECTING GROUPS FOR ALKENE FLUORINATION

Abstract	212
INTRODUCTION	
RESULTS AND DISCUSSION	217
References	
SUPPORTING INFORMATION	

Acknowledgements

Thanks to: Dean, for ideas, direction, a space in a great lab, and creating an environment which fosters collaborative work and creative thinking.

Mom: it was relaxing to come home, and do nothing, go for a hike (or shopping), or share a meal.

Dad, thanks for your continued support and advice over the years.

Colleagues in the Toste group, you all were very helpful, somewhat professional, and made coming into lab a pleasure. Thanks to Chen, baller and friend; Yi-ming in 613 for exuding enthusiasm, being a great collaborator, and not setting me on fire; Mika, we should hang out more! Aaron, thanks for friendship in lab and outside of lab. Good luck to all of you!

Thanks to former colleagues Greg and Vivek for friendship, and teaching me so much.

The Lins, babies and all! You've all been great family.


Oz, you're a great friend and the nicest person I know, and I enjoyed being able to talk to someone about chemistry who is outside of the Berkeley bubble. I hope you move back to the bay area sometime!

Thanks to all of my first year chemistry friends who have stuck together from Raleigh's/Tahoe to Free House/Russian River, helped me gain a few pounds of "muscle," and never got tired of the north Asian ghetto. You all helped make these years really fun.

Finally... Thao, thanks for being supportive and loving. It was awesome when you came back to help celebrate my qualifying exam. It is always awesome when you are there.

Preface

Enantioselective catalysis continues to advance since the transformations developed by pioneers such as Knowles, Noyori, and Sharpless, who each received the Nobel prize in chemistry in 2001 for their efforts in this field.¹ The ability to distinguish between two enantiotopic faces for the formation of either R or S (left or right handed) chiral centers has been achieved by biological systems and nature, but only relatively recently has it become within the repertoire of synthetic chemists. Continuing advancements driven by industrial demands as well as academic pursuits have evolved the field into an increasingly diverse and fruitful one. The applications of enantioselective catalysis are diverse, and arguably the most important has been in agrochemicals and pharmaceuticals. Currently, methods identified as useful are often relevant to the construction of moieties commonly found in the molecules desired by these particular industries. The distinctions chemists commonly use to classify the myriad methods can be based on identity of the catalyst, mode of reactivity, or chemical transformation. Historically, transition-metal and enzyme catalysis were the two common branches. The field of enantioselective transition-metal catalysis is further divided depending on the identity of the metal and where it lies on the periodic table; or whether it acts as a Lewis acid, a pi-acid, a redox-active cross-coupling catalyst; or by the transformation from substrate to product.²



Scheme 1. A general breakdown of the different classes of enantioselective catalysis.

The advent of enantioselective organocatalysis as the third branch in the field has created a new type of reaction which are distinguished by the *lack* of metals (Scheme 1).³ Within organocatalysis, several structures and scaffolds have been developed, including but not limited to amines, thioureas, Brønsted acids, N-heterocyclic carbenes, and peptides (Figure 1). They operate *via* hydrogen-bonding interactions, covalent interactions, and ionic interactions.




Figure 1. A: Chiral-pool-derived organocatalysts. B: Synthetic (resolved) chiral organocatalysts.

Generally, the benefits of organocatalysis from a practical perspective include the avoidance of expensive metals and concomitant contamination, favorable functional group compatibility, stability to air and moisture, and the potential for being more economical.

A broad generalization of enantioselective transition-metal catalyzed methods and enantioselective organocatalytic methods reveals that while seminal examples of the former involve the functionalization of alkenes' unsaturated C-C pi bonds, oxidation, or reduction, seminal examples of the latter involve activation and reaction with unsaturated carbon-heteroatom bonds.^{2, 3} This is largely the result of organocatalysis's reliance on hydrogen-bonding interactions or polar ionic interactions, which makes carbon-heteroatom bonds more reasonable substrates. This also presents a limitation in that these interactions are almost impossible to achieve with alkenes.⁴ One reasonable solution to the problem of scope, which exists for all types of methods, is the combination of different approaches applied to one method or transformation.⁵ For example more recently in our own group, organocatalysts have been used in conjunction with transition-metals, and supramolecular clusters in conjunction with enzymes, allowing for transformations not possible with just one type of catalysis.⁶ I explore using an organocatalyst in palladium-catalyzed reactions in the first chapter. However, another approach to solving this problem is to stay within organocatalysis and further develop the catalysts, and applications. In the rest of my work, I explore the idea that design of new organocatalysts, and

implementation of new approaches with known organocatalysts can successfully functionalize alkenes enantioselectively without the use of metals.

My work has centered on the use of chiral BINOL-derived phosphoric acids. Chiral phosphoric acids have been widely developed and utilized in the last decade, most well represented by the success of TRIP, a commercially available variant first discovered by List and coworkers.⁷ Although the first BINOL-derived chiral phosphoric acid catalysts were reported by Terada and Akiyama, TRIP has proved to be the most versatile analog, owing to the 2,4,6-triisopropylphenyl groups in the 3,3'-positions.⁸ The initial and still predominant use of these phosphoric acids has been as chiral Brønsted acids, focusing on LUMO lowering of imine and carbonyl groups *via* protonation and resultant hydrogen-bonding with the heteroatom. Many reports have validated this approach to achieving enantioselective nucleophilic attack onto such functional groups. One key in the success is the ability of the phosphate to interact with the protonated substrate as well as the incoming nucleophile, both *via* hydrogen-bonding interactions (Figure 2A).⁹




Figure 2. **A:** Two well-precedented activation modes of C-X double bonds. **B:** An example of asymmetric counteranion direct catalysis – an enantioselective epoxidation of enals *via* imminium chiral ion pair. **C**: Toste's TRIP counteranion ion paired with meso-aziridinium intermediate.

In the last five years, an extension in terms of modes of enantioinduction with chiral phosphoric acids has been developed, to rely on ion-pairing of cationic intermediates with chiral phosphates. Generally when used in this fashion, the counteranion phosphate is referred to as a chiral anion (Figure 2B, 2C).¹⁰ However, alkene functionalization is still outside the scope of these transformations because with the necessity of hydrogen-bonding replaced with electrostatic interactions, polar groups are still required. This sub-field of chiral anion catalysis is an important development in the ability to use these organocatalysts in a variety of reactions. In the combination of organocatalysis with transition-metal catalysis, the distinction has been made that

the chiral anion in these cases is not necessarily a ligand on the metal, but rather a counterion which is typically achiral such as a halide or borate. Arguably, the genesis for the Toste group's interest in TRIP and its derivatives was Greg Hamilton's project using a chiral counteranion with gold-catalyzed reactions.^{6b} An important further development was work by the same colleagues, who showed that a phase-transfer reaction with chiral phosphate solubilizing an achiral silver salt, allowing for chiral ion pairing with a cationic aziridinium intermediate. This was an example of chiral anion catalysis which did not rely on transition-metal reactivity.

These successes were indication that exploring the potential expansion of the roles these types of catalysts play in the reaction could be very fruitful. From there, the Toste group has developed many successful organocatalytic reactions in the last few years, marking a new area of focus. So, as we have found out, chiral phosphoric acids and the derivative phosphate anion can be very versatile in synthesis, and exploitation of their privileged C-2 symmetric structure and bifunctional phosphate group can be achieved with relatively small changes to the catalyst. In short, I aimed to work on these developments, with a thought process which predominantly considers the mode of reactivity, activation, and mechanism, rather than the classification of transformation, product class, or end-user applications. (Of course, working with air- and water-tolerant reactions is highly desirable for any chemist.) As shown in the figure below, I have been able to apply and develop chiral phosphoric acids as catalysts in new methods which incorporate new approaches. Most of these methods continue to utilize the chiral counteranion of chiral phosphoric acids (the *phosphate*). These methods also feature either use as chiral ligands in palladium-catalysis, newly designed covalent catalysts, new halogenating phase-transfer reagents, and directing groups for allylic fluorination (Figure 3).




Figure 3. Projects revolving around chiral phosphoric acids includes covalent catalyst design, halogenation reagent design, and implementation of directing groups to interact with chiral phosphates.

Herein I describe the specifics of my work toward further increasing the types of reactions possible with these catalysts for enantioselective reactions with alkenes.¹¹ Each project chapter will contain a separate introduction which will address more specific precedent based on the transformation developed, and explain how it relates to the general goals described above.


References

- 1. "The Nobel Prize in Chemistry 2001", Nobelprize.org.
- 2. "Fundamentals of Asymmetric Catalysis" Walsh P., Kowzlowski M. University Science Books, **2008**.
- 3. "Asymmetric Organocatalysis" Berkessel A., Groger H. Wiley and Sons, 2005.
- 4. Schreiner P. R. Chem. Soc. Rev. 2003, 289-296.
- 5. Shao Z., Zhang H. Chem. Soc. Rev. 2009, 2745-2755.
- A) Wang Z. J., Clary K. N., Bergman R. G., Raymond K. N., Toste F. D. *Nature Chem.* 2013, 100-103. B) Hamilton G. L., Kang E. J., Mba M., Toste F. D. *Science*, 2007, *317*, 496-499.
- 7. Hoffman S., Seayad, A. M., List B. Angew. Chem. Int. Ed. 2005, 44, 7424-7427.
- A) Akiyama T., Itoh J., Yokota K., Fuchibe K. Angew. Chem. Int. Ed. 2004, 43, 1566-1568. B) Uraguchi D., Terada M. J. Am. Chem. Soc. 2004, 126, 5356-5367.
- 9. Simon L., Goodman J. M. J. Org. Chem. 2011, 76, 1775-1788.
- A) Phipps R. J., Hamilton, G. L., Toste F. D. Nat. Chem. 2012, 4, 603-614. B) Mahlau M., List B. Angew. Chem. Int. Ed. 2013, 52, 518-533. C) Brak K., Jacobsen E. N. Angew. Chem. Int. Ed. 2013, 52, 534-561.
- A) Wu J., Wang Y.-M., Drljevic A., Rauniyar V., Phipps R., Toste F. D. *Proc. Acad. Nat. Sci. Under Review* 2013. B) Wang Y.-M., Wu J., Hoong C., Rauniyar V., Toste F. D. *J. Am. Chem. Soc.* 2012, *134*, 12928-12931. C) Shapiro N. D., Rauniyar V., Hamilton G. L., Wu J., Toste F. D. *Nature*, 2011, *470*, 245-250.

CHAPTER 1: DESIGN OF NEW CHIRAL PHOSPHORIC ACIDS FOR PALLADIUM CATALYZED 1,6-ENYNE CYCLOISOMERIZATION

Abstract


The combination of a chiral phosphoric acid organocatalyst with a palladium (0) source was found to undergo formal oxidative addition, creating a chiral palladium(II) catalyst for 1,6enyne cycloisomerization, providing chiral carbocycles in good yield and moderate to high enantioselectivity. The development of novel chiral phosphoric acids was instrumental in achieving higher enantioselectivity across a number of substrates. However, the methodology suffered similar disadvantages as previously reported versions of this reaction. Thus, although this approach did not necessarily produce significant progress for this particular transformation, the concept of applying chiral phosphoric acids to palladium catalysis was validated.



Introduction

Although the use of chiral Brønsted acids with palladium catalysis was reported by Trost and co-workers for 1,6-enyne cycloisomerization with encouraging results, developments in chiral Brønsted acid catalysis have not been applied to this reaction. Trost had employed several chiral carboxylic Brönsted acids, of which binaphthoic acid provided **2** with an enantiomeric excess of 33% (Scheme 1).¹ While this concept was applied to the use of TRIP as a counteranion to palladium-intermediates by List and coworkers, examples of the combination of metalcatalysis and organocatalysis are relatively rare.² The ability to utilize chiral organocatalysts as ligands or counterions in metal-catalyzed reactions should in theory expand the possibilities for creating catalysts with new or improved reactivity and chiral induction. In our lab, we have explored the use of TRIP in gold-catalysis as a chiral counteranion with impressive results.³ Interestingly, there was a cooperative effect in choice of chiral ligand and chiral counteranion, which opens the door to finding matched dual-sources of chiral ligand and chiral phosphoric acids to render the cycloisomerization reaction more highly enantioselective, and provide another demonstration of the benefits of combining transition-metal catalysis and organocatalysts.

Due to their abundance in biologically interesting natural products, extensive efforts have been made to develop an efficient method for the synthesis of chiral 5-membered ring structures. Trost reported a 1,6-enyne cycloisomerization reaction that provides an atom-economical and powerful method for the synthesis of cyclic and bicyclic structures. A representative reaction scheme is shown below (Scheme 1). Both ruthenium and palladium catalysts have been investigated, and several methods have been developed to catalyze the reaction efficiently and with a substrate scope that includes 5-membered and 6-membered carbo- and heterocycles.⁴



Scheme 1. Chiral binaphthoic acid induces enantioselectivity.

One plausible mechanism proposed by Trost proceeds *via* hydropalladation of the palladium-enyne complex (Figure 1).⁵ First, palladium (0) undergoes formal oxidative addition with the Brönsted acid, generating a catalytically active palladium(II)-hydride species. Complexation of an enyne substrate is followed by hydropalladation of the alkyne, and migratory insertion generates the 5-membered ring structure and the chiral center. Finally, β -hydride elimination may take place with either of two adjacent hydrogens, providing either the 1,3- or 1,4-diene product.

Since Trost's initial report, other methods of inducing enantioselectivity have been developed, mostly by identifying effective chiral phosphine ligands. Much of the work has been done by Mikami, who has reported high enantioselectivities using axially chiral ligands such as Segphos and other modified BINAP ligands (Figure 2).⁶




Figure 1. Proposed hydropalladation reaction pathway.





Figure 2. Chiral ligands used in 1,6-enyne cycloisomerization reactions.



Scheme 2. N,P-ligand as a chiral ligand, achieving high enantioselectivity but limited substrate scope.

In addition, N,P- and Skewphos ligands both provide high enantioselectivity (Scheme 2).⁷ However, these methods require highly specific substrates to obtain selectivity, therefore limiting the scope of the reaction. In addition, Ito utilized a chiral diphosphane-palladium complex which achieved enantioselectivity ranging from 34% to 95%, also with a high dependency on the substrate substitution pattern.⁹

Results and Discussion

Since Trost's initial report does not contain a detailed experimental procedure, our studies were initiated by examining the effect of prolonging the stirring time prior to addition of substrate (pre-stirring, Table 1). The combination of palladium (0) pre-catalyst, phosphine ligand, and Brönsted acid, according to the proposed mechanism (Figure 1), generates the catalytically active palladium (II) species. We hypothesized that the some reaction time would be required to generate the chiral active catalyst, and addition of substrate too early might affect the reactivity and selectivity of the transformation.

MeO ₂ C MeO ₂ C	2.5% Pd ₂ (dba) ₃ CHC 5% PPh ₃ <u>5% TRIP</u> toluene (0.1 M) rt, 18-24 h 1	Cl ₃ MeO ₂ C CO ₂ Me	$\langle\!\langle$	(1)
entry	pre-stir time (min)	conv (%) ^a	ee (%) ^b	
1	2	25	_c	
2	5	50	70	
3	20	68	81 ^d	
4	30	12	_c	
5	45	14	_c	

^a Conversion determined by NMR. ^b Enantiomeric excess determined by chiral HPLC. ^c Not determined due to low amount of product. ^d Average of two experiments

Table 1. Dependence on stirring catalyst and ligands prior to addition of substrate.

To test this hypothesis, we performed the cycloisomerization of 1 with different pre-stirring times. Indeed, significantly different results were obtained in experiments performed with 2, 5, 20, 30 and 45 minute pre-stirring times (Table 1). Surprisingly, the reaction was much less successful with a 30 minute or longer stirring time. From these results, a pre-stirring time of 20 minutes was from here on incorporated into our procedure.

The effects of various solvents and palladium sources were investigated (Table 2), which included halogenated, ethereal, and aromatic solvents. Within each class of solvents we obtained different results. However, in all cases, the reaction proceeded with moderate to good conversion, and with moderate to good enantioselectivity. For example, using toluene instead of benzene increased the yield and enantiomeric excess significantly.

entry	solvent	cat.	conv (%) ^b	ee (%) ^c
1	m-xy l ene	Pd ₂ (dba) ₃ CHCl ₃	76	80
2	toluene	Pd ₂ (dba) ₃ CHCl ₃	68	81
3	benzene	Pd ₂ (dba) ₃ CHCl ₃	35	65
4	MTBE	Pd ₂ (dba) ₃ CHCl ₃	53	70
5	p-d i oxane	Pd ₂ (dba) ₃ CHCl ₃	95	78
6	DCE	Pd ₂ (dba) ₃ CHCl ₃	43	_d
7	chloroform	Pd ₂ (dba) ₃ CHCl ₃	17	_d
8	DCM	Pd ₂ (dba) ₃ CHCl ₃	76	55
9 ^e	toluene	Pd(PPh ₃) ₄	76	76
10 ^e	m-xylene	Pd(PPh ₃) ₄	99	84
11 ^e	p-d i oxane	Pd(PPh ₃) ₄	67	74
12	toluene	Pd(OAc) ₂	99	33

^a Conditions: Pd (5 mol%), PPh₃ (5 mol%), TRIP (5 mol%), rt,18-24 h. ^b Conversion determined by NMR. ^c Enantiomeric excess determined by

chiral HPLC. ^d Not determined due to low amount of product. ^e PPh₃ was not added.

 Table 2^a. Solvent and palladium catalyst optimization of (1).

In our hands, benzene was one of the worst performing solvents for this reaction, despite being the preferred solvent in previously reported studies.¹ With Pd₂(dba)₃CHCl₃ as a catalyst, mxylene and p-dioxane demonstrated increased reactivity compared to toluene; however, they were not beneficial for enantioselectivity. Pd(OAc)₂ catalyzed the reaction efficiently but with low enantioselectivity. Interestingly, Pd(PPh₃)₄ proved more effective both in reactivity and selectivity, providing the desired product in quantitative yield and 84% ee in m-xylene. Using Pd(PPh₃)₄ also has other advantages - for example, no phosphine ligand is added, and therefore no pre-stirring is necessary. We reasoned that when using Pd₂(dba)₃CHCl₃ the dibenzylideneacetone needed to be displaced by the phosphine ligand, which is what occurred in the pre-stirring. Interestingly, using a greater than 1:1 ratio of PPh₃ to Pd₂(dba)₃CHCl₃ shut down the reaction. When using an old bottle of $Pd(PPh_3)_4$, we obtained quantitative yield and 85% ee in toluene. Unfortunately, we were not able to reproduce this result using a new bottle of Pd(PPh₃)₄. This made us cautious of using Pd(PPh₃)₄ because there may be trace unidentified palladium species which are catalyzing the reaction. In addition, our initial substrate scope studies demonstrated that Pd(PPh₃)₄ did not effectively catalyze the cycloisomerization on substrates with different functional groups. Therefore, all further studies were performed with $Pd_2(dba)_3CHCl_3$ in toluene.

Next, we examined the effect of concentration and amount of chiral phosphoric acid used (Table 3). As the reaction concentration was increased, the reactivity increased dramatically, but

with a slightly decreased enantiomeric excess. Doubling the chiral acid loading to 0.10 equivalents increased enantioselectivity from 75% to 85%, which was the optimal result. Thus, both changes in concentration and chiral acid loading provided modest increases in enantioselectivity.

entry	concentration (M)	TRIP (equiv)	conv (%) ^b	ee (%) ^c
1	0.05	0.05	53	81
2	0.10	0.05	74	75
3	0.20	0.05	99	77
4	0.10	0.075	99	78
5	0.10	0.10	99	85

^a Conditions: Pd₂(dba)₃CHCl₃ (2.5 mol%), PPh₃ (5 mol%), toluene, rt,18-24 h.

^b Conversion determined by NMR. ^c Enantiomeric excess determined by

chiral HPLC

Table 3^a. Concentration and catalyst loading optimization of (1).

However, we continued efforts to keep the chiral-inducing element at a low amount, and pursued higher selectivity by exploring novel phosphoric acids which may be more efficient than TRIP. It is unclear whether the low enantioselectivity was a result of undesired background reaction with racemic palladium species, or whether the chiral environment is not discerning between the two diastereomeric transition-states. The increase in enantioselectivity with higher catalyst loading does indicate that the former is probably true.





Figure 4. Substrates synthesized for 1,6-enyne cycloisomerization.

With these optimized reaction conditions, we decided to study the substrate scope of this system. Substrates (Figure 4) with different linkers were synthesized following previously reported procedures and subjected to the standard reaction conditions. Initial studies with substrates 9 and 10 were not promising – formation of desired product was not observed in either case when acetic acid was used as the proton source (following Trost's original racemic reaction procedure). The results of the substrate scope study are summarized in Table 4. Both substrates 5 and 7 did not react with high enantioselectivity, achieving only 53% and 17% ee, respectively.


This was not a promising result because our method encountered the same problems as others specifically, limited substrate scope with regard to substitution patterns on the alkene as well as functional groups in the central tether position. Thus, the TRIP phosphate ligand is not necessarily more versatile than phosphine ligands which were somewhat effective in previous reports.

To address this problem, novel chiral phosphoric acids were synthesized to investigate the effect of minor changes in steric and electronic properties of the chiral phosphoric acid on enantioselectivity and substrate scope. We aimed to extend the chiral information from the 3,3'positions on the BINOL scaffold and project steric bulk further from the phosphate center. The ionic nature of the phosphate is important for interactions with the metal; however, the phosphate is not interacting with the substrate itself, and thus may be further away from the actual bondforming event. To this end, analogs of TRIP were synthesized that contained different paraposition substitutions (Scheme 4; **24**, **25**). A synthetic scheme that utilized an efficient Suzuki coupling reaction, followed by a Kumada coupling reaction, was seen as an expedient way to explore electronic and steric effects at that position.



Scheme 3. Synthesis of aryl Grignard reagents 16 and 17.

This approach took advantage of the many diversely substituted phenylboronic acids that are commercially available, thereby allowing us to prepare chiral phosphoric acids with substituents of varying steric size without significantly changing the electronic properties. Conversely, we could explore electron-donating and electron-withdrawing substituents without significantly changing the steric properties. For example, comparing a 4-methoxyphenyl substitution with a phenyl substitution keeps the size of the phenyl group but provides a substituent with significantly different electronics. We began by synthesizing para-phenyl and para-1-naphthyl substituted phosphoric acids. The common Suzuki coupling partner **13** was synthesized from commercially available 2,6-diisopropylaniline in two steps. Reaction of **13** with either phenyl boronic acid or 1-naphthyl boronic acid followed by treatment with Mg powder generated aryl Grignard reagents (Kumada coupling partners) **16** and **17** (Scheme 3).




Scheme 4. Synthetic route toward novel chiral phosphoric acids.

These aryl Grignard reagents were coupled with **19**, which was prepared from (*R*)-BINOL **18** in two steps (Scheme 4). The Kumada coupling products were deprotected with HCl to reveal the respective diols (**22**, **23**). The phosphoric acids were then obtained by subjecting each diol to $POCl_3$ followed by hydrolysis. With these two novel catalysts (**24**, **25**) in hand, we proceeded with substrates **1**, **5**, and **7** to determine the impact on substrate scope of phenyl and 1-naphthyl substitutions in the para-position.

Phenyl substituted chiral acid **24** demonstrated an approximately 17% increase in enantioselectivity for substrates with three different linkers. However, the bulkier naphthyl **25** provided similar enantioselectivity as the isopropyl substituted TRIP. Therefore, we have demonstrated that changing the size of the substituent at the para-position does have an effect on enantioselectivity, despite being distant from the phosphoric acid proton.

entry	substrate	chiral acid	R	ee ^a (%)
1	1	4	i-Pr	83
2	3	4	i-Pr	53
3	5	4	i-Pr	17
4	1	24	Ph	79
5	3	24	Ph	66
6	5	24	Ph	32
7	1	25	naphthyl	73
8	3	25	naphthyl	53
9	5	25	naphthyl	26
10	1	26	adamantyl	_ b
11	3	26	adamantyl	49
12	5	26	adamantyl	19




^a Enantiomeric excess determined by chiral HPLC. ^b Reaction did not proceed.

Table 4. Enantioselectivity of reaction (1) using various chiral phosphoric acids.

Installation of the bulky adamantyl group helped probe the steric space at the para-position, while being readily prepared *via* our current synthetic approach. Catalyst **26** was prepared in similar yields and provided enantioselectivity, except in the case of substrate **1** where low conversion was observed. In addition, adamantyl was the sole nonaromatic substituent in the catalyst.

In addition to the substrates reported above, there were diverse compounds found in the literature which did not work for our reaction. Shown below in Figure 5 are substrates which did not undergo the desired cyclization reaction – thus the effective substrate scope is limited to what is presented above. Small changes to the alkene substitution pattern and linker between the alkene and alkyne were not tolerated with our catalytic system, as was the case in most precedented reports of this reaction.



^a Conditions: Pd₂(dba)₃CHCl₃ (2.5 mol%), TRIP (10 mol%), PPh₃ (5 mol%), toluene, rt,18-24 h. ^b Conversion determined by NMR.


Figure 5^{a,b,c}. Additional substrates explored revealed scope limitations.

It is important to note that more recently a report has been published which utilized TRIP as a counterion in iridium-catalyzed cycloisomerization reactions. Although a different metal was used, a similar goal in the combination of BINOL-derived phosphoric acids with the piactivation of metals for inducing enantioselectivity in enyne cycloisomerization reactions was achieved. In our work, analogs of TRIP were synthesized, and we demonstrated that substitutions in the para-position of the 3,3'-aromatic rings have the potential to improve enantioselectivity. These results are further evidence that BINOL-derived phosphoric acids are not only versatile Brönsted acids, but can also act as sterically and electronically tunable ligands in transition-metal chemistry.


References

- 1. Trost B. M., Lee D. C., Rise F. Tetrahedron Lett. 1989, 30, 651-654.
- 2. Mukherjee S., List B. J. Am. Chem. Soc. 2007, 129, 37, 11336-11337.
- 3. Hamilton G. L., Kang E. J., Mba M., Toste F. D. Science, 2007, 317, 496-499.
- A) Trost B. M., Toste F. D. J. Am. Chem. Soc. 2000, 122, 714-715. B) Tietze L. F., Ila H., Bell H. P. Chem. Rev. 2004, 104, 3453-3516.
- A) Trost B. M. Acc. Chem. Res. 1990, 23, 34-42. B) Trost B. M., Romero D. L., Rise F. J. Am. Chem. Soc. 1994, 116, 4268-4278.
- 6. Hatano M., Terada M., Mikai K. Angew. Chem. Int. Ed. 2001, 40, 249-253.
- A) Hatano M., Yamanaka M., Mikami K. *Eur. J. Org. Chem.* 2003, 2552-2555. B) Mikami K., Yusa Y., Hatano M., Wakabayashi K., Aikawa K. *Tetrahedron*, 2004, 60, 4475–4480.
- 8. Goeke A., Sawamura M., Kuwano R., Ito Y. Angew. Chem. Int. Ed. 1996, 35, 662-663.
- 9. Barbazanges M., Auge M., Moussa J., Amouri H., Aubert C., Desmarets C., Fensterbank L., Gandon V., Malacria M., Ollivier C. *Chem. Eur. J.* **2011**, *17*, 13789-13794.


Supporting Information




1 Was prepared following previously reported methods.¹ Spectroscopic data are consistent with previously reported values. ¹H NMR (300 MHz, CDCl₃): δ 4.909-4.857 (m, 1H), 3.724 (s, 6H), 2.782-2.760 (m, 4H), 1.991 (t, 1H, J = 2.7 Hz), 1.683 (s, 3H), 1.639 (s, 3H).



2 Pd₂(dba)₃CHCl₃ (0.027 g, 0.0053 mmol, 0.05 equiv), triphenylphosphine (0.0014 g, 0.0053 mmol, 0.05 equiv), and (*S*)-TRIP (0.0048 g, 0.0053 mmol, 0.05 equiv) were stirred in toluene (0.60 mL) for 20 min. A solution of **1** (0.025 g, 0.105 mmol, in 0.4 mL of toluene) was then added by syringe, and the reaction mixture was stirred for 18-24 h at rt. The reaction mixture was purified by silica gel chromatography (3.5% ethyl acetate in hexanes) to afford **2** and starting material **1** as an inseparable mixture. Spectroscopic data is consistent with previously reported values.¹ ¹H NMR (400 MHz, CDCl₃): δ 5.02 (bs, 1H) 4.84 (bs, 2H), 4.80 (d, 1H, J = 2.4 Hz), 3.75-3.72 (m, 6H), 3.31-3.26 (m, 1H), 3.10-3.06 (m, 1H), 2.95-2.90 (m, 1H), 2.55-2.50 (m, 1H), 2.16-2.13 (m, 1H), 1.65 (s, 3H). % ee was determined by HPLC with a Chiralpak AD-H column (99.9% hexane: 0.01% 2-propanol), t_r = 8.752 min for major enantiomer, t_r = 8.016 min for minor enantiomer.



5 Compound **5** was prepared following previously reported methods.¹ Spectroscopic data is consistent with previously reported values. ¹H NMR (400 MHz, CDCl₃): δ 8.14-8.12 (m, 4H), 7.74-7.70 (m, 2H), 7.60-7.57 (m, 4H), 5.40 (t, 1H, J = 6.4 Hz), 3.18 (d, 2H, J = 2.4 Hz), 3.05 (d, 2H, J = 6.4 Hz), 2.11 (t, 1H, J = 2.8 Hz), 1.77 (s, 3H), 1.58 (d, 3H, J = 2.4 Hz).




6 Compound **6** was prepared following the procedure described for **2**. Spectroscopic data is consistent with previously reported values.² ¹H NMR (300 MHz, CDCl₃): δ 8.08-8.02 (m, 4H), 7.75-7.68 (m, 2H), 7.62-7.57 (m, 4H), 4.951 (d, 1H, *J* = 2.1 Hz), 4.86-4.77 (m, 3H), 3.53-3.46 (m, 1H), 3.44-3.15 (m, 2H), 2.64 (d, 2H, *J* = 9.9 Hz), 1.57 (s, 3H). % ee was

determined by HPLC with a Chiralpak AD-H column (90% hexane: 10% 2-propanol), $t_r = 18.453$ min for major enantiomer, $t_r = 19.941$ min for minor enantiomer.




7 Compound 7 was prepared following previously reported methods.³ Spectroscopic data is consistent with previously reported values. ¹H NMR (400 MHz, CDCl₃): δ 7.74 (d, 2H, *J* = 8.0 Hz), 7.30 (d, 2H, *J* = 8.4 Hz), 5.11 (t, 1H, *J* = 7.2 Hz), 4.07 (d, 2H, *J* = 2.4 Hz), 3.82 (d, 2H, *J* = 7.2 Hz), 2.43 (s, 3H), 1.98 (t, 1H, *J* = 2.4 Hz), 1.73 (s, 3H), 1.68 (s, 3H).




8 Compound **8** was prepared following the procedure described for **2**. Spectroscopic data is consistent with previously reported values.³ ¹H NMR (300 MHz, CDCl₃): δ 7.70 (d, 2H, J = 8.1 Hz), 7.33 (d, 2H, J = 8.1 Hz), 5.01-4.99 (m, 1H), 4.87-4.80 (m, 3H), 3.88 (d, 1H, J = 13.8 Hz), 3.81-3.75 (m, 1H), 3.48-3.43 (m, 1H), 3.30 (bt, 1H, J = 7.2 Hz), 3.14-3.08 (m, 1H), 2.43 (s, 3H), 1.58 (s, 3H). % ee was determined by HPLC with a Chiralpak AD-H column (95% hexane: 5% 2-propanol), t_r = 10.955 min for major enantiomer, t_r = 12.485 min for minor enantiomer.




9 TMS Compound **9** was prepared following previously reported methods.³ Spectroscopic data is consistent with previously reported values. ¹H NMR (400 MHz, CDCl₃): δ 5.08 (t, 1H, *J* = 6.8 Hz), 2.59 (t, 2H, *J* = 7.6 Hz), 2.36 (q, 2H, *J* = 6.8 Hz), 1.69 (s, 3H), 1.63 (s, 3H), 0.25 (s, 9H).




10 Compound **10** was prepared following previously reported methods.⁴ Spectroscopic data is consistent with previously reported values. ¹H NMR (400 MHz, CDCl₃): δ 5.12-5.08 (m, 1H), 3.74 (s, 6H), 2.86 (d, 2H, *J* = 2.4 Hz), 2.11-2.07 (m, 2H), 2.01 (bs, 1H), 1.92-1.86 (m, 2H), 1.68 (s, 3H), 1.59 (bs, 3H).



12 $^{\text{NH}_2}$ Iodine (4.81 g, 1.90 mmol, 0.40 equiv) and iodic acid (1.76 g, 1.02 mmol, 0.215 equiv) were combined in HOAc (75 mL), H₂O (2.0 mL), and H₂SO₄ (conc., 0.50 mL) at rt and stirred for 10 min, followed by addition of 2,6-dimethylaniline (8.40 g, 47.4 mmol). The reaction mixture was heated at 70 °C for 5 h, then returned to room temperature and quenched with 200 mL of K₂CO₃ (sat aq). The reaction mixture was diluted with ethyl acetate and the organic layer was washed with sodium bisulfite (aq), then brine. The organic layer was dried over MgSO₄ and concentrated in vacuo. The crude oil was filtered with a plug of silica gel to provide **12** (12.0 g, 84%). Spectroscopic data is consistent with previously reported values.⁵ ¹H NMR (300 MHz, CDCl₃): δ 7.27 (s, 2H), 3.73 (bs, 2H), 2.83 (septet, 2H, *J* = 6.9 Hz), 1.23 (d, 12H, *J* = 6.9 Hz).




13 ¹ Br ¹ Aniline **12** (5.00 g, 16.5 mmol), HOAc (40 mL), and H₂SO₄ (16.5 mL) were stirred at 0 °C for 10 min, followed by dropwise addition of isoamyl nitrite (3.57 g, 30.5 mmol, 1.85 equiv). This mixture was stirred at 0 °C for 30 min and was added to a stirring solution of CuBr (3.31 g, 23.1 mmol, 1.40 equiv) in HBr (reagent grade, 48%, 60mL) at 0 °C. The reaction mixture was stirred at room temperature for 18 h, then poured into ice water. This mixture was extracted with hexanes (3 x 75 mL), and the combined organic layers were sequentially washed with sodium bisulfite (sat aq), HCl (10% v/v aq), then brine. The organic layer was dried over MgSO₄, filtered through Celite, and concentrated in vacuo. The crude product was purified by silica gel chromatography (100% hexanes) to provide oil **13** (4.05 g, 66%). Spectroscopic data is consistent with previously reported values.⁶ ¹H NMR (400 MHz, CDCl₃): δ 7.40 (s, 2H), 3.43 (septet, 2H, J = 6.8 Hz), 1.23 (d, 12H, J = 6.8 Hz).




14 ¹ Br ¹ Solutions of Na₂CO₃ (0.432 g, 4.08 mmol, 3.0 equiv) in H₂O (2.0 mL) and phenylboronic acid (0.249 g, 2.04 mmol, 1.5 equiv) in ethanol (2.5 mL) were added to **13** (0.500 g, 1.36 mmol) in toluene (6.5 mL) at rt. The reaction mixture was then heated at 70 °C for 18 h, then cooled to rt and partitioned between diethyl ether and H₂O. The aqueous layer was extracted with diethyl ether and the organic layers were combined and washed with NaOH (1 M, aq), then brine. The organic layer was dried over MgSO₄, filtered through filter paper, and concentrated in vacuo. Silica gel chromatography (100% hexanes) afforded oil **14** (0.40 g, 93%). ¹H NMR (400 MHz, CDCl₃): δ 7.58-7.55 (m, 2H), 7.44 (t, 2H, *J* = 7.8 Hz), 7.38-7.31(m, 3H), 3.52 (septet, 2H,


J = 6.9 Hz), 1.29 (d, 12H, J = 6.0 Hz). ¹³C NMR (400 MHz, CDCl₃): δ 148.18, 141.22, 140.58, 128.90, 127.49, 127.28, 125.96, 123.25, 34.82, 23.25. HRMS calcd for C₁₈H₂₁Br 316.0827, found 316.0824.




15 Br Compound **15** was prepared following the procedure described for **14**. ¹H NMR (400 MHz, CDCl₃): δ 7.94-7.85 (m, 3H), 7.56-7.44 (m, 4H), 7.27 (s, 2H), 3.60 (q, 2H, J = 7.2 Hz), 1.29 (d, 12H, J = 6.8 Hz). ¹³C NMR (400 MHz, CDCl₃): δ 147.65, 139.95, 139.76, 133.85, 133.45, 131.54, 128.38, 127.89, 127.78, 126.84, 126.19, 126.03, 125.89, 125.84, 125.60, 125.40, 34.70, 23.15. HRMS calcd for C₂₂H₂₃Br₁ 366.0983, found 366.0988.



19 To a -78 °C solution of protected (*R*)-BINOL (4.0 g, 9.9 mmol) in THF (35 mL) was added BuLi (2.5 M in hexanes, 13.9 mL, 13.4 mmol, 3.5 equiv). The reaction mixture was stirred at 0 °C for 1 h, then cooled to -78 °C. Iodine (9.40 g, 37.1 mmol, 3.75 equiv) was added and the reaction mixture was warmed to 0 °C for 45 min. The reaction was then quenched with Na₂CO₃ (sat aq), and the aqueous layer was extracted with diethyl ether. The combined organic layers were washed with Na₂CO₃ (sat aq), then brine. The organic layer was dried over MgSO₄, filtered through filter paper, and concentrated in vacuo to afford crude **19** (90% clean by NMR, 3.60 g, 56%). ¹H NMR (400 MHz, CDCl₃): δ 8.55 (s, 2H), 7.79 (d, 2H, *J* = 8.0 Hz), 7.44-7.40 (m, 2H), 7.32-7.18 (m, 2H), 7.18-7.16 (m, 2H), 4.89 (d, 2H, *J* = 5.6 Hz), 4.73 (d, 2H, *J* = 6.0 Hz), 3.12-3.04 (m, 2H), 2.72-2.64 (m, 2H), 0.68-0.66 (m, 6H). ¹³C NMR (400 MHz, CDCl₃): δ 152.23, 139.98, 133.75, 132.19, 127.19, 126.83, 126.46, 126.07, 125.81, 98.12, 92.70, 65.01, 14.41. HRMS calcd for C₂₆H₂₄O₄I₂ 653.9764, found 653.9763.




20 i-Pr Ph To a flame-dried flask, magnesium powder (0.035 g, 1.4 mmol, 1.0 equiv) and THF (2.0 mL) were added, followed by 14 (1 drop) and 1,2-dibromoethane (4 drops). After 5 min, the remainder of 14 (0.430 g, 1.39 mmol) was added dropwise, and the reaction mixture heated at 65 °C for 16 h. The resulting Grignard solution was cooled to rt and added by syringe to a solution of **19** (0.150 g, 0.23 mmol), NiCl₂(PPh₃)₂ (0.018 g, 0.023 mmol, 0.1 equiv) in diethyl ether (3.0 mL), and stirred for 4 h. Solid NH₄Cl was added to the reaction mixture, which was stirred for 5 min, and filtered with Celite. Silica gel chromatography (30-50% methylene chloride in hexanes) afforded **20** (0.110 g, 55%). ¹H NMR (400 MHz, CDCl₃): δ 7.96-7.94 (m, 2H), 7.89 (s, 2H), 7.74-7.72 (m, 4H), 7.55-7.39 (m, 16H), 4.40 (s, 4H), 3.00 (septet, 4H, J = 6.8 Hz), 2.66-2.47 (m, 4H), 1.44-1.25 (m, 18H), 1.11-1.10 (m, 6H), 0.54 (t, 6H, J = 6.8 HZ). ¹³C NMR (400 MHz, CDCl₃): δ 152.44, 148.34, 147.62, 142.09, 140.90, 135.10, 133.86, 133.79, 130.90, 130.43, 128.73, 127.92, 127.24, 127.10, 126.33, 126.22, 126.10, 124.98, 121.95, 121.59, 96.61, 63.75, 31.11, 30.97, 26.00, 25.31, 23.35, 23.20, 14.38.




21


Compound 21 was prepared following the procedure described for preparation of **20**. ¹H NMR (400 MHz, CDCl₃): δ 8.18-8.16 (m, 2H), 8.06-7.99 (m, 8H), 7.68-7.46 (m, 18H), 4.55 (q, 4H, J = 5.2 Hz), 3.16-3.11, 3.14 (sextet, 4H, J = 6.4 Hz), 2.88-2.77 (m, 4H), 1.48-1.36 (m, 18H), 1.25-1.19 (m, 6H), 0.76-0.72 (m, 6H). ¹³C NMR (400 MHz, CDCl₃): 8 152.46, 147.95, 147.18, 141.16, 140.29, 134.93, 134.12, 134.01, 133.93, 131.79, 131.11, 130.55, 128.46, 128.04, 127.56, 126.97, 126.48, 126.25, 126.22, 126.14, 126.04, 125.80, 125.54, 125.10, 124.93, 124.58, 96.74, 63.96, 34.75, 31.17, 31.05, 26.06, 25.37, 25.32, 23.44, 23.34, 14.67.



22 To a stirring solution of **20** (0.110 g, 0.126 mmol) in dioxane (2.5 mL) was added HCl (conc., 0.35 mL). The reaction mixture was heated at 60 °C for 8 h, then cooled to rt. The reaction mixture was diluted with methylene chloride, and the organic layer washed with sodium bicarbonate (sat aq), and then brine. The organic layer was dried over MgSO₄, filtered, and concentrated in vacuo to afford crude **22** (0.100 g, 0.132 mmol). This material was used as is in the next step. ¹H NMR (400 MHz, CDCl₃): δ 8.00-7.98 (m, 2H), 7.90 (s, 2H), 7.76-7.74 (m, 4H), 7.59-7.36 (m, 16H), 5.08 (s, 2H), 3.01 (quintet, 2H, *J* = 6.8 Hz), 2.86 (quintet, 2H, *J* = 6.8 Hz), 1.385-1.18 (m, 21H), 0.98-0.91 (m, 3H). ¹³C NMR (400 MHz, CDCl₃): δ 150.67, 148.48, 148.42, 141.80, 141.73, 133.49, 132.45, 130.89, 128.16, 128.83, 128.75, 128.41, 127.35, 127.30, 126.97, 124.50, 124.07, 122.22, 122.18, 112.88, 31.08, 31.05, 24.38, 24.31, 23.94, 23.77, 22.84, 22.71. HRMS calcd for C₅₆H₅₄O₂Li₁ 765.4278, found 765.4294.




23 Compound **23** was prepared following the procedure described for preparation of **22**. ¹H NMR (400 MHz, CDCl₃): δ 8.06-8.04 (m, 2H), 7.97-7.88 (m, 7H), 7.60-7.38 (m, 15H), 7.27 (s, 4H), 5.08 (s, 2H), 2.99 (m, 2H), 2.83 (m, 2H), 1.28-1.26 (m, 9H), 1.20-1.16 (m, 9H), 1.12-1.11 (m, 3H), 0.89-0.84 (m, 3H). ¹³C NMR (400 MHz, CDCl₃): δ 150.73, 148.00, 147.93, 141.04, 140.79, 133.95, 133.50, 132.18, 131.69, 130.89, 129.21, 128.95, 128.43, 128.40, 127.64, 127.01, 126.18, 126.08, 125.79, 125.49, 125.11, 124.50, 124.10, 113.00, 34.71, 31.06, 24.35, 24.00, 23.80. HRMS calcd for C₆₄H₅₈O₂Li₁ 865.4591 found 865.4607.




24

To a solution of 22 (0.100 g, 0.132 mmol) in pyridine (0.50 mL) was added by syringe POCl₃ (0.040 g, 0.26 mmol, 2.0 equiv), and the reaction mixture was heated at 60 °C for 15 h. The reaction mixture was then cooled to 0 °C, charged with 0.1 mL of H₂O, and returned to heating at 60 °C for 7 h. After cooling to rt, the reaction mixture was diluted with methylene chloride, and washed with HCl (10% v/v aq) two times. The organic layer was dried over MgSO₄, filtered, and concentrated in vacuo. Silica gel chromatography (0% MeOH in 1:1 methylene chloride: hexanes to 5% MeOH in 1:1 methylene chloride : hexanes) provided a white powder which was then dissolved in methylene chloride and washed with HCl (10% v/v aq). The organic layer was dried over MgSO₄, filtered, and concentrated in vacuo to provide **24** (0.070 g, 65%). ¹H NMR (400 MHz, CDCl₃): δ 7.96-7.94 (m, 2H), 7.88 (s, 2H), 7.55-7.54 (m, 6H), 7.40-7.26 (m, 14H), 6.07 (brs, 2H), 2.66-2.57 (m, 4H), 1.10 (d, 6H, J = 6.4 Hz), 0.99 (d, 6H, J = 6.4 Hz), 0.91 (d, 6H, J = 6.8 Hz), 0.71 (d, 6H, J = 6.4 Hz). ¹³C NMR (400 MHz, CDCl₃): δ 148.61, 148.12, 145.71, 145.62, 141.85, 141.02, 132.85, 132.51, 132.35, 131.78, 130.97, 127.51, 128.24, 127.33, 127.26, 126.98, 126.36, 125.76, 122.24, 122.01, 121.22, 31.07, 30.76, 26.38, 24.88, 23.18, 22.71. ³¹P NMR (400 MHz, CDCl₃): δ 2.96. FTMS calcd for C₅₆H₅₂O₄P₁ 819.36, found 819.3603.



25

Compound 25 was prepared following the procedure described for preparation of **24.** ¹H NMR (400 MHz, CDCl₃): δ 8.00-7.96 (m, 6H), 7.86-7.79 (m, 4H), 7.57-7.54 (m, 4H), 7.40-7.22 (m, 14H), 6.72 (brs, 2H), 2.75-2.67 (m, 4H), 1.12-1.10 (m, 6H), 1.03-1.02 (m, 6H), 0.92-0.91 (m, 6H), 0.73 (brs, 6H). ¹³C NMR (400 MHz, CDCl₃): δ 148.21, 147.60, 145.81, 145.72, 140.77, 140.42, 133.75, 132.70, 132.39, 131.85, 131.57, 131.03, 128.22, 128.07, 127.34, 126.92, 126.44, 126.29, 125.98, 125.82, 125.55, 125.25, 125.18, 124.13, 122.10, 31.10, 30.77, 26.35, 24.91, 23.26, 22.83. ³¹P NMR (400 MHz, CDCl₃): δ 2.93. FTMS calcd for C₆₄H₅₆O₄P₁ 919.39, found 919.3893.



Compound 26 was prepared following the procedure 26 described for preparation of 24. ¹H NMR (400 MHz, CDCl₃): 7.90(m, 2H), 7.88(s, 2H), 7.53-7.52(m, 2H), 7.40-7.36(m, 4H), 7.11-7.06(m, 4H), 2.67-2.52(m, 4H), 2.10 (brs, 6H), 1.92(brs, 12H), 1.75(brs, 6H), 1.05-0.94(m, 18H). ¹³C NMR (400 MHz, CDCl₃): δ 150.6, 147.5, 146.9, 145.9, 145.8, 132.5, 132.4, 131.1, 130.9, 128.1, 127.4, 126.1, 125.6, 122.1, 119.4, 118.4, 43.1, 36.9, 36.3, 31.1, 30.8, 29.7, 29.0, 26.4, 25.1, 23.4, 22.6. ³¹P NMR (400 MHz, CDCl₃): δ 2.48.

20

Compounds 27-31, see references below.

References

1. Muñoz M. P., Méndez M., Nevado C., Cárdenas D. J., Echavarren A. M. Synthesis, 2003, 18, 2898-2902.


- 2. Porcel S., Echavarren A. M. Angew. Chem. Int. Ed. 2007, 46, 2672-2676.
- 3. Trost B. M., Toste F. D. J. Am. Chem. Soc. 2002, 124, 5025-5036.

4. Nishizawa M., Yadav V. K., Skwarczynaki M., Takao H., Imagawa H., Sugihara T. Org. Lett. 2003, 5, 1609-1611.


5. Knox J. R., Toia R. F., Casida J. E. J. Agric. Food Chem. 1992, 40, 909-913.

6. Sasaki S., Yoshifuji M. J. Organomet. Chem. 2005, 690, 2664-2672.


¹H NMR




2^{1} H NMR




2 HPLC 99.9% Hexanes, 0.01% Isopropylalcohol, Racemic




2 HPLC 99.9% Hexanes, 0.01% Isopropylalcohol, Chiral




¹H NMR




¹H NMR




6 HPLC 90% Hexanes, 10% Isopropylalcohol, Racemic




6 HPLC 90% Hexanes, 10% Isopropylalcohol, Chiral







$\mathbf{8}^{1}$ H NMR




8 HPLC 95% Hexanes, 5% Isopropylalcohol, Racemic




8 HPLC 95% Hexanes, 5% Isopropylalcohol, Chiral








10 ¹H NMR





28



























210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 ppm


33





























24 31 P NMR





FTMS




$25 ^{1} H NMR$









FTMS












CHAPTER 2: DITHIOPHOSPHORIC ACIDS AS COVALENT CATALYSTS FOR HYDROAMINATION AND HYDROARYLATION OF ALKENES

Abstract

The first organocatalytic enantioselective hydroamination was achieved with newly designed dithiophosphoric acid catalysts. Markovnikov ionic addition of the Brønsted acid catalyst to alkenes resulted in covalent intermediates which then underwent intramolecular enantioselective nucleophilic attack. The substrate scope includes dienes and styrenes, with both amine and carbon nucleophiles. These reactions provided various heterocycles in good to high yield and enantioselectivity, while it was found that probably due to mechanistic and steric considerations, dienes were more successful than styrenes as substrates. However, we believe that the concepts revealed in this work will prove applicable to other asymmetric functionalizations of unsaturated systems.




Introduction

Transition-metal catalysis, through the use of chiral ligands, has mediated functionalization of olefins with high enantioselectivity. In addition, the use of racemic Brønsted acids has also been utilized to catalyze the addition of alcohols and other nucleophiles to olefins. However, the expansion of their reactivity to produce enantioselective products from olefins has been a longstanding challenge. As an illustration of the challenge, the only application toward this type of reaction resulted in low enantioselectivity (17% ee).¹ Organocatalytic methods have become highly desirable because they avoid the use of toxic and expensive metals and are generally insensitive to air and moisture.² An organocatalyst capable of achieving asymmetric hydroamination of unactivated olefins would represent not only a potential practical improvement for this important reaction, but also an expansion of the range of transformations amenable to organocatalysis. Typically polar unsaturated bonds are activated by chiral acids, due to the increased basicity as well as the potential for hydrogen bonding. At the time we began work to realize this concept, the general consensus from the organocatalysis community was that chiral Brønsted acids require hydrogen-bonding interaction between the protonated substrate and the conjugate base in order to attain selectivity.³ A significantly different approach – most likely the design of new catalyst - was needed to achieve the desired enantioselective additions to olefins. There are two main roadblocks to this type of reactivity. First, the acid must be very acidic, such as triflic acid (pKa = -5.9). Second, the intermediate carbocation is planar and generally lacks sufficient attractive interactions with the chiral source and thus cannot provide an energy difference between the two diastereomeric transition states. The first issue of increasing acidity has been previously explored in the design of new catalysts, which are more acidic than the well-precedented BINOL-derived chiral phosphoric acid such as TRIP. Reactions requiring more acidic catalysts have been rendered enantioselective by Yamamoto and others using Ntriflylphosphoramides and sulfonic acid derivatives.⁴ However, these stronger acids have still only been utilized to more highly activate polar functional groups derived from ketones and aldehydes. Instead of solely increasing acidity, we envisioned also increasing the nucleophilicity of the conjugate base, in order to perform an ionic Brønsted acid addition to an alkene to form a covalent intermediate. Ideally this intermediate would mimic the known addition of many simple Brønsted acids such as hydrobromic acid to olefins (Figure 1B). This intermediate with a tethered nucleophile could then undergo intramolecular $S_N 2$ or $S_N 2'$ attack, depending on whether a styrene or diene is reacting. Because the chiral catalyst is directly bound to the substrate in the nucleophilic addition step, we hypothesized that the key intermediate is now chiral and could undergo an intramolecular reaction with high enantioselectivity. Although enamine and iminium catalysis also take advantage of covalent catalysis mechanisms, they are a result of condensation with ketones, a mechanism significantly different from addition of a Brønsted acid to an alkene.⁵

The approach we took to increasing the nucleophilicity of the counteranion was to use dithiophosphoric acids. The counterion is expected to be more nucleophilic due to polarizability because of its size.⁶ It is precedented that simple dithiophosphoric acids add to dienes efficiently, and chiral dithiophosphoric acids have been synthesized but have not been shown to catalyze any reactions with high enantioselectivity (the best example to date: 7:3 dr, 63% ee).^{7,8}

Furthermore, we aimed to extend this type of covalent catalysis to substrates which bear no hydrogen-bond donors. To demonstrate the lack of reliance on hydrogen-bonding and the vastly

different requirements of this type of catalysis, we aimed to look at carbon nucleophiles in the formation of C-C bonds. This type of reaction is even less well-precedented in organocatalysis due to the non-hydrogen bonding nature of both reactive functional groups. We postulated that the chiral intermediate featuring a chiral leaving group could provide enough differentiation between the enantiotopic faces to facilitate highly enantioselective nucleophilic additions.



Scheme 1. Mechanistic distinctions between precedented chiral phosphoric acid activation reactions and our hypothesis for alkene functionalization: A: Protonation of an imine with a chiral Brønsted acid leads to a hydrogen-bonded iminium, while protonation of an olefin results in a carbocation which cannot form a hydrogen bond. B: Proposed new mechanism where a novel Brønsted chiral acid adds to styrene, then undergoes enantioselective $S_N 2$ displacement. C: Proposed new mechanism where a Brønsted chiral acid adds to a diene, then undergoes enantioselective $S_N 2$ displacement.

Results and discussion

The initial foray involved the intramolecular hydroamination reaction of styrenes with nitrogen nucleophiles. The substrate design was straightforward and similar to other hydroamination substrates used in the past by our group and others for metal-catalyzed enantioselective variants; it relied on a benzylic carbocationic intermediate and its potential interaction with the chiral dithiophosphate counteranion. Initial experiments with hydroamination were attemped with a 4-methoxystyrene substrate, with hopes that an electron-donating group would facilitate the initial protonation and interaction with catalyst. In addition to using **7** as a substrate, intermediates **4**, **5**, and **6** were subjected to dithiophosphoric acid catalyst, with **5** providing quantitative conversion and 6% ee while **4** was formed with no enantioselectivity. After obtaining hydroamination in quantitative yield and 7% ee with **7**, unactivated styrenyl substrates (without the methoxy-substituent) were explored.




Figure 1. Straight-forward synthesis of styrene substrates for intramolecular hydroamination.

The optimization of the reaction continued with the parent phenyl compound, synthesized in a similar fashion. However, it was found that the methoxy-substitution did indeed provide a larger effect than we anticipated and with the parent compound **8**, heat was required to drive the reaction to completion. Even with slight heating the pyrrolidine product was obtained in 13% ee in benzene. A solvent screen revealed that fluorobenzene as solvent increased enantioselectivity to 19% ee. Various dithiophosphoric acid catalysts were investigated (Table 1). With 3,3'-substituents identical to TRIP, we obtained 7% ee, and with anything larger the reaction was sluggish or did not proceed. This may be due to steric crowding of the quaternary carbon center where nucleophilic attack must occur. In the case of these substrates, it is likely that there is actually not a stable covalent adduct formed, but rather a strongly stabilized benzylic carbocation is ion-paired with the counteranion thiophosphate. Other tethered nucleophiles were explored including alcohol, carboxylic acid, and N-tosylamide. It is common to see the Thorpe-Ingold effect used to improve reactivity in intramolecular reactions; however, in our case the use of dimethyl-substituted linkers was detrimental for reactivity, probably due to the two contiguous quaternary centers in the desired product.

\land		cat. (10 mol%)	Ts N
	8	solvent (0.25M) 55 °C 18-36h	9
entry ^a	solvent	cat.	ee (%) ^b
1	benzene	10	13
2	fluorobenzene	10	19
3	fluorobenzene	11	_c
4	fluorobenzene	12	7

^a Reactions run to >90% completion, monitored by TLC. ^b Enantiomeric excess determined by chiral HPLC. ^d Not determined due to low amount of product.




Table 1. Optimization of reaction conditions and catalyst.





Figure 2. Conditions **A**: Triflic acid in methylene chloride, at room temperature. Conditions **B**: Dithiophosphoric acid catalyst (10 mol%) in fluorobenzene at 55 °C.

From here, I began working on dienes rather than styrenes (Scheme 1B vs. Scheme 1C). Work on 1,3-diene substrates included using fluorobenzene as solvent, and lowering the temperature of the reaction to 15 °C. Unlike the previous styrene substrates, changing the 3,3' substituents to anthracenyl groups led to a substantial boost in enantioselectivity, presumably because the projection of chiral information is required due to the less proximal S_N2' attack. Along these lines, the addition of aryl substituents to the 10-position of the anthracene further increased enantioselectivity in this reaction. The H8-type BINOL backbone also provided improvements in selectivity (entry 5). Thus, we postulate that the change in mechanism (from S_N2 to S_N2') is critical for success in this type of reaction, because S_N2 displacements are very unlikely at quaternary carbon centers. Notably, both mesityl catalyst **16** and 3,5-t-butylphenyl catalyst **15** provided exceptional enantioselectivity even at room temperature. Both of these catalysts were used in the substrate scope studies.



Scheme 2. Overall modification to design new catalysts includes transition to a more acidic dithiophosphoric acid, and the extension of the 3,3'-position groups.

Various substrates, including modifications to the diene alkyl substituents, and changes in the Thorpe-Ingold linker, were synthesized (Table 2). We found that spirocyclic products as well as dienes with cyclic alkyl substitutions performed well under optimized reaction conditions. In addition, the protecting sulfonyl group could be changed to nosyl.




Figure 3. Synthesis of substrates.




Table 2. Substrate scope of hydroamination.

With 1,3- and 1,2-dienes (allenes), we expected similar results, which indeed was observed. They should proceed *via* a common intermediate, which is the chiral covalent adduct. This observation helps verify our mechanistic hypothesis. In addition, we were able to change the nucleophile to hydroxylamines to generate isoxazolidine heterocycles with high enantioselectivity. This stronger nucleophile (due to the alpha-effect) was required in the lone substrate without the gem-dialkyl linker.

To further confirm that the reaction is proceeding by our proposed mechanism, we aimed to observe the covalent intermediate which demonstrates that the dithiophosphoric acid is acting as a covalent chiral Brønsted acid catalyst. Gratifyingly, following the course of the transformation by TOF-MS allowed us to directly observe the covalent intermediate. This work was done with the assistance of the mass spectrometry facility in Stanley Hall. The formation of this intermediate is also supported by literature precedent which has observed addition of dithiophosphoric acids to alkenes and dienes.⁷ One possible mechanism consists of a covalent intermediate is being formed, followed by formation of a tight ion pair, which may not observed. We cannot discount this process, but whether the covalent intermediate is directly converted to product or proceeding *via* a more reactive intermediate, the transformation proceeds by a reaction mechanism unprecedented in enantioselective organocatalysis.

As mentioned earlier, we investigated carbon nucleophiles to further demonstrate the potential for this type of transformation. We chose to work with indoles, which are highly nucleophilic, heteroaromatic, and generally alkylate at the 2- or 3-positions, when the nitrogen is protected. Additions of indoles to alkenes have not been demonstrated with organocatalysts.⁹ A few substrates were designed and synthesized with similar structural characteristics as the substrates described above. They contained a gem-dimethyl linker in order to keep the Thorpe-Ingold effect, and an indole and allene were tethered to either side. We were gratified to find that indoles do react with high efficiency to form tetrahydrocarbazoles in high yield and enantioselectivity (Figure 3). Notably, there are no hydrogen-bond donors on the nucleophile in this case. Thus the interaction between chiral catalyst and substrate in the form of a covalent bond provides sufficient differentiation between the two diastereomeric transition states. This is a rare example of an enantioselective transformation using chiral Brønsted acids without any hydrogen-bonding capability on either reaction partner. The analogous covalent intermediate between the indole substrate and catalyst was similarly detected by MS studies (See supporting information).




Figure 4. Dithiophosphoric acid catalyzed hydroarylation of indole derivatives.


We have demonstrated that with the design of dithiophosphoric acid catalysts, we were able to achieve organocatalytic hydroamination and hydroarylation. The reaction proceeds *via* a covalent intermediate which is produced in similar fashion as classic Brønsted acid addition to alkenes. This intermediate then undergoes intramolecular nucleophilic attack generating heterocycles in high enantioselectivity. The value in this method is mainly in the demonstration of a new mechanism for chiral Brønsted acid catalysis, allowing for the functionalization of alkenes rather than imines or carbonyls. The further evolution of chiral Brønsted acids, based on the well-precedented TRIP, was explored by using dithiophosphoric acids rather than phosphoric acids, and extension of the 3,3-substituents to a bulkier substituent.

References

- 1. Ackermann L., Althammer A. Synlett, 2008, 995–998.
- 2. "Asymmetric Organocatalysis" Berkessel A., Groger H. Wiley and Sons, 2005.
- 3. Terada M. Chem. Commun. 2008, 4097–4112.
- 4. Nakashima D., Yamamoto H. J. Am. Chem. Soc. 2006, 128, 9626-9627.
- 5. MacMillan D. W. C. Nature, 2008, 455, 304–308.
- A) Kabachnik M. I., Mastrukova T. A., Shipov A. E., Melentyeva T. A. *Tetrahedron*, 1960, 10–28. B) Mastryukova T. A., Spivak L. L., Grigoreva A. A., Urzhuntseva E. K., Kabachnik M. I. *Zh. Obshch. Khim.* 1971, *41*, 1938–1941. C) Leavitt C. M., Gresham G. L., Benson M. T., Gaumet J.-J., Peterman D. R., Klaehn J. R., Moser M., Aubriet F., Van Stipdonk M. J., Groenewold G. S. *Inorg. Chem.* 2008, *47*, 3056–3064.
- 7. Mueller W. H., Oswald A. A. J. Org. Chem. 1966, 31, 1894–1898.
- 8. Pousse G., Devineau, A., Dalla V., Humphreys L., Lasne M.-C., Rouden J., Blanchet J. *Tetrahedron*, **2009**, *65*, 10617–10622.
- 9. Liu C., Widenhoefer R. A. Org. Lett. 2007, 9, 1935–1938.

Supporting Information

General procedure for acid-catalyzed enantioselective hydroamination reaction. To a 1dram screw cap vial was added the diene or the allene substrate (0.1 mmol, 1.0 equiv) followed by the dithiophosphoric acid catalyst (0.01 mmol, 0.1 equiv) and activated 4 Å molecular sieves (20 mg). To the mixture was added fluorobenzene 0.5 mL at room temperature. The vial was sealed and allowed to stand at room temperature for 48 h at the indicated temperature. After the reaction was complete, the entire mixture was loaded onto silica gel and the product was eluted with EtOAc/hexanes.



S1: A 100 mL flame-dried round-bottom flask was charged with 9-bromoanthracene (3.81 g, 15 mmol, 1.0 equiv), 2,4,6-trimethylphenylboronic acid (3.69 g, 22.5 mmol, 1.5 equiv), Pd(OAc)₂ (101.02 mg, 0.45 mmol, 0.03 equiv), SPhos (369.5 mg, 0.90 mmol, 0.06 equiv), K₃PO₄ (7.96 g, 37.5 mmol, 2.5 equiv), and anhydrous toluene (120 mL). The resulting mixture was subjected to freeze-pump-thaw cycles (3x) and heated at 105 °C for 18 h. After this time, the reaction mixture was cooled to room temperature and poured over water (50 mL). The organic layer was separated, and the aqueous layer was extracted with CH₂Cl₂ (2 X 50 mL). The organic extracts were combined and dried over anhydrous MgSO₄, filtered, and concentrated in vacuo. The resulting dark reddish-brown semi-solid was dissolved in minimal amount of CH₂Cl₂ and triturated with MeOH. The desired product S1 precipitated as a reddish-brown solid, and was filtered and washed with ice-cold MeOH. The solid mass was dried under high vacuum for 2 h until a constant mass of 4.22 g (96% yield) was obtained. ¹H NMR (300 MHz, CDCl₃): δ 8.48 (s, 1H), 8.06 (d, 2H, J = 8.4 Hz), 7.50-7.43 (m, 4H), 7.35-7.30 (m, 2H), 7.10 (s, 2H), 2.46 (s, 2 3H), 1.71 (6H, s). ¹³C NMR (100 MHz, CDCl₃): δ 137.6, 137.1, 135.7, 134.5, 131.6, 129.7, 128.6, 128.2, 126.0, 126.0, 125.5, 125.1, 21.2, 20.0.


S2: To a flame-dried 250 mL flask was added 9-(2,4,6-trimethylphenyl)-anthracene (**S1**) (3.20 g, 10.8 mmol, 1.0 equiv) and CCl₄ (40 mL). To the resulting solution was added dropwise over 5 minutes Br₂ (612 μ L, 11.9 mmol, 1.1 equiv). The reaction mixture was allowed to stir for 15 min at room temperature and quenched with saturated Na₂SO₃ (30 mL). The biphasic mixture was extracted with CH₂Cl₂ (2 X 50 mL) and the combined organic layers were dried over anhydrous MgSO₄, filtered and concentrated *in vacuo*. The product **S2** (3.24 g, 73% yield) was obtained by recrystallization from CH₂Cl₂/MeOH as a dark green solid. ¹H NMR (300 MHz, CDCl₃): δ 8.63 (d, 2H, *J* = 9.0 Hz), 7.63-7.58 (m, 2H), 7.51 (d, 2H, *J* = 8.7 Hz), 7.40-7.35 (m, 2H), 7.11 (s, 2H), 2.47 (s, 3H), 1.71 (s, 6H). ¹³C NMR (75 MHz, CDCl₃): δ 137.4, 137.4, 136.6, 134.1, 130.5, 130.5, 128.3, 128.1, 127.0, 126.4, 125.9, 122.2, 21.2, 20.0.

S4: A 100 mL flame-dried round-bottom flask was charged with (R)-3,3'-diiodo-5,5',6,6',7,7',8,8'-octahydro-2,2'-bis(ethoxymethyloxy)-1,1'-binaphthyl¹ (818 mg, 1.24 mmol, 1.0 equiv), 9-(2,4,6-trimethylphenyl)10-anthracenylboronic acid (S3, 6.0 equiv, prepared by metallation of the bromide precursor (7.41 mmol) using nBuLi (18.5 mmol, 2.5 equiv), THF 250 mL, B(O-iPr)₃ (22.2 mmol, 3.0 equiv) and used as crude material), Pd(OAc)₂ (27.8 mg, 0.124 mmol, 0.1 equiv), SPhos (101.5 mg, 0.25 mmol, 0.2 equiv), K₃PO₄ (1.31 g, 6.18 mmol, 2.5 equiv), and anhydrous toluene (25 mL). The resulting mixture was subjected to 3 freeze-pumpthaw cycles and heated at 105 °C for 18 h. After this time, the reaction mixture was brought to room temperature and poured over water (25 mL). The organic layer was separated and the aqueous layer was extracted with CH₂Cl₂ (2 X 50 mL). The organic extracts were combined and dried over anhydrous MgSO₄, filtered, and concentrated *in vacuo* and the crude product was purified by flash chromatography (5-40% CH₂Cl₂/hexanes) to yield 950.5 mg of S4 in 77% yield as faint yellow solid. ¹H NMR (300 MHz, CDCl₃): δ 8.10 (d, 2H, J = 8.7 Hz), 8.00-7.96 (m, 2H), 7.68-7.60 (m, 4H), 7.57-7.52 (m, 2H), 7.46-7.33 (m, 8H), 7.29 (s, 2H), 7.22 (s, 4H), 4.54-4.50 (m, 4H), 2.99 (br, 6H), 2.62-2.45 (m, 12H), 2.01 (m, 8H), 1.90 (s, 6H), 1.87 (s, 6H), 0.70 (t, 6H, J = 7.2 Hz). ¹³C NMR (75 MHz, CDCl₃): δ 151.2, 137.6, 137.3, 137.1, 137.0, 135.6, 134.8, 133.9, 133.1, 131.6, 130.4, 130.4, 129.4, 129.3, 129.3, 128.2, 127.7, 127.5, 126.0, 125.8, 125.3, 125.1, 96.5, 77.2, 63.8, 29.5, 27.9, 23.4, 23.0, 21.2, 20.1, 20.0, 14.5.


S5: Compound **S4** (840 mg, 0.84 mmol) was suspended in dioxane (50 mL). To the mixture was added conc. HCl (5 mL) and the mixture was heated to 70 °C for 2 h. The reaction mixture was cooled to room temperature and concentrated *in vacuo*. The resulting semi-solid was dissolved in CH₂Cl₂ (70 mL) and washed with water (25 mL) and saturated NaHCO₃ (25 mL) and dried over anhydrous MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified by recrystallization from CH₂Cl₂/hexanes to yield 789 mg (94% yield) of the desired product **F** as a faint yellow solid. ¹H NMR (400 MHz, CDCl₃): δ 7.92 (d, 2H, *J* = 8.8 Hz), 7.80-7.78 (m, 2H), 7.53-7.46 (m, 6H), 7.40-7.36 (m, 2H), 7.32-7.27 (m, 4H), 7.21 (s, 2H), 7.13 (brs, 4H), 4.70 (s, 2H), 3.72 (s, 2H), 2.90 (m, 4H), 2.80-2.62 (m, 4H), 2.48 (s, 6H), 1.95-1.89 (m, 8H), 1.80 (s, 6H), 1.75 (s, 6H). ¹³C NMR (100 MHz, CDCl₃): δ 149.3, 137.7, 137.6, 137.1, 136.4, 134.7, 133.2, 131.4, 130.6, 130.5, 129.9, 129.6, 128.3, 126.9, 126.4, 126.2, 125.7, 125.5, 125.4, 122.5, 121.0, 67.1, 29.3, 27.5, 23.4, 23.1, 21.3, 20.1, 20.1. HRMS (ESI) calc. for [M+H]⁺ (C₆₆H₅₉O₂) 883.4510, found 883.4493.

3h: The following procedure is representative for all the dithioacid catalysts used in this study. A flame dried flask was charged with diol **S5** (650 mg, 0.74 mmol, 1.0 equiv), P_2S_5 (81.9 mg, 0.37 mmol, 0.5 equiv), and anhydrous m-xylene (10 mL). The flask was equipped with a condenser and placed in an oil-bath preheated to 150 °C. The progress of the reaction was monitored by disappearance of the phenolic protons (¹H NMR). After 2 h, the reaction was judged complete and allowed to cool to room temperature. The solution was decanted into a flame-dried 100 mL flask and the solvent was evaporated *in vacuo*. The crude product was dissolved in anhydrous CH₂Cl₂ (5 mL) and treated with hexanes (50 mL). At this point, a fine precipitate was observed. The solvent was then partially evaporated until about 2 to 3 mL solvent was left. The precipitate was then collected by filtration and washed with ice-cold hexanes. Following this procedure, the product **16** (617 mg) was obtained as a faint-yellow powder in 85% yield.


3 1 H NMR (300 MHz, CDCl₃): δ 7.98 (d, 2H, J = 6.9 Hz), 7.00 (d, 2H, J = 9.0 Hz), 3.86(s, 3H), 3.31-3.24 (m, 2H), 2.67 (t, 2H, J = 6.3 Hz).



4 0 ¹H NMR (400 MHz, CDCl₃): δ 7.38-7.35 (m, 2H), 6.96-6.83 (m, 2H), 5.27 (s, 1H), 5.04-5.03 (m, 1H), 2.83 (t, 2H, J = 8.0 Hz), 2.56-2.52 (m, 2H).



5 O IH NMR (400 MHz, CDCl₃): δ 7.38-7.35 (m, 2H), 6.88-6.85 (m, 2H), 5.24 (s, 1H), 5.01 (s, 1H), 3.64 (t, 2H, J = 6.4 Hz), 2.59 (t, 2H, J = 6.8 Hz), 1.75-1.68 (m, 2H), 1.88 (brs, 1H).




7 • ¹H NMR (400 MHz, CDCl₃): δ 7.77-7.71 (m, 2H), 7.29-7.24 (m, 4H), 6.85-6.82 (m, 2H), 5.18 (s, 1H), 4.92 (s, 1H), 4.75 (t, 1H, *J* = 12.4 Hz), 3.81 (s, 3H), 2.97-2.92 (m, 2H), 2.49-2.45 (m, 2H), 2.42 (s, 3H), 1.63-1.56 (m, 2H). ¹³C NMR (125 MHz, CDCl₃): δ 159.1, 146.3, 143.3, 136.9, 132.8, 129.7, 127.1, 127.0, 113.7, 111.5, 55.3, 42.7, 32.2, 27.9, 21.5.

Ts

7b MeO¹H NMR (400 MHz, CDCl₃): δ 7.56 (d, 2H, J = 8.0 Hz), 7.31-7.27 (m, 2H), 7.27-7.21 (m, 2H), 6.83-6.79 (m, 2H), 3.81 (s, 3H), 3.71-3.55 (m, 2H), 2.41 (s, 3H),

55


2.16-2.10 (m, 1H), 1.99-1.93 (m, 1H), 1.87 (s, 3H), 1.85-1.84 (m, 2H). Enantiopurity was determined by HPLC analysis (Chiralpak AD column, 92:08 hexanes/ethanol, 1 mL/min) t_R 18.78 min (major), 22.02 min (minor).




8 ¹H NMR (400 MHz, CDCl₃): δ 7.72 (d, 2H, J = 8.0 Hz), 7.32-7.29 (m, 7H), 5.25 (s, 1H), 5.01 (s, 1H), 4.57 (t, 1H, J = 8.0 Hz), 2.98-2.93 (m, 2H), 2.52-2.49 (m, 2H), 2.43 (s, 3H), 1.63-1.60 (m, 2H). ¹³C NMR (125 MHz, CDCl₃): δ 147.0, 143.3, 140.5, 136.9, 129.7, 128.4, 127.5, 127.0, 126.0, 113.1, 53.4, 42.7, 32.2, 27.9, 21.5.



9 ¹H NMR (400 MHz, CDCl₃): δ 7.59 (d, 2H, *J* = 8.0 Hz), 7.42-7.39 (m, 2H), 7.32-7.25 (m, 5H), 3.74-3.69 (m, 1H), 3.59-3.53 (m, 1H), 2.42 (s, 3H), 2.18-1.95 (m, 2H), 1.90 (s, 3H), 1.87-1.78 (m, 2H). Enantiopurity was determined by HPLC analysis (Chiralpak AD column, 95:05 hexanes/ethanol, 1 mL/min) t_R 17.52 min (minor), 20.35 min (major).




10 NMR analysis of this and related compounds (**3c** and **3d**) is complicated by the presence of multiple conformers due to slow rotation around the 3,3'-biaryl bonds and the unsymmetrical nature of the 1-naphthyl substituent. ¹H NMR (400 MHz, CDCl₃): δ 8.12-7.33 (m, 24H). ³¹P NMR (162 MHz, CDCl₃): δ 93.4, 93.2, 93.1.




11

¹H NMR (400 MHz, CDCl₃): δ 8.47 (s, 2H), 8.04-7.97 (m, 6H), 7.68 (d, 2H, J = 8.8 Hz), 7.49-7.27 (m, 10H), 3.13-2.68 (m, 6H), 2.05-1.78 (m, 10H). ³¹P NMR (162 MHz, CDCl₃): δ 90.9. HRMS (ESI) calc. for $[M+H]^+$ (C₄₈H₃₈O₂PS₂) 741.2045, found 741.2057.




¹H NMR (400 MHz, CDCl₃): δ 7.55 (d, 2H, J = 8.0 Hz), 7.41-13 7.25 (m, 7H), 5.27 (s, 1H), 5.03 (s, 1H), 4.52 (t, 1H, J = 6.8 Hz), 2.58-2.52 (m, 2H), 2.50 (s, 2H), 2.48 (s, 3H), 0.79 (s, 6H). ¹³C NMR (125 MHz, CDCl₃): δ 154.4, 146.0, 143.3, 143.1, 136.8, 129.6, 128.5, 128.3, 127.4, 126.9, 126.4, 117.6, 55.9, 44.8, 35.2, 25.6, 21.5.



15

t-Bu ¹H NMR (400 MHz, CDCl₃): δ 8.11 (d, 2H, J = 9.2 Hz), 7.76-7.72 (m, 4H), 7.68 (d, 2H, J = 8.0 Hz), 7.56 (s, 2H), 7.46 (s, 2H) 7.37 (t, 2H, J = 8.8 Hz), 7.29-7.14 (m, 10H), 3.15-2.96 (m, 6H), 2.78-2.68 (m, 2H), 2.15-1.73 (m, 8H), 1.41 (s, 18H), 1.38 (s, 18H). ³¹P NMR (162 MHz, CDCl₃): δ 91.5. HRMS (ESI) calc. for [M+H]⁺ (C₇₆H₇₈O₂PS₂) 1117.5175, found 1117.5185.



¹H NMR (300 MHz, CDCl₃): δ 8.09 (d. 2H, J = 8.8 Hz). 16 7.77 (d, 2H, J = 8.8 Hz), 7.51-6.99 (m, 18H), 3.13-3.05 (m, 6H), 2.77-2.72 (m, 2H), 2.46 (s, 6H), 2.07-2.01 (m, 8H), 1.83 (s, 6H), 1.60 (s, 6H). ¹³C NMR (100 MHz, CDCl₃): δ 137.3, 137.0, 136.7, 135.7, 134.9, 134.3, 131.0, 130.7, 129.9, 129.6, 129.1, 128.3, 128.1, 128.0, 126.8, 126.1, 126.0, 125.9, 125.6, 125.1, 125.0, 124.5, 29.4, 28.4, 22.8, 22.8, 21.3, 21.2, 20.1, 19.8. ³¹P NMR (162 MHz, CDCl₃): δ 89.7. HRMS (ESI) calc. for [M+H]⁺ (C₆₆H₅₈O₂PS₂) 977.3610, found 977.3617.

Substrates were prepared by the methods of Widenhoefer and coworkers² according to the general scheme shown in Supporting Figure 2. Dienyl bromides were prepared by the method of Ollis and coworkers³.

17c: ¹H NMR (300 MHz, CDCl₃) δ 7.76 (d, 2H, J = 7.2 Hz), 7.30 (d, 2H, J = 7.2 Hz), 6.09 (d, 1H, J = 15.2 Hz), 5.53 (dt, 1H, J = 15.2, 7.8 Hz), 5.03 (t, 1H, J = 6.8 Hz), 4.88 (s, 1H), 4.86 (s, 1H), 2.66 (d, 2H, J = 6.8 Hz), 2.00 (d, 2H, J = 7.8 Hz), 1.78 (s, 3H), 0.86 (s, 6H).

¹³C NMR (75 MHz, CDCl₃) δ 162.7, 141.8, 135.9, 131.4, 129.2, 125.8, 115.0, 114.2, 55.6, 52.8, 42.7, 34.6, 25.0, 18.7.

17a: ¹H NMR (300 MHz, CDCl₃) δ 7.50 (s, 2H), 7.17 (s, 1H), 6.09 (d, 1H, J = 15.3 Hz), 5.55 (dt, 1H, J = 15.3, 7.8 Hz), 5.22 (t, 1H, J = 6.8 Hz), 4.87 (s, 1H), 4.85 (s, 1H), 2.67 (d, 2H, J = 6.8Hz), 2.36 (s, 3H), 2.01 (d, 2H, J = 7.8 Hz), 1.78 (s, 3H), 0.87 (s, 6H). ¹³C NMR (75 MHz, CDCl₃) & 142.1, 139.9, 139.3, 136.2, 134.5, 126.2, 124.8, 115.3, 53.1, 43.0, 35.0, 25.2, 21.5, 19.0. HRMS (ESI) calc. for $[M+H]^+$ (C₁₈H₂₈NO₂S) 322.1835, found 322.1832.

17b: ¹H NMR (300 MHz, CDCl₃) δ 7.80 (d, 2H, J = 8.7 Hz), 7.46 (d, 2H, J = 8.7 Hz), 6.08 (d, 1H, J = 15.6 Hz), 5.51 (dt, 1H, J = 15.6, 7.8 Hz), 5.21 (t, 1H, J = 6.8 Hz), 4.87 (s, 1H), 4.85 (s, 1H), 2.66 (d, 2H, J = 6.8 Hz), 1.98 (d, 2H, J = 7.8 Hz), 1.76 (s, 3H), 0.85 (s, 6H). ¹³C NMR (75) MHz, CDCl₃) δ 142.0, 139.3, 138.7, 136.4, 129.7, 128.8, 125.8, 115.5, 53.1, 42.9, 35.0, 25.2, 18.9. HRMS (ESI) calc. for $[M+H]^+$ (C₁₆H₂₃ClNO₂S) 328.1133, found 328.1136.

17h: ¹H NMR (300 MHz, CDCl₃) δ 7.74 (d, 2H, *J* = 8.1 Hz), 7.27 (d, 2H, *J* = 8.1 Hz), 5.94 (d, 1H, *J* = 15.6 Hz), 5.59 (bs, 1H), 5.37 (dt, 1H, *J* = 15.6, 7.5 Hz), 5.09 (t, 1H, *J* = 6.9 Hz), 2.63 (d, 2H, *J* = 6.9 Hz), 2.40 (s, 3H), 2.12-1.98 (m, 4H), 1.94 (d, 2H, *J* = 7.5 Hz), 1.68-1.50 (m, 4H), 0.82 (s, 6H). ¹³C NMR (75 MHz, CDCl₃) δ 143.1, 136.8, 136.5, 135.3, 129.5, 127.8, 127.0, 121.3, 52.7, 42.7, 34.5, 25.6, 24.9, 24.5, 22.5, 22.4, 21.4. HRMS (ESI) calc. for [M+H]⁺ (C₂₀H₃₀NO₂S) 348.1992, found 348.1988.

17k: ¹H NMR (300 MHz, CDCl₃) δ 7.73 (d, 2H, *J* = 8.4 Hz), 7.27 (d, 2H, *J* = 8.4 Hz), 5.98 (d, 1H, *J* = 15.3 Hz), 5.45-5.31 (m, 2H), 4.91 (t, 1H, *J* = 6.8 Hz), 2.64 (d, 2H, *J* = 6.8 Hz), 2.40 (s, 3H), 1.95 (d, 2H, *J* = 7.5 Hz), 1.68 (d, 3H, *J* = 6.9 Hz), 1.64 (s, 3H), 0.83 (s, 6H). ¹³C NMR (75 MHz, CDCl₃) δ 143.1, 137.8, 136.8, 134.1, 129.6, 127.0, 125.3, 121.8, 52.7, 42.7, 34.5, 24.9, 21.4, 13.6, 12.0. HRMS (ESI) calc. for [M+H]⁺ (C₁₈H₂₈NO₂S) 322.1835, found 322.1831.

17k-2: Isolated as about a 6:1 mixture of *E* and *Z* olefin isomers. ¹H NMR (300 MHz, CDCl₃) δ 7.75 (d, 2H, *J* = 8.1 Hz), 7.30 (d, 2H, *J* = 8.1 Hz), 6.03 (d, 1H, *J* = 15.9 Hz), 5.63-5.53 (m, 1H), 4.96-4.86 (m, 2H), 2.66 (d, 2H, *J* = 6.9 Hz), 2.42 (s, 3H), 2.16 (q, 2H, *J* = 7.5 Hz) 1.98 (d, 2H, *J* = 7.5 Hz), 1.05 (t, 3H, *J* = 7.5 Hz), 0.89 (s, 6H). ¹³C NMR (75 MHz, CDCl₃) δ 147.4, 143.2, 136.8, 135.2, 129.6, 127.0, 124.8, 112.9, 52.8, 42.8, 34.6, 24.9, 24.8, 21.5, 12.6.

17f: ¹H NMR (300 MHz, CDCl₃) δ 7.76 (d, 2H, J = 8.1 Hz), 7.31 (d, 2H, J = 8.1 Hz), 6.02 (d, 1H, J = 15.6 Hz), 5.62 (dt, 1H, J = 15.6, 7.8 Hz), 4.96 (T, 1H, J = 6.8 Hz), 4.90 (app s, 2H), 3.63 (t, 2H, J = 6.3 Hz), 2.67 (d, 2H, J = 6.8 Hz), 2.43 (s, 3H), 2.22 (t, 2H, J = 7.7 Hz), 2.00 (d, 2H, J = 7.8 Hz), 1.67 (app quintet, 2H, J = 6.9 Hz), 0.90 (s, 9H), 0.87 (s, 6H), 0.06 (s, 6H). ¹³C NMR (75 MHz, CDCl₃) δ 145.9, 143.5, 137.2, 135.4, 130.0, 127.3, 125.5, 114.4, 63.0, 53.7, 53.2, 43.1, 35.0, 31.7, 28.6, 26.2, 25.2, 21.8, 18.6, -5.0. HRMS (ESI) calc. for [M-H]⁺ (C₂₅H₄₂NO₃SSi) 464.2649, found 464.2650.

171: ¹H NMR (300 MHz, CDCl₃) δ 7.74 (d, 2H, *J* = 8.1 Hz), 7.27 (d, 2H, *J* = 8.1 Hz), 6.09 (d, 1H, *J* = 15.6 Hz), 5.46 (dt, 1H, *J* = 15.6, 7.5 Hz), 5.06 (t, 1H, *J* = 6.7 Hz), 4.85 (s, 1H), 4.83 (s, 1H), 2.70 (d, 2H, *J* = 6.8 Hz), 2.39 (s, 3H), 2.09 (d, 2H, *J* = 7.5 Hz), 1.72 (s, 3H), 1.60-1.45 (m, 4H), 1.45-1.30 (m, 4H). ¹³C NMR (75 MHz, CDCl₃) δ 145.5, 142.1, 137.0, 136.0, 130.0, 127.4, 126.7, 115.3, 50.5, 46.3, 40.8, 35.5, 25.1, 21.8, 18.9. HRMS (ESI) calc. for [M+H]⁺ (C₁₉H₂₈NO₂S) 334.1835, found 334.1834.

17m: ¹H NMR (300 MHz, CDCl₃) δ 7.73 (d, 2H, J = 8.1 Hz), 7.27 (d, 2H, J = 8.1 Hz), 6.09 (d, 1H, J = 15.6 Hz), 5.47 (dt, 1H, J = 15.6, 7.8 Hz), 5.89-5.78 (m, 3H), 2.70 (d, 2H, J = 6.9 Hz), 2.40 (s, 3H), 2.05 (d, 2H, J = 7.8 Hz), 1.73 (s, 3H), 1.42-1.20 (m, 10H). ¹³C NMR (75 MHz, CDCl₃) δ 143.5, 142.1, 137.0, 136.1, 129.9, 127.4, 125.7, 115.4, 53.7, 49.5, 39.4, 37.1, 33.7, 26.3, 21.8, 21.6, 18.9. HRMS (ESI) calc. for [M+H]⁺ (C₂₀H₃₀NO₂S) 348.1992, found 348.1987.

17c-2: ¹H NMR (400 MHz, CDCl₃) δ 7.73 (d, 2H, *J* = 7.7 Hz), 7.29 (d, 2H, *J* = 7.7 Hz), 4.81 (m, 1H), 4.60 (t, 1H, *J* = 7.1 Hz), 2.71 (d, 2H, *J* = 7.1 Hz), 2.42 (s, 3H), 1.83 (d, 2H, *J* = 8.1 Hz), 1.61 (s, 3H), 1.60 (s, 3H), 0.86 (s, 6H). ¹³C NMR (100 MHz, CDCl₃) δ 203.3, 143.3, 137.2, 129.7, 127.1, 94.2, 84.2, 52.5, 39.8, 34.5, 24.8, 21.5, 20.5. HRMS (ESI) calc. for [M+H]⁺ (C₁₇H₂₆NO₂S) 308.1679, found 308.1685.

17d: ¹H NMR (300 MHz, CDCl₃) δ 8.13-8.07 (m, 1H), 7.88-7.82 (m, 1H), 7.76-7.71 (m, 2H), 5.31 (t, 1H, *J* = 6.9 Hz), 4.88-4.79 (m, 1H), 2.88 (d, 2H, *J* = 6.9 Hz), 1.88 (d, 2H, *J* = 7.8 Hz), 1.63 (s, 3H), 1.62 (s, 3H), 0.90 (s, 6H). ¹³C NMR (75 MHz, CDCl₃) δ 203.4, 147.9, 133.5, 132.7, 131.0, 125.2, 94.2, 83.7, 52.9, 39.6, 34.6, 24.6, 20.4. HRMS (ESI) calc. for [M+H]⁺ (C₁₆H₂₃N₂O₄S) 339.1373, found 339.1377.

17e: ¹H NMR (300 MHz, CDCl₃) δ 7.93-7.86 (m, 4H), 7.52-7.40 (m, 6H), 4.88-4.79 (m, 1H), 2.88 (br, 1H), 2.76 (t, 2H, *J* = 6.9 Hz), 1.88 (d, 2H, *J* = 8.1 Hz), 1.59 (s, 3H), 1.58 (s, 3H), 0.90 (s, 6H). ¹³C NMR (75 MHz, CDCl₃) δ 203.1, 133.4, 132.1, 132.0, 131.7, 128.5, 128.3, 94.0, 84.3, 50.4, 39.9, 34.9, 34.8, 24.7, 20.4. HRMS (ESI) calc. for [M+H]⁺ (C₂₂H₂₉NOP) 354.1981, found 354.1988.

17g: ¹H NMR (300 MHz, CDCl₃) δ 7.79 (d, 2H, J = 8.7 Hz), 6.96 (d, 2H, J = 8.7 Hz), 4.90-4.81 (m, 2H), 3.85 (s, 3H), 2.68 (d, 2H, J = 6.9 Hz), 2.04-1.98 (m, 4H), 1.84 (d, 2H, J = 8.1 Hz), 1.57-1.43 (m, 6H), 0.86 (s, 6H).¹³C NMR (75 MHz, CDCl₃) δ 199.8, 162.6, 131.6, 129.0, 114.1, 101.3, 83.9, 55.5, 52.3, 40.1, 34.4, 31.4, 27.2, 25.9, 24.6. HRMS (ESI) calc. for [M+H]⁺ (C₂₀H₃₀NO₃S) 364.1941, found 364.1950.

17i: ¹H NMR (300 MHz, CDCl₃) δ 7.81 (d, 2H, *J* = 8.4 Hz), 7.33 (d, 2H, *J* = 8.4 Hz), 7.07 (s, 1H), 4.87 (app septet, 1H, *J* = 3.0 Hz), 3.79 (s, 2H), 2.49 (s, 3H), 1.65 (s, 3H), 1.64 (s, 3H), 0.97 (s, 6H). ¹³C NMR (75 MHz, CDCl₃) δ 200.0, 144.7, 133.7, 129.6, 128.6, 97.3, 96.5, 86.1, 35.8, 25.0, 21.6, 20.6. HRMS (ESI) calc. for [M+H]⁺ (C₁₆H₂₄NO₃S) 310.1471, found 310.1478.

18j: ¹H NMR (300 MHz, CDCl₃) δ 7.81 (d, 2H, J = 8.1 Hz), 7.33 (d, 2H, J = 8.1 Hz), 7.03 (s, 1H), 4.92-4.86 (m, 1H), 4.01 (t, 2H, J = 6.9 Hz), 2.44 (s, 3H), 2.25 (q, 2H, J = 6.9 Hz), 2.08-2.02 (m, 4H), 1.60-1.46 (m, 6H).¹³C NMR (75 MHz, CDCl₃) δ 199.0, 144.7, 133.5, 129.6, 128.5, 103.0, 84.1, 31.5, 28.2, 27.3, 26.0, 21.6.

20a: ¹H NMR (400 MHz, CDCl₃) δ 7.14 (d, 1H, *J* = 8.8 Hz), 7.03 (d, 1H, *J* = 2.4 Hz), 6.84 (m, 2H), 4.96 (m, 1H), 3.85 (s, 3H), 3.70 (s, 3H), 3.66 (s, 3H), 3.44 (s, 2H), 2.65 (d, 2H, *J* = 7.6 Hz), 2.13 (m, 4H), 1.60 (m, 6H). ¹³C NMR (100 MHz, CDCl₃) δ 200.5, 171.6, 153.8, 132.0, 128.8, 111.7, 109.8, 107.8, 102.4, 100.9, 83.1, 58.8, 55.9, 52.3, 32.8, 32.7, 31.5, 27.4, 27.1, 26.0.

21a: ¹H NMR (400 MHz, CDCl₃) δ 7.66 (s, 1H), 7.25 (d,1H, *J* = 8.4 Hz), 7.11 (d, 1H, *J* = 8.4 Hz), 6.90 (s, 1H), 4.90 (m, 1H), 3.71 (s, 3H), 3.68 (s, 6H), 3.41 (s, 2H), 2.62 (d, 2H, *J* = 7.6 Hz), 2.15 (m, 4H), 1.60 (m, 6H). ¹³C NMR (100 MHz, CDCl₃) δ 200.7, 171.3, 135.2, 130.1, 129.5, 124.2, 121.6, 112.4, 110.7, 108.0, 102.5, 82.9, 58.5, 52.4, 32.9, 32.7, 31.6, 27.2, 27.1, 26.0.

19a: ¹H NMR (400 MHz, CDCl₃) δ . 7.57 (d, 1H, *J* = 8.0 Hz), 7.27 (m, 1H), 7.19 (dt, 1H, *J* = 7.2, 0.8 Hz), 7.09 (dt, 1H, *J* = 8.0, 0.8 Hz), 6.86 (s, 1H), 4.96 (m, 1H), 3.73 (s, 3H), 3.67 (s, 6H), 3.48 (s, 2H), 2.63 (d, 2H, *J* = 7.6 Hz), 1.73 (s, 3H), 1.73 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 203.8, 171.5, 136.6, 128.6, 128.1, 121.4, 118.9, 118.8, 109.1, 108.4, 95.2, 83.4, 58.9, 52.2, 32.6, 32.6, 27.6, 20.6.

18c: ¹H NMR (300 MHz, CDCl₃) δ 7.65 (d, 2H, J = 8.4 Hz), 7.26 (d, 2H, J = 8.4 Hz), 5.00 (d, 1H, J = 8.5 Hz), 4.34 (app q, 1H, J = 8.5 Hz), 3.20 (d, 1H, J = 9.9 Hz), 3.10 (d, 1H, J = 9.9 Hz), 2.40 (s, 3H), 1.74 (dd, 1H, J = 12.6, 7.2 Hz), 1.66 (s, 3H), 1.61 (s, 3H), 1.40 (dd, 1H, J = 12.6, 8.5 Hz), 1.03 (s, 3H), 0.77 (s, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 143.1, 136.8, 133.1, 129.5, 127.7, 126.8, 61.2, 58.0, 48.1, 37.7, 26.7, 26.3, 26.0, 21.8, 18.2. HRMS (ESI) calc. for [M+H]⁺ (C₁₇H₂₆NO₂S) 308.1679, found 308.1675. Enantiopurity was determined by HPLC analysis (Chiralpak AD-H column, 98:2 hexanes/ethanol, 1 mL/min) t_R 8.9 min (minor), 11.6 min (major). Absolute configuration was assigned by comparison with a previous report, and the rest of the products were assigned by analogy⁴.

18a: ¹H NMR (300 MHz, CDCl₃) δ 7.38 (s, 2H), 7.15 (s, 1H), 5.01 (d, 1H, *J* = 9 Hz), 4.36 (dd, 1H, *J* = 16.2, 9 Hz), 3.24 (d, 1H, *J* = 9.9 Hz), 3.10 (d, 1H, *J* = 9.9 Hz), 2.36 (s, 6H), 1.75 (dd, 1H, *J* = 12.3, 7.2 Hz), 1.68 (s, 3H), 1.64 (s, 3H), 1.41 (dd, 1H, *J* = 12.3, 9 Hz), 1.04 (s, 3H), 0.81 (s, 3H). NMR (75 MHz, CDCl₃) δ 139.1, 138.4, 133.8, 132.8, 126.4, 124.9, 60.8, 57.7, 47.8, 37.3, 26.4, 25.9, 25.6, 21.2, 17.9. HRMS (ESI) calc. for [M+H]⁺ (C₁₈H₂₈NO₂S) 322.1835, found 322.1830. Enantiopurity was determined by HPLC analysis (Chiralpak AS-H column, 99.5:0.5 hexanes/ethanol, 1 mL/min) t_R 11.5 min (minor), 14.5 min (major).

18b: ¹H NMR (300 MHz, CDCl₃) δ 7.72 (dt, 2H, J = 8.7, 2.1 Hz), 7.45 (dt, 2H, J = 8.7, 2.1 Hz), 4.91 (doublet of septets, 1H, J = 9.3, 1.2 Hz), 4.43 (ddd, 1H, J = 9.3, 8.7, 7.5 Hz), 3.29 (dd, 1H, J = 9.9, 1.2 Hz), 3.09 (d, 1H, J = 9.9 Hz), 1.80 (ddd, 1H, J = 12.6, 7.5, 1.2 Hz), 1.68 (d, 3H, J = 1.2 Hz), 1.62 (d, 3H, J = 1.2 Hz), 1.42 (dd, 1H, J = 12.6, 8.7 Hz), 1.06 (s, 3H), 0.88 (s, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 138.9, 138.8, 133.9, 129.1, 129.0, 126.2, 61.1, 58.1, 48.1, 37.8, 26.5, 26.3, 25.9, 18.2. Enantiopurity was determined by HPLC analysis (Chiralpak AS-H column, 99:1 hexanes/ethanol, 1 mL/min) t_R 14.1 min (minor), 15.5 min (major).

18h: ¹H NMR (300 MHz, CDCl₃) δ 7.69 (d, 2H, *J* = 8.1 Hz), 7.28 (d, 2H, *J* = 8.1 Hz), 4.99 (d, 1H, *J* = 9 Hz), 4.41 (dd, 1H, *J* = 16.2, 8.7 Hz), 3.24 (d, 1H, *J* = 9.9 Hz), 3.13 (d, 1H, *J* = 9.9 Hz),

2.42 (s, 3H), 2.30-2.05 (m, 2H), 2.05-1.95 (m, 2H), 1.80-1.32 (m, 8H), 1.05 (s, 3H), 0.79 (s, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 142.8, 140.6, 136.5, 129.2, 127.4, 123.2, 61.0, 56.9, 37.4, 36.8, 29.0, 28.1, 27.5, 26.7, 26.4, 26.0, 21.5. HRMS (ESI) calc. for [M+H]⁺ (C₂₀H₃₀NO₂S) 348.1992, found 348.1988. Enantiopurity was determined by HPLC analysis (Chiralpak AS-H column, 99:1 hexanes/ethanol, 1 mL/min) t_R 13.4 min (minor), 14.9 min (major).

18k: Using **4d** as starting material, **5d** was isolated as a 4.7:1 mixture of olefin isomers favoring the *E* isomer. Using **4e** as starting material, the product was isolated as a 2:1 mixture of isomers favoring the *Z* isomer. NMR data are reported for the 4.7:1 mixture. The *E* and *Z* isomers were assigned on the basis of a 2D ¹H-¹H NOESY experiment. ¹H NMR (300 MHz, CDCl₃) δ 7.67 (d, 2H, *J* = 8.4 Hz), 7.30-7.25 (m, 2H), 5.02-4.96 (m, 1H), 4.45-4.35 (m, 1H), 3.30-3.20 (m, 1H), 3.17-3.09 (m, 1H), 2.41 (s, 3H), 2.24-2.14 (m, 0.18H), 2.07-1.87 (m, 0.18H), 1.91 (q, 1.48H, *J* = 7.4 Hz), 1.76 (ddd, 0.82H, *J* = 12.6, 8.4, 1.2 Hz), 1.80-1.70 (m, 0.18H), 1.67 (d, 2.46H, *J* = 0.9 Hz), 1.62 (d, 0.54H, *J* = 1.2 Hz), 1.47-1.35 (m, 1H), 1.06 (s, 2.46H), 1.05 (s, 0.54H), 1.01 (t, 0.54H, *J* = 7.5 Hz), 0.91 (t, 2.46H, *J* = 7.4 Hz), 0.82 (s, 2.46H), 0.80 (s, 0.54H). ¹³C NMR (75 MHz, CDCl₃) δ 142.8, 137.9, 136.7, 129.2, 127.3, 124.8, 60.9, 57.6, 47.9, 37.4, 32.0, 26.4, 26.0, 21.5, 16.3, 12.0. HRMS (ESI) calc. for [M+H]⁺ (C₁₈H₂₈NO₂S) 322.1835, found 322.1832. Enantiopurity was determined by HPLC analysis (Chiralpak AD-H column, 99.5:0.5 hexanes/ethanol, 1 mL/min) t_R 15.5 min (*Z* diastereomer, minor enantiomer), 17.0 min (*E* diastereomer, minor enantiomer), 18.5 min (*Z* diastereomer, major enantiomer), 26.4 min (*E* diastereomer, major enantiomer).

18f: Isolated as a 78:22 mixture of olefin isomers. ¹H NMR (600 MHz, CDCl₃) δ 7.68-7.64 (m, 2H), 7.28-7.26 (m, 2H), 5.05-5.02 (m, 1H), 5.04 (m, 0.22H), 4.41-4.35 (m, 1H), 3.60 (t, 0.44H, *J* = 6.3 Hz), 3.57 (t, 1.56H, *J* = 6.6 Hz), 3.25-3.20 (m, 1H), 3.14-3.10 (m, 1H), 2.41 (s, 3H), 2.32-2.25 (m, 0.22H), 1.97-1.92 (m, 1.77H), 1.78-1.73 (m, 1.23H), 1.67 (d, 2.34H, *J* = 0.6 Hz), 1.63 (d, 0.66H, *J* = 0.6 Hz), 1.61-1.47 (m, 2H), 1.45-1.39 (m, 1H), 1.05 (s, 2.34H), 1.04 (s, 0.66H), 0.892 (s, 7.02H), 0.888 (s, 1.98H), 0.80 (s, 2.34H), 0.79 (s, 0.66H), 0.06 (s, 4.68H), 0.06 (s, 1.32H). ¹³C NMR (75 MHz, CDCl₃) δ 162.3, 142.8, 136.5, 136.1, 129.2, 127.4, 127.2, 62.9, 60.8, 57.3, 48.2, 37.4, 31.4, 28.3, 26.4, 25.9, 23.2, 21.5, 18.3, -5.3. HRMS (ESI) calc. for [M+H]⁺ (C₂₅H₄₄NO₃SSi) 466.2806, found 466.2805. Enantiopurity was determined by HPLC analysis after deprotection of the alcohol with tetrabutylammonium fluoride (Regis Technologies Whelk-O1 column, 97:3 hexanes/ethanol, 1 mL/min) t_R 51.4 min (*Z* diastereomer, minor enantiomer), 57.1 min (*Z* diastereomer, major enantiomer), 73.1 min (*E* diastereomer, minor enantiomer), 83.3 min (*E* diastereomer, major enantiomer).

181: ¹H NMR (300 MHz, CDCl₃) δ 7.67 (d, 2H, J = 8.1 Hz), 7.28 (d, 2H, J = 8.1 Hz), 5.06 (d, 1H, J = 8.3 Hz), 4.30 (app q, 1H, J = 8.3 Hz), 3.26 (d, 1H, J = 9.9 Hz), 3.20 (d, 1H, J = 9.9 Hz), 2.42 (s, 3H), 1.84 (dd, 1H, J = 12.3, 7.2 Hz), 1.68 (s, 3H), 1.64 (s, 3H), 1.63-1.45 (m, 7H), 1.25-1.15 (m, 2H). ¹³C NMR (75 MHz, CDCl₃) δ 143.1, 136.6, 133.0, 129.5, 127.7, 126.9, 59.8, 58.3, 48.9, 46.4, 37.2, 36.7, 26.0, 24.9, 24.8, 21.8, 18.3. HRMS (ESI) calc. for [M+H]⁺ (C₁₉H₂₈NO₂S) 334.1835, found 334.1832. Enantiopurity was determined by HPLC analysis (Chiralpak AS-H column, 99:1 hexanes/ethanol, 1 mL/min) t_R 20.7 min (minor), 28.1 min (major).

18m: ¹H NMR (300 MHz, CDCl₃) δ 7.67 (d, 2H, J = 8.4 Hz), 7.28 (d, 2H, J = 8.4 Hz), 5.06 (d, 1H, J = 8.5 Hz), 4.30 (app q, 1H, J = 8.5 Hz), 3.36 (d, 1H, J = 10.2 Hz), 3.10 (d, 1H, J = 10.2 Hz), 2.42 (s, 3H), 1.83 (dd, 1H, J = 12.63, 7.2 Hz), 1.67 (s, 3H), 1.64 (s, 3H), 1.48-1.22 (m, 9H), 1.10-1.00 (m, 2H). ¹³C NMR (75 MHz, CDCl₃) δ 143.1, 136.4, 132.9, 129.5, 127.7, 126.9, 58.7, 57.3, 46.1, 41.4, 36.8, 34.7, 26.2, 26.0, 24.0, 23.2, 23.2, 21.8, 18.3. HRMS (ESI) calc. for [M+H]⁺ (C₁₉H₂₈NO₂S) 334.1992, found 334.1990. Enantiopurity was determined by HPLC analysis (Chiralpak AS-H column, 99:1 hexanes/ethanol, 1 mL/min) t_R 22.1 min (minor), 28.5 min (major).

18d: ¹H NMR (300 MHz, CDCl₃) δ 7.93-7.87 (m, 1H), 7.63-7.55 (m, 3H), 4.72-4.62 (m, 2H), 3.57 (dd, 1H, *J* = 10.5, 0.6 Hz), 3.16 (d, 1H, *J* = 10.2 Hz), 1.89-1.82 (m, 1H), 1.64 (s, 3H), 1.48-1.44 (m, 1H), 1.39 (s, 3H), 1.09 (s, 3H), 1.07 (s, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 147.7, 135.4, 135.2, 132.8, 131.0, 130.8, 124.5, 123.7, 61.3, 57.8, 47.8, 44.4, 37.5, 25.5, 25.4, 17.7. HRMS (ESI) calc. for [M+H]⁺ (C₁₆H₂₃N₂O₄S) 339.1373, found 339.1376. Enantiopurity was determined by HPLC analysis (Chiralpak IA column, 98:2 hexanes/isopropanol, 1 mL/min) t_R 11.7 min (major), 12.6 min (minor).

18e: ¹H NMR (300 MHz, CDCl₃) δ 7.95-7.81 (m, 4H), 7.44-7.31 (m, 6H), 5.08 (d, 1H, *J* = 9.3 Hz), 4.39 (app quintet, 1H, *J* = 8.4 Hz), 3.05-2.88 (m, 2H), 3.16 (d, 1H, *J* = 10.2 Hz), 1.82 (dd, 1H, *J* = 12.3, 7.5 Hz), 1.42 (dd, 1H, *J* = 12.6, 8.7 Hz), 1.36 (s, 3H), 1.17 (s, 3H), 1.04 (s, 3H), 0.92 (s, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 134.3, 133.6, 132.8, 132.6, 132.3, 131.9, 131.5, 131.1, 131.0, 128.3, 128.2, 127.9, 127.7, 60.1, 56.3, 48.6, 38.8, 26.1, 25.2, 16.7. HRMS (ESI) calc. for [M+H]⁺ (C₂₂H₂₉NOP) 354.1981, found 354.1988. Enantiopurity was determined by HPLC analysis (Chiralpak IA column, 98:2 hexanes/isopropanol, 1 mL/min) t_R 34.5 min (major), 42.4 min (minor).

18g ¹H NMR (300 MHz, CDCl₃) δ 7.79-7.71 (m, 2H), 7.00-6.92 (m, 2H), 5.00 (d, 9H), 4.39 (dd, 1H, *J* = 16.2, 9 Hz), 3.87 (s, 3H), 3.23 (d, 1H, *J* = 9.9 Hz), 3.13 (d, 1H, *J* = 9.9 Hz), 2.30-1.96 (m, 4H), 1.80-1.33 (m, 8 H), 1.05 (s, 3H), 0.79 (s, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 162.5, 140.4, 131.3, 129.4, 123.3, 113.7, 61.0, 56.8, 55.5, 48.4, 37.3, 36.9, 29.0, 28.2, 27.5, 26.7, 26.4, 26.0. HRMS (ESI) calc. for [M+H]⁺ (C₂₀H₃₀NO₃S) 364.1941, found 364.1934. Enantiopurity was determined by HPLC analysis (Chiralpak AS-H column, 98:2 hexanes/ethanol, 1 mL/min) t_R 25.0 min (minor), 30.1 min (major).


18i: ¹H NMR (300 MHz, CDCl₃) δ 7.88 (d, 2H, J = 8.1 Hz), 7.37 (d, 2H, J = 8.1 Hz), 5.21 (d, 1H, J = 9.6 Hz), 4.17 (d, 1H, J = 9.6 Hz), 3.57 (d, 1H, J = 8.1 Hz), 3.42 (d, 1H, J = 8.1 Hz), 2.46 (s, 3H), 1.83 (s, 3H), 1.76 (s, 3H), 1.08 (s, 3H), 0.94 (s, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 144.8, 137.4, 132.3, 129.6, 129.4, 119.2, 80.3, 66.4, 47.7, 26.3, 21.7, 21.1, 18.3. HRMS (ESI) calc. for [M+H]⁺ (C₁₆H₂₄NO₃S) 310.1471, found 310.1468. Enantiopurity was determined by HPLC analysis (Chiralpak AS-H column, 99:1 hexanes/ethanol, 1 mL/min) t_R 16.3 min (minor), 19.1 min (major).

18j: ¹H NMR (300 MHz, CDCl₃) δ 7.85 (d, 2H, J = 8.1 Hz), 7.34 (d, 2H, J = 8.1 Hz), 5.13 (d, 1H, J = 8.7 Hz), 5.05-4.97 (m, 1H), 4.08-3.96 (m, 2H), 2.44 (s, 3H), 2.41-1.96 (m, 6H), 1.63-1.55 (m, 6H). ¹³C NMR (75 MHz, CDCl₃) δ 144.9, 144.0, 133.4, 129.7, 129.3, 120.4, 70.1, 56.7, 37.0, 36.7, 29.3, 28.4, 27.7, 26.7, 21.8. Enantiopurity was determined by HPLC analysis (Chiralpak AS-H column, 98:2 hexanes/ethanol, 1 mL/min) t_R 14.2 min (minor), 29.7 min (major).

20b: ¹H NMR (400 MHz, CDCl₃) δ 7.11 (d, 1H, J = 8.8 Hz), 6.97 (d, 1H, J = 2.4 Hz), 6.83 (dd, 1H, J = 8.8, 2.4 Hz), 5.06 (d, 1H, J = 9.2 Hz), 4.11 (q, 1H, J = 8.8 Hz), 3.86 (s, 3H), 3.78 (s, 3H), 3.65 (s, 3H), 3.55 (s, 3H), 3.45 (d, 1H, J = 15.6 Hz), 3.23 (dd, 1H, J = 15.2, 1.6 Hz), 2.66 (ddd, 1H, J = 13.6, 6.4, 1.6 Hz), 2.35 (m, 2H), 2.14 (m, 2H), 1.98 (dd, 1H, J = 13.6, 9.2 Hz), 1.61 (m, 6H). ¹³C NMR (100 MHz, CDCl₃) δ 172.2, 171.4, 153.7, 141.1, 136.9, 133.0, 126.7, 123.1, 110.8, 109.2, 105.8, 100.3, 56.0, 54.3, 52.7, 52.6, 37.0, 36.8, 30.3, 28.9, 28.5, 27.7, 27.6, 26.8. Enantiopurity was determined by HPLC analysis (Chiralpak IA column, 98:2 hexanes/isopropanol, 1 mL/min) t_R 19.7 min (minor), 27.2 min (major).

21b: ¹H NMR (400 MHz, CDCl₃) δ 7.61 (d, 1H, J = 2.0 Hz), 7.23 (dd, 1H, J = 8.8, 2.0 Hz), 7.08 (d, 1H, J = 8.8 Hz), 5.04 (d, 1H, J = 9.2 Hz), 4.11 (q, 1H, J = 9.6 Hz), 3.77 (s, 3H), 3.65 (s, 3H), 3.56 (s, 3H), 3.41 (d, 1H, J = 15.2 Hz), 3.19 (dd, 1H, J = 15.6, 2.0 Hz), 2.65 (dd, 1H, J = 11.6, 4.8 Hz), 2.34 (m, 2H), 2.13 (m, 2H), 1.97 (dd, 1H, J = 13.6, 9.2 Hz), 1.61 (m, 6H). ¹³C NMR (100 MHz, CDCl₃) δ 172.0, 171.2, 141.7, 137.6, 136.3, 128.1, 123.7, 122.5, 120.6, 112.0, 110.0, 106.0, 54.1, 52.8, 52.7, 37.0, 36.8, 30.4, 30.3, 28.9, 28.4, 27.7, 27.4, 26.7. Enantiopurity was determined by HPLC analysis (Chiralpak IA column, 98:2 hexanes/isopropanol, 1 mL/min) t_R 11.4 min (minor), 21.5 min (major).


19b: ¹H NMR (400 MHz, CDCl₃) δ 7.54 (d, 1H, *J* = 7.6 Hz), 7.29 (d, 1H, *J* = 8.0 Hz), 7.22 (t, 1H, *J* = 7.2 Hz), 7.13 (t, 1H, *J* = 7.6 Hz), 5.16 (d, 1H, *J* = 9.2 Hz), 4.11 (q, 1H, *J* = 8.8 Hz), 3.81 (s, 3H), 3.69 (s, 3H), 3.59 (s, 3H), 3.51 (d, 1H, *J* = 8.4 Hz), 3.30 (dd, 1H, *J* = 15.6, 2.0 Hz), 2.73 (dd, 1H, *J* = 13.6, 6.4, 1.6 Hz), 2.02 (dd, 1H, *J* = 13.2 Hz, 9.2 Hz), 1.88 (s, 3H, 1.81 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 172.3, 171.3, 137.7, 136.2, 133.3, 126.5, 126.4, 121.0, 118.8, 118.0, 108.6, 106.3, 54.2, 52.7, 52.6, 36.3, 31.2, 30.0, 27.5, 25.6, 17.8. Enantiopurity was determined by HPLC analysis (Chiralpak AS-H column, 99:1 hexanes/isopropanol, 1 mL/min) t_R 8.4 min (major), 9.7 min (minor).




Supporting Figure 3. Reaction analyzed by mass spectrometry.

Studies of reaction intermediate by TOF-MS

A one-dram screw cap vial was charged with catalyst **S6** (0.01 mmol), substrate **1** (0.1 mmol), and fluorobenzene (0.2 mL). The mixture was stirred for 14 h. 0.1 mL of the mixture was diluted with 1 mL CH₃CN, and this solution was analyzed by TOFMS⁻ (negative mode). A peak fully consistent with the proposed intermediate was observed at 1198.43. The peak had an isotopic distribution in excellent agreement with the theoretical pattern (Supporting Figure 4). This species was then subjected to further ionization (TOFMSMS⁻), which revealed a fragment corresponding to the regenerated catalyst as the sole negative ion with mass of 892.26 (Supporting Figure 5).



Supporting Figure 4. Comparison of measured and theoretical isotopic mass distributions for the observed intermediate.




Supporting Figure 5. MS/MS of the intermediate ion yields a fragmentation peak corresponding to reformed catalyst.

References

- 1. Sattely E. S., Meek S. J., Malcolmson S. J., Schrock R. R., Hoveyda A. H. J. Am. Chem. Soc. 2009, 131, 943–953.
- 2. Zhang Z., Bender C. F., Widenhoefer R. A. J. Am. Chem. Soc. 2007, 129, 14148–14149.
- a) Laird T., Ollis W. D., Sutherland I. O. J. Chem. Soc., Perkin Trans. 1980, 1, 2033–2048. b) LaLonde, R. L., Sherry B. D., Kang E. J., Toste F. D. J. Am. Chem. Soc. 2007, 129, 2452–2453.
- 4. Gironès J., Duran J., Polo A., Real J. Chem. Commun. 2003, 1776-1778.


¹H NMR

JW-02-171 AV-300 Dual C-H probe proton starting parameters 7/23/03




4b 1 H NMR

 $_{\rm JW-02-190p1~AVQ-400~QNP}$ Proton starting parameters. 7/16/03. Revised



Sample ID: JW-02-178 Filename: C:\EZStart\Projects\Default\Data\JWu\JW-02-178_OJ995005IP_55min.met10-9-2009 2-59-06 PM.dat Method: C:\EZStart\Projects\Default\Method\JWu\OJ\JW-OJ995005_55min_pt5.met Injection volume: 5 uL

Description: {Data Description}




1: 210 mm,	4 nm Results Retention Time	Area	Area Percent
	34.661	6319455	49.919
	47.600	6339932	50.081


Sample ID: JW-02-181 Filename:


C:\EZStart\Projects\Default\Data\JWu\JW-02-181_0J995005IP_55min.met10-9-2009 9-42-08 AM.dat Method:


```
C:\EZStart\Projects\Default\Method\JWu\OJ\JW-OJ995005_45min_pt5.met
Injection volume: 5 uL
```

















Description: {Data Description}





1: 210 nm, 4 nm Results		
Retention Time	Area	Area Percent
18.784	6620440	53.134
22.021	5839511	46.866

JW-02-189 AVQ-400 QNP Proton starting parameters. 7/16/03. Revised 7





































Jual C-H probe proton starting parameters 7/23









.Dual C-H probe proton starting parameters 7/23







Dual C-H probe proton starting parameters 7/23









Dual C-H probe proton starting parameters 7/23





AV-300 Dual C-H probe proton starting parameters 7/23/03 RN.






















" AV-300 Dual C-H probe proton starting parameters 7/23/03 RN.
























































Copies of HPLC traces (racemic on top)

18a

```
Sample ID:VRT-1-152D-RacFilename:C:\EZStart\Projects\Default\Data\Vivek\Hydroamination\VRT-1-152D_Rac-AS99505-30min.met3-19-2010 4-15-43 PM.datC:\EZStart\Projects\Default\Method\Vivek\AS99505ET-30min.metC:\EZStart\Projects\Default\Method\Vivek\AS99505ET-30min.metInjection volume:1 uL
```


```
Description: {Data Description}
```



1: 230 nm,	4 nm Results		
	Retention Time	Area	Area Percent
	11.829	2417646	49.976
	14.400	2419995	50.024

```
Sample ID:VRT-1-152DFilename:C:\EZStart\Projects\Default\Data\Vivek\Hydroamination\VRT-1-152DAS99505-30min.met3-19-2010 4-36-34 PM.datMethod:C:\EZStart\Projects\Default\Method\Vivek\AS99505ET-30min.metInjection volume:2 uL
```


Description: {Data Description}



4: 220 nm,	4 nm Results		
	Retention Time	Area	Area Percent
	11.541	408348	4.370
	14.512	8936979	95.630


Sample ID:JW-03-107DFilename:C:\EZStart\Projects\Default\Data\JWu\JW-03-107D_AS9901ET_40min.met3-16-201012-34-05 AM.datMethod:C:\EZStart\Projects\Default\Method\Vivek\AS9901ET-40min.metInjection volume:5 uL

```
Description: {Data Description}
```



	Sample ID:	JW-03-107D	chiral
	Filename:		
C:\E2	ZStart\Project	s\Default\Data\J	Wu\JW-03-107Dchiral_AS9901ET_30min.met3-16
-2010	0 1-19-42 PM.0	iat Met	hod:
C:\E2	ZStart\Project	s\Default\Method	\Vivek\AS9901Et-30min.met
Injec	ction volume:	5 uL	

Description: {Data Description}




18b


18c

```
Sample ID:JW-03-107BFilename:C:\EZStart\Projects\Default\Data\JWu\JW-03-107B_AS9901ET_40min.met3-15-201011-20-55 PM.datMethod:C:\EZStart\Projects\Default\Method\Vivek\AS9901ET-40min.metInjection volume:5 uL
```


Description: {Data Description}




2: 254 nm	, 4 nm Results		
	Retention Time	Area	Area Percent
	19.035	948215	51.478
	22.624	893783	48.522











C:\EZStart\Projects\Default\Data\glh\VRT-152G_IA995005Et_50min.met3-18-2010 10-51-12 PM.dat



18e

```
JW-03-107C
C:\EZStart\Projects\Default\Method\wataru\IC 100%D 1ml min 60min.met
3/17/2010 9:07:14 AM
C:\EZStart\Projects\Default\Data\Jeff\JW-03-107C_IA9802IP_45min3-16-2010
4-38-51 PM.dat
```





Retention Time	Area	Area Percent	Lambda Max
35.224	4058715	52.359	206
42.404	3692945	47.641	205

JW-03-107Cchiral

C:\EZStart\Projects\Default\Method\wataru\IC 100%D 1ml min 60min.met 3/17/2010 2:59:32 PM


C:\EZStart\Projects\Default\Data\Jeff\JW-03-107Cchiral.dat





Sample ID: VRT-1-133C-Racemic Filename: C:\EZStart\Projects\Default\Data\Vivek\Hydroamination\VRT-1-133C-RacemicWH97 03ET-90min.met3-20-2010 3-50-04 PM.dat Method: C:\EZStart\Projects\Default\Method\Vivek\WH9703ET-90min.met Injection volume: 1 uL


Description: {Data Description}



1:	230	nm,	4 nm Results		
			Retention Time	Area	Area Percent
			51.648	475163	12.333
			57.611	487115	12.644
			73.504	1420619	36.874
			83.488	1469762	38.149

Sample ID:VRT-1-152FFilename:C:\EZStart\Projects\Default\Data\Vivek\Hydroamination\VRT-1-152FWH9703ET-90min.met3-20-2010 5-26-36 PM.datMethod:C:\EZStart\Projects\Default\Method\Vivek\WH9703ET-90min.metInjection volume:1 uL

Description: {Data Description}




21 200 11,	Retention Time	Area	Area Percent
	51.429	35226	0.505
	57.104	5525286	79.170
	73.056	1279889	18.339
	83.264	138592	1.986

18f

Sample ID:VRT-1-154C-RacemicFilename:C:\EZStart\Projects\Default\Data\Vivek\Hydroamination\VRT-1-154C-RacemicAS9802-40min.met3-19-2010 1-35-31 PM.datC:\EZStart\Projects\Default\Method\Vivek\AS9802-40min.metInjection volume:2 uL


Description: {Data Description}



± .	Retention Ti	me Area	Area	Percent
_	24.8	375 20418087		50.126
	30.7	20315717	1	49.874

Sample ID:VRT-1-154CFilename:Filename:C:\EZStart\Projects\Default\Data\Vivek\Hydroamination\VRT-1-154C-AS9802-40minn.met3-19-2010 2-17-34 PM.datMethod:C:\EZStart\Projects\Default\Method\Vivek\AS9802-40min.metInjection volume:2 uL

Description: {Data Description}



Retention Time	Area	Area Percent
25.003	759114	1.467
30.112	50996378	98.533

18g

 Sample ID:
 VRT-1-139-7-rac

 Filename:
 Filename:

 C:\EZStart\Projects\Default\Data\Vivek\Hydroamination\VRT-1-139-7-racAS9901E


 t-30min.met2-15-2010
 7-40-36

 PM.dat
 Method:

 C:\EZStart\Projects\Default\Method\Vivek\AS9901Et-30min.met

 Injection volume:
 5 uL


Description: {Data Description}



1: 230 1	nm, 4 nm Results Retention Time	Area	Area Percent
	17.584	7213123	55.650
	19.691	5748433	44.350

Sample ID:VRT-1-139-7Filename:C:\EZStart\Projects\Default\Data\Vivek\Hydroamination\VRT-1-139-7AS9901Et-30min.met2-15-2010 8-12-29 PM.datMethod:C:\EZStart\Projects\Default\Method\Vivek\AS9901Et-30min.metInjection volume:5 uL

Description: {Data Description}




Retention Time	Area	Area Percent
17.184	724444	2.884
18.997	24397158	97.116

18h

Sample ID: JW-03-108C Filename: C:\EZStart\Projects\Default\Data\JWu\JW-03-108c_AS9901ET_40min.met3-16-2010 10-23-08 PM.dat Method: C:\EZStart\Projects\Default\Method\Vivek\AS9901ET-40min.met Injection volume: 5 uL

Description: {Data Description}



1: 2	210 nm,	4 nm Results Retention Time	Area	Area Percent
		Recention lime	Area	Area Percent
		15.947	14518430	50.435
		19.237	14268032	49.565

```
Sample ID: JW-03-108Cchiral

Filename:


C:\EZStart\Projects\Default\Data\JWu\JW-03-108cChiral_AS9901ET_40min.met3-16

-2010 11-36-11 PM.dat Method:

C:\EZStart\Projects\Default\Method\Vivek\AS9901ET-40min.met

Injection volume: 5 uL
```


Description: {Data Description}





18i

Sample ID:VRT-1-145B-RacFilename:C:\EZStart\Projects\Default\Data\Vivek\Hydroamination\VRT-1-145B-RacAS9802-3Omin.met2-25-20102-55-10PM.datC:\EZStart\Projects\Default\Method\Vivek\AS9802-30min.metInjection volume:5 uL

Description: {Data Description}








18j

18k

```
Sample ID:15-174AFilename:C:\EZStart\Projects\Default\Data\Nathan\ns15-174A-12-19-2009 1-19-37PM-AD995005ET.met.datMethod:C:\EZStart\Projects\Default\Method\Nathan\AD995005ET 45min.metInjection volume:4 uL
```


Description: {Data Description}



Retention Time	Area	Area Percent
14.821	443995	8.802
15.808	2067084	40.980
16.885	494466	9.803
22.096	2038556	40.415

```
Sample ID:VRT-1-137EFilename:C:\EZStart\Projects\Default\Data\Vivek\Hydroamination\VRT-1-137EVRT-1-136D.met2-11-2010 7-29-21 AM.datMethod:C:\EZStart\Projects\Default\Method\Vivek\VRt-1-136D.metInjection_volume:2 uL
```

Description: {Data Description}



Retention Time	Area	Area Percent
15.579	39375	0.781
17.077	107920	2.139
18.437	803826	15.935
26.421	4093302	81.145

18l

```
Sample ID: JW-03-108A

Filename:


C:\EZStart\Projects\Default\Data\JWu\JW-03-108A_AS9901ET_40min.met3-16-2010

7-57-01 PM.dat Method:

C:\EZStart\Projects\Default\Method\Vivek\AS9901ET-40min.met

Injection volume: 5 uL
```

```
Description: {Data Description}
```




1: 210 nm, 4 nm Results		
Retention Time	Area	Area Percent
20.219	5234845	48.972
27.984	5454555	51.028

Sample ID: VRT-1-152B

Filename: C:\EZStart\Projects\Default\Data\Vivek\Hydroamination\VRT-1-152BAS9901ET-40m in.met3-10-2010 10-10-04 PM.dat Method: C:\EZStart\Projects\Default\Method\Vivek\AS9901ET-40min.met Injection volume: 5 uL

```
Description: {Data Description}
```



18m

```
Sample ID: JW-03-108B

Filename:


C:\EZStart\Projects\Default\Data\JWu\JW-03-107B_AS9901ET_40min.met3-16-2010

9-10-05 PM.dat Method:

C:\EZStart\Projects\Default\Method\Vivek\AS9901ET-40min.met

Injection volume: 5 uL
```


Description: {Data Description}



1: 210 nm,	4 nm Results		
	Retention Time	Area	Area Percent
	21.392	5735548	50.661
	28.197	5585924	49.339

Sample ID:	VRT-1-152A
Filename:	
C:\EZStart\Project	<pre>\Default\Data\Vivek\Hydroamination\VRT-1-152AAS9901ET-40m</pre>
in.met3-10-2010 9-	8-10 PM.dat Method:
C:\EZStart\Project	<pre>>Default\Method\Vivek\AS9901ET-40min.met</pre>
Injection volume:	5 uL


```
Description: {Data Description}
```



19b

```
Sample ID:VRT-2-109-RacFilename:C:\EZStart\Projects\Default\Data\Vivek\Hydroamination\VRT-2-109-Rac-AS9901IP.met9-24-2010 10-40-59 AM.datMethod:C:\EZStart\Projects\Default\Method\AS\AS9901IP.metInjection volume:1 uL
```

Description: {Data Description}



3: 277 nm,	4 nm Results		
	Retention Time	Area	Area Percent
	8.368	1580236	50.323
	9.771	1559957	49.677


Sample	ID:	VRT-2-109
Dampre	<u> </u>	VICI - 2 - 109


1 uL

Filename:

```
C:\EZStart\Projects\Default\Data\Vivek\Hydroamination\VRT-2-109-AS9901IP.met
9-24-2010 10-27-39 AM.dat Method:
C:\EZStart\Projects\Default\Method\AS\AS9901IP.met
```

```
Injection volume:
```





49.602 234 50.398 234


12.448

21.204

1221545

1241156


20b



CHAPTER 3: NEW HALOGENATION REAGENTS DESIGNED FOR CHIRAL ANION PHASE-TRANSFER CATALYSIS: HALOCYCLIZATION

Abstract

New electrophilic halogenation reagents have been designed specifically for use in chiral anion phase-transfer catalysis. The key characteristics of these reagents include low solubility in nonpolar organic solvents, the ability to undergo ion-exchange with chiral phosphates, and bench stability. These ionic reagents include both brominating and iodinating reagents and were shown to react with various alkenes to generate benzoxazines with high enantioselectivity. The amide nucleophile tethered to the arene core is essential for interactions with the chiral ion pair which is generated in-situ by the phase-transfer process. Very wide substrate scope was demonstrated with a variety of alkene substitution patterns. An impressive demonstration of low catalyst loading (0.1 mol%) is also presented, which is generally unseen in organocatalytic reactions.




Introduction

In addition to exploring catalyst modifications for enantioselective functionalization of alkenes, this project focused on the development of new reagents for precedented catalytic systems. We demonstrate that while the generation of new modes of reactivity can be achieved by modifications to the catalyst (as shown in chapter 2), new reactions and methods can also be developed by the design of new reagents. Due to the high presence of halogenated chiral motifs in natural products, and importance as synthetic intermediates, we chose to investigate halogenations.^{1,2} This work is largely based on the fluorination reactions developed in the Toste group, which rely on the same chiral anion phase-transfer catalytic cycle. However, known bromination and iodination reagents were not found to be amenable in the system – thus, the design of new reagents was required. These transformations present a different challenge from fluorination due to the increased reactivity and electrophilicity of bromination and iodination reagents, which makes achieving enantioselectivity more difficult.

There are a few precedented examples of enantioselective electrophilic addition reactions.³ Among these types of transformations, metal-catalyzed variants have been developed.⁴ Meanwhile, organocatalytic methods generally rely on hydrogen-bonding activation of the electrophilic reagent by chiral hydrogen-bonding catalysts: cinchona alkaloids, chiral diaminocyclohexane derivatives, C₃-symmetric imidazoline derivatives, peptides, and phosphoric acids.⁵⁻⁹ The success of these methods is due to the increased reactivity of the reagent when in the presence of the catalyst compared with the background racemic reaction which occurs when the substrate and reagent react in the absence of the chiral catalyst. In order to overcome this small difference in reactivity between catalyzed (chiral) and uncatalyzed (racemic) reaction, long reaction times and low temperatures are often employed.

A look at the chiral anion phase-transfer catalytic system that has been developed shows that there is the possibility for "plugging in" various electrophilic salts in place of Selectfluor to achieve a wider range of transformations. Presumably, these reagents would have to have similar characteristics as Selectfluor in terms of solubility and interactions with chiral phosphates.¹⁰ With this in mind, we began the design of new reagents using a DABCO scaffold in order to mimic the reactivity and favorable properties of Selectfluor.



Scheme 1. Proposed expansion of chiral anion phase transfer catalysis from fluorination to bromination and iodination (E^+ = electrophile, Phos*⁻ = chiral phosphate anion).

Results and Discussion

Beginning with DABCO as a simple modifiable scaffold, and precedented aminebromine complexes which have been used as brominating and oxidation reagents, we subjected monoalkylated DABCO salts to bromine (Figure 1).¹¹




Figure 1. Preparation of reagent **1** and confirmation of structure by X-ray crystallography (ellipsoids at 50% probability level, counterions and H's omitted for clarity).

The bench stability was found to be slightly worse than Selectfluor, and the powder was kept in vials in the -20 °C refrigerator for months. Similar to homogeneous reactions with Selectfluor, reagent 1 was subjected to 3a and promoted cyclization in high yield and short reaction time. Running the reaction with 3a in nonpolar solvents such as hexane, toluene, and methylene chloride in the absence of phase-transfer catalyst demonstrated that the insolubility of 1 prevented any background (racemic) reaction. When run in the presence of chiral phase-transfer catalyst 2a, however, we observed formation of desired product. With these results in hand, we were ready to optimize the reagent and catalyst.

Lipophilicity and electrophilicity were tuned with various changes to the alkyl substituents on the DABCO framework. We postulated that electron-withdrawing substituents could inductively increase electrophilicity of the reagent. Further, highly lipophilic reagent **1d** was found to improve enantioselectivity probably due to increased solubility in the presence of phase-transfer catalyst (Table 1, entries 1-4). Changes to the solvent choice showed that more hydrophobic

solvents were		vere	beneficial	for enantioselect		ectivity		
		~	1a-1d (1.3 equiv) 2a-2c (10 mol%)	Br				
NH O Ph			base (4.0 equiv) solvent (0.05M)	N Ph				
		3a				4a		
	entry	reagent	catalys	st solvent	base	time	conv. ^a	ee ^b
-	1	1a	2a	toluene	Na ₂ CO ₃	1 d	82%	59%
	2	1b	2 a	toluene	Na ₂ CO ₃	1 d	67%	70%
	3	1c	2 a	toluene	Na ₂ CO ₃	1 d	30%	20%
	4	1d	2a	toluene	Na ₂ CO ₃	1 d	67%	83%
	5	1d	2 a	<i>p</i> -xylene	Na ₂ CO ₃	16 h	62%	86%
	6	1d	2 a	p-xyl/hex (1:1)	Na ₂ CO ₃	16 h	90%	89%
	7	1d	2a	hexanes	Na ₂ CO ₃	16 h	21%	60%
	8	1d	2b	p-xyl/hex (1:1)	Na ₂ CO ₃	17 h	90%	89%
	9	1d	2c	p-xyl/hex (1:1)	Na ₂ CO ₃	17 h	90%	91%
	10	1d	2c	p-xyl/hex (1:1)	Na ₂ CO ₃ ^c	17 h	100%	90%
	11	1d	2c	p-xyl/hex (1:1)	Na ₃ PO ₄ ^c	17 h	100%	92%
_	12	1d ^{<i>d</i>}	2c [⊕]	p-xyl/hex (1:1) ^f	Na ₃ PO ₄ ^c	4 h	100% ^g	94%

^aDetermined by 1H NMR of crude product after workup. ^bDetermined by chiral HPLC. ^cFinely ground and dried. ^dReprecipitated from MeNO₂. ^e5 mol%. ^f0.025 M. ^g82% isolated yield.




Table 1. Optimization of bromocyclization conditions.

Commonly used phosphoric acid catalyst TRIP (2b) provided high enantioselectivities, while the inclusion of 6,6'-TIPS substituents (2c, TIPS-TRIP) provided improvements (entries 8, 9) due either to increased solubility in nonpolar solvent, or a slightly different angle between the naphthyl substituents.

After optimization of reaction conditions, we proceeded to investigate the substrate scope by first varying substitutions on the alpha- positions of the styrene. In terms of functional group tolerance, substrates containing silvl ether or alcohol did not undergo side reactions or lack reactivity. In addition, pyridine rather than phenyl derivatives could be subjected to reaction conditions, providing product in high yield and enantioselectivity. Heterocyclic substituents were also well-tolerated, although more polar solvent mesitylene was used in these cases after noticing that results improved when changing the solvent from benzene to toluene to xylene.

6).




Figure 2. Synthesis of trisubstituted alkenes via vinyl chloride and subsequent Suzuki reaction.

We next explored substrates bearing substitution at both α and β positions of the styrenyl system. The vinyl chloride formed *via* a Wittig reaction provided a versatile compound for diversification at the alkene and at the amine. This route was used for compounds 4g - 4i. Despite forming more than one stereocenter, only one diastereomer was observed in all of these cases. A wide variety of steric and electronic changes were well-tolerated. Thus, although only one type of nucleophile was employed, resulting in only one type of heterocycle, the ability to change every other moiety on the substrate demonstrates a wide tolerance in this reaction regarding with respect to functional groups, steric bulk, and electronic changes.





Table 2. Substrate scope of bromocyclization with new reagent **1d**. Conditions: **1d** (1.3 equiv), TIPS-TRIP (5 mol%), Na₃PO₄ (4.0 equiv), *p*-xylene/hexanes (1:1, 0.025 M), 4 h. Enantioselectivities determined by chiral HPLC. ^{*a*}1.5 equiv **1d** in mesitylene/hexanes (1:1).

The generation of iodination reagents was achieved following a protocol similar to that employed in the synthesis of bromination reagent **1**. After the synthesis of **5d** we investigated various substrates representing a wide range of structures. Without modification of the reaction conditions, we were able to attain iodocyclization products in similar yields and enantioselectivities as the bromocyclization reaction (Scheme 2). This analogous study further

demonstrates the ability to design new reagents in a straight-forward manner for use in the chiral anion phase-transfer system.



Scheme 2. Analogous enantioselective electrophilic iodination.

New reagents were designed and synthesized for phase-transfer halocyclization reactions. High enantioselectivities and yields were demonstrated for a variety of compounds including heterocyclic and spirocyclic substrates, and a variety of substitution patterns on the alkene. These reactions were run under air and without the exclusion of moisture, and offers an efficient organocatalytic method for the formation of benzoxazines. The use of a new iodination reagent further highlights the ability to change the reagent in the phase-transfer system without loss of enantioselectivity and yield. Future work in this area may include the design of new electrophilic reagents for non-halogenation reactions, possibly achievable for trifluoromethylation.


References

- Halogenation in natural products: A) Wagner C., El Omari M., König G. M. J. Nat. Prod. 2009, 72, 540-553. B) Vaillancourt F. H., Yeh E., Vosburg D. A., Garneau-Tsodikova S., Walsh C. T. Chem. Rev. 2006, 106, 3364-3378. C) Gribble G. W. J. Nat. Prod., 1992, 55, 1353-1395. For recent advances in bromocyclization in natural product synthesis, see: D) Werness J. B., Tang W. Org. Lett. 2011, 13, 3664-3666. E) Snyder S. A., Treitler D. S. Angew. Chem. Int. Ed. 2009, 48, 7899-7903.
- Cross coupling of alkyl halides: A) Rudolph A., Lautens M. Angew. Chem. Int. Ed. 2009, 48, 2656-2670. B) Phapale V. B. and Cárdenas D. J. Chem. Soc. Rev. 2009, 38, 1598-1607.
 C). Nicolaou K. C., Bulger P. G., Sarlah D. Angew. Chem. Int. Ed. 2005, 44, 4442-4489.
- Selected reviews on enantioselective halogenation: A) Hennecke U. Chem. Asian J. 2012, 7, 456-465. B) Tan C. K., Zhou L., Yeung Y.-Y. Synlett. 2011, 1335-1339. C) Castellanos A., Fletcher S. P. Chem. Eur. J. 2011, 17, 5766-5776. D) Ma S., Chen G. Angew. Chem. Int. Ed. 2010, 49, 8306-8308. E) France S., Weatherwax A., Lectka T. Eur. J. Org. Chem. 2005, 475-479.
- A) Kang S. H., Lee S. B., Park C. M. J. Am. Chem. Soc. 2003, 125, 15748-15749. B) Sakurada I., Yamasaki S., Göttlich R., Iida T., Kanai M., Shibasaki M. J. Am. Chem. Soc. 2000, 122, 1245-1246. C) El-Qisairi A., Hamed O., Henry P. M. J. Org. Chem. 1998, 63, 2790-2791. D) Inoue T., Kitagawa O., Kurumizawa S., Ochiai O., Taguchi T. Tetrahedron Lett. 1995, 36, 1479-1482.
- A) Chen Z-M., Zhang Q-W., Zhang Z-H., Li H., Tu Y-Q., Zhang F-M., Tan J-M. J. Am. Chem. Soc. 2011, 133, 8818-8821. B) Nicolaou K. C., Simmons N. L., Ying Y., Heretsch P. M., Chen J. S. J. Am. Chem. Soc. 2011, 133, 8134-8317. C) Lozano O., Blessley G., del Campo T. M., Thompson A. L., Giuffredi G. T., Bettati M., Walker M., Borman R., Gouverneur V. Angew. Chem. Int. Ed. 2011, 50, 8105-8109. D) Jaganathan A., Garzan A., Whitehead D. C., Staples R. J., Borhan B. Angew. Chem. Int. Ed. 2011, 50, 2593-2596. E) Zhou L., Tan C. K., Jiang X., Chen F., Yeung Y. Y. J. Am. Chem. Soc. 2010, 132, 15474-15476. F) Zhang W., Zheng S., Liu N., Werness J. B., Guzei I. A., Tang W. J. Am. Chem. Soc. 2010, 132, 3664-3665. G) Ishimaru T., Shibata N., Horikaw T., Yasuda N., Nakamura S., Toru T., Shiro M. Angew. Chem. Int. Ed. 2008, 42, 3291-3294. H) Juliá S., Ginebreda A. Tetrahedron Lett. 1979, 20, 2171-2174.
- 6. Veitch G. E., Jacobsen E. N. Angew. Chem. Int. Ed. 2010, 49, 7332-7335.
- 7. Murai K., Matsushita T., Nakamura A., Fukushima S., Shimura M., Fujioka H. Angew. Chem. Int. Ed. 2010, 49, 9174-9177.
- 8. Gustafson J. L., Lim D., Miller S. J. Science, 2010, 328, 1251-1255.
- A) Huang D., Wang H., Xue F., Guan H., Li L., Peng X., Shi Y. Org. Lett., 2011, 13, 6350-6353.
 B) Hennecke U., Müller C. H., Fröhlich R. Org. Lett. 2011, 13, 860-863. Use of a Lewis basic co-catalyst: C) Denmark S. E., Burke M. T. Org. Lett., 2012, 14, 256-259. Earlier study of Lewis base catalysis: D) Denmark S. A., Burke M. T. Proc. Natl. Acad. Sci. USA, 2010, 107, 20655-20660.
- 10. A) Rauniyar V., Lackner A. D., Hamilton G. L., Toste F. D. Science, 2011, 334, 1681-1684.
 B) Phipps R. J., Hiramatsu K., Toste F. D. J. Am. Chem. Soc. 2012, 134, 8376-8379.
- Early structural studies: A) Blair L. K., Parris K. D., Hii P. S., Brock C. P. J. Am. Chem. Soc. 1983, 105, 3649-3653. B) Bowmaker G. A., Hannan S. F. Aust. J. Chem. 1972, 25, 1151-1158. C) Eia G., Hassel O. Acta Chem. Scand. 1956, 10, 139-141. Synthetic

applications: D) Rousseau G., Robin S., *Tetrahedron Lett.* **1997**, *38*, 2467-2470. E) *J. Org. Chem.* **1992**, 57, 1600-1603.

Supporting Information

Synthesis of bromination reagents 1a-d and iodination reagent 5d. Reagents 1a-d were prepared according to the following scheme.



S6d: A solution of 2,3,4,5,6-pentamethylbenzyl chloride (8.61 g, 43.8 mmol, 1.00 equiv) and 1,4-diazabicyclo[2.2.2]octane (4.91 g, 43.8 mmol, 1.00 equiv) in diethyl ether (200 mL) was heated under reflux for 18 h. The resultant white solid was isolated by filtration and washed repeatedly with diethyl ether, air-dried overnight, and used directly in the next step.

The crude product from above and sodium tetrafluoroborate (24.0 g, 219 mmol, 4.99 equiv) were suspended in acetonitrile (300 mL) in an Erlenmeyer flask and sonicated for 2 h with occasional swirling. The reaction mixture was filtered and washed with acetonitrile, and the filtrate was evaporated to dryness. The crude product was purified by recrystallization (EtOH/MeCN) to give the title product (11.6 g, 32.2 mmol, 74%) as a white solid.

¹H NMR (300 MHz, CD₃NO₂, ¹H res. δ 4.33) δ 4.79 (s, 2H), 3.39-3.30 (m, 6H), 3.19-3.09 (m, 6H), 2.38 (s, 6H), 2.31 (s, 3H), 2.26 (s, 6H). ¹³C NMR (75 MHz, CD₃NO₂, δ 60.5) δ 126.8, 135.0, 133.5, 120.2, 62.6, 51.2, 44.2, 43.5, 17.4, 15.0. ¹⁹F NMR (376 MHz, CD₃NO₂) δ -151.9, -152.0. Anal. calcd. for C₁₉H₂₉BF₄N₂: C, 60.01; H, 8.11; N, 7.78, found: C, 60.19; H, 7.79; N, 7.80.

1d: As a precaution, the following procedure was performed with fume hood lights turned off. To an open-flask, stirred solution of S6d (1.00 g, 2.78 mmol, 1.00 equiv) and silver tetrafluoroborate (298 mg, 1.53 mmol, 0.55 equiv) in acetonitrile (100 mL) was added bromine (275 mg, 1.72 mmol, 0.62 equiv) in acetonitrile (10 mL) via Pasteur pipette over 3 min. The flask was capped, and the reaction mixture was stirred for 5 min after addition was completed, and then vacuum-filtered through a fritted funnel (fine porosity), which was rinsed with additional acetonitrile (50 mL). To the homogeneous filtrate was added dichloromethane (100 mL) and hexanes (200 mL). The resultant suspension was sonicated for 5 min and vacuumfiltered. The precipitate was washed with hexanes and dried by suction for a few minutes to give a very slightly yellow cake of solid. This material may be used directly for bromocyclization without adversely affecting yield or enantioselectivity, although longer reaction times were required. To further purify the reagent, the cake was broken up with a spatula and nitromethane (25 mL) was added to the filter funnel to redissolve the solid. The resultant slightly cloudy solution was vacuum-filtered, and the residue was rinsed with additional nitromethane (25 mL). To the colorless homogeneous filtrate was added dichloromethane (75 mL) and hexanes (100 mL). The resultant suspension was sonicated for 5 min and vacuum-filtered. The precipitate was washed with dichloromethane and then washed thoroughly with hexanes and dried under high vacuum to afford the title product as a colorless and odorless fluffy solid (910 mg, 1.03)

mmol, 74%). Crystals suitable for X-ray diffraction were obtained by cooling a saturated solution in nitromethane to -20 °C overnight. *Note:* Reagent 1d can be stored at -20 °C for at least a month in a tightly sealed vial. However, solutions of 1d in acetonitrile or nitromethane start to degrade after several hours at room temperature.

¹H NMR (600 MHz, CD₃NO₂, ¹H res. δ 4.33) δ 4.95 (s, 2H), 3.86 - 3.56 (m, 12H), 2.36 (s, 6H), 2.31 (s, 3H), 2.25 (s, 6H). ¹³C NMR (151 MHz, CD₃NO₂, δ 60.5) δ 137.7, 135.1, 134.0, 119.2, 63.5, 51.6, 49.6, 17.2, 15.2, 15.0. ¹⁹F NMR (376 MHz, CD₃NO₂) δ -151.7, -151.8.

Bromination reagents **1a** – **1c** were prepared analogously.

1a: ¹H NMR (600 MHz, CD₃NO₂, ¹H res. δ 4.33) δ 5.22 (s, 2H), 4.10 - 3.75 (m, 12H). **1b**: ¹H NMR (600 MHz, CD₃NO₂, ¹H res. δ 4.33) δ 8.23 (s, 4H), 8.16 (s, 2H), δ 4.85 (s, 2H), 3.95 - 3.70 (m, 12H). **1c**: ¹H NMR (300 MHz, CD₃NO₂, ¹H res. δ 4.33) δ 4.80 (s, 2H), 4.05 - 3.70 (m, 12H).


Iodination reagent **5d** was prepared in analogy to bromination reagent **5d**, starting from **S6d** (1.00 g, 2.78 mmol, 1.00 equiv), silver tetrafluoroborate (296 mg, 1.53 mmol, 0.55 equiv), and iodine (424 mg, 1.67 mmol, 0.60 mmol). The reaction mixture was stirred for 15 min, instead of 5 min for the preparation of **1d**. After an identical workup procedure, **5d** was obtained as a very slightly yellow solid (980 mg, 1.05 mmol, 75%), pure enough for use in the iodocyclization reactions. Analytically pure product could be obtained as colorless crystals by cooling a saturated solution of **5d** in nitromethane to -20 °C overnight. Use of the crude product was not detrimental to yield or enantioselectivity of the iodocylization reactions.

¹H NMR (500 MHz, CD₃NO₂, ¹H res. δ 4.33) δ 4.93 (s, 2H), 3.89 - 3.55 (m, 12H), 2.35 (s, 6H), 2.31 (s, 3H), 2.25 (s, 6H). ¹³C NMR (126 MHz, CD₃NO₂, δ 60.5) δ 137.6, 135.1, 133.9, 119.1, 63.8, 51.7, 51.0, 17.2, 15.2, 15.0.

General procedure for halocyclizations. Prior to use in halocyclization reactions, sodium phosphate was stirred overnight at 60 °C under high vacuum. To a 4 mL vial was added substrate (0.0421 mmol, 1.00 equiv), **2c** (2.2 mg, 0.00207 mmol, 0.05 equiv), and sodium phosphate (28.0 mg, 0.171 mmol, 4.07 equiv). Solvent (0.84 mL hexanes and 0.84 mL *p*-xylene) was added, followed by **1d** (45.0 mg, 0.0507mmol, 1.20 equiv), and the reaction was stirred using a 1/2° x 1/8° octagonal stirbar at 700 rpm. After 4 h (16 h for iodocyclization), the reaction mixture was filtered through Celite with hexanes, and solvent was evaporated under a stream of nitrogen. (More polar products **4f**, **4n**, and **4o** were filtered through silica with ethyl acetate instead.) The residue was purified by preparative thin-layer chromatography to afford the bromocyclization product. Iodocyclization was carried out in an analogous manner.

Halocyclization of 3j with 0.1 mol % catalyst loading. Sodium phosphate was dried and ground as described above immediately before performing the reaction. A stock solution of 2.0 mg 2c / 2.0 mL hexanes was made, of which 50 µL (0.0469 µmol) was added to 3j (13.0 mg, 0.0469 mmol), sodium phosphate (31.0 mg), hexanes (0.94 mL), and *p*-xylene (0.89 mL). Brominating reagent 1d (53.0 mg) was added, and the reaction mixture was stirred for 16 h. Workup as described above afforded 4j in 86-88% yield (2 runs) and 90-93% ee (4 runs).


Synthesis of substrates. The synthesis of substrates is summarized below.




To a stirred solution of Grignard reagent (3.0 equiv; 3.0 M EtMgBr, 1.0 M iPrMgBr) in diethyl ether at 0 °C was added anthranilonitrile (1.0 equiv, 10 - 20 mmol scale) as a solid. The reaction mixture was allowed to warm to room temperature and was stirred overnight. Saturated aqueous NH₄Cl was then cautiously added dropwise by syringe until gas evolution ceased. The reaction mixture was then diluted with water and dichloromethane. Standard aqueous workup (CH₂Cl₂) followed by flash column chromatography (20:1 to 10:1 hexanes/EtOAc) afforded the ketone product **S7b** and **S7c**. 2-Aminoacetophenone (**S7a**) was available commercially and was used as received.

To a solution of **S7a-c** (1.00 equiv) in DCM (0.3 M) was added sequentially triethylamine (1.50 equiv) and benzoyl chloride (1.05 equiv). Water was added after 30 min. Subsequent standard aqueous workup (DCM) followed by recrystallization (EtOAc for **S7a**, **S7b**; hex/EtOAc for **S7c**) afforded the amide product.

To a stirred suspension of methyltriphenylphosphonium bromide (1.30 equiv) in dry diethyl ether (100 mL for 1.50 g phosphonium salt) at 0 °C was added sodium *t*-butoxide (2.60 equiv). The reaction mixture was stirred for 30 min after which the amide product from above (1.00 equiv) was added. The reaction mixture was allowed to warm to room temperature and then heated at reflux overnight. Saturated aqueous NH_4Cl (5 mL) was added dropwise. Dilution with water and EtOAc, followed by standard aqueous workup (EtOAc) and column chromatography (20:1 to 10:1 hexanes/EtOAc) afforded substrates **3a-3c**.



Amide **3d** was prepared from 2-aminobenzophenone by Wittig olefination followed by benzoylation, using the procedures described for **3a-3c** above.



To a stirred, degassed solution of 2-iodoaniline (1.00 g, 4.56 mmol), palladium acetate (51 mg, 5 mol%), triphenylphosphine (240 mg, 20 mol%), and triethylamine (2.5 mL, 4.0 equiv) in toluene (5 mL) was added pinacolborane (1.75 g, 3.0 equiv) dropwise by syringe (hydrogen evolution!). Upon cessation of bubbling, the reaction mixture was heated to 90 °C for 2 h. Upon cooling to room temperature, the reaction mixture was filtered through a plug of silica (EtOAc

eluent), and the filtrate was concentrated to dryness. Column chromatography (1:1 hexanes/DCM to DCM) afforded 2-aminophenylboronic acid pinacol ester (550 mg, 55%) as an orange solid.

To a solution of the boronic acid pinacol ester from above (550 mg, 1.0 equiv) in DCM (100 mL) was added sequentially triethylamine (0.7 mL) and benzoyl chloride (0.31 mL, 1.05 equiv). After 10 min, water (100 mL) was added. Standard aqueous workup (DCM) followed by crystallization (hexanes/toluene) afforded 2-benzamidophenylboronic acid pinacol ester as a yellow solid.

A mixture of the amide from above (323 mg, 1.0 equiv), **S8** (335 mg, 1.2 equiv), SPhos (41 mg, 10 mol%), potassium phosphate (849 mg, 4.0 equiv), dioxane (5.0 mL), and water (0.5 mL) was degassed. Palladium acetate (11 mg, 5 mol%) was added, and the reaction mixture was once again degassed and then stirred and heated at 90 °C. After 30 min, the reaction mixture was filtered through a plug of silica (DCM eluent), and the filtrate was concentrated to dryness. Column chromatography (20:1 hexanes/EtOAc) afforded **3e** as a yellow oil (321 mg, 81%).

To a stirred solution of amide 3e (663 mg, 1.0 equiv) in THF (30 mL) at 0 °C was added TBAF (1.84 mL, 1.0 M solution in THF, 1.1 equiv). The reaction mixture was allowed to warm to room temperature and stirring was continued for 30 min. The reaction mixture was diluted with water. Standard aqueous workup (EtOAc) followed by column chromatography (1:1 hexanes/EtOAc) afforded **3f** (460 mg, 96%) as a yellow oil.


3g-3i

To a stirred solution of diisopropylamine (3.5 mL, 2.5 equiv) in THF (100 mL) was added a 2.5 M *n*-BuLi solution in hexane (10 mL, 2.5 equiv) at -78 °C. The reaction mixture was warmed to 0 °C in an ice bath for 15 min and then cooled back to -78 °C. Chloromethyltriphenylphosphonium bromide (9.78 g, 2.5 equiv) was added, and the reaction mixture was warmed to room temperature for 15 min. The reaction mixture was again cooled to -78 °C, and 2-aminoacetophenone (1.35 g, 10 mmol) was added dropwise. After 18 h, aqueous saturated ammonium chloride was added. Standard aqueous workup (Et₂O) followed by column chromatography afforded (*E*)-2-(1-chloroprop-1-en-2-yl)aniline (**S9**) as a single isomer by NMR.

Triethylamine (1.5 equiv) and benzoyl chloride (0.35 mL, 1.02 equiv) were added dropwise to **S9** (0.5 g, 2.98 mmol) in THF (15 mL) at 0 °C. After 30 min of stirring at room temperature the reaction mixture was filtered and then partitioned between ether and water. The organic layer was dried with magnesium sulfate and concentrated. The crude solid was washed with hexane to provide **3h** as a white solid (0.51g, 63%).

A mixture of amide **3h** (0.1 g, 0.368 mmol), palladium acetate (8 mg, 0.1 equiv), SPhos (0.030 g, 0.2 equiv), phenylboronic acid (0.135 g, 3.0 equiv), and potassium phosphate (finely powdered, 0.39 g, 5 equiv) in toluene (2.5 mL) was degassed, and then stirred vigorously at 70 °C for 18 h. The reaction mixture was then filtered with Celite and partitioned between water and EtOAc and extracted (EtOAc). The combined organic layers were washed with brine and dried with MgSO₄. Column chromatography (0-10% ethyl acetate in hexane) provided a product which was suspended in hexane and filtered to provide **3i** as a white solid (0.060 g, 55%).

Amide 3g was prepared in analogy to 3i, with trimethylboroxine (2.5 equiv) in place of phenylboronic acid.




A solution of LDA was prepared by addition of *n*-BuLi (3.40 mL, 1.10 equiv, 2.5 M solution in hexanes) to a stirred solution of diisopropylamine (1.20 mL, 1.10 equiv) in THF (20 mL) at 0 °C and allowing deprotonation to occur over 30 min. The LDA solution was cooled to -78 °C, and a solution of cyclohept-2-en-1-one (0.853 g, 1.00 equiv) in THF (2 mL) was added dropwise. Stirring was continued for 2 h at -78 °C, whereupon a solution of phenyl bistriflimide (2.77 g, 1.00 equiv) was added dropwise. The reaction mixture was allowed to warm to room temperature, with stirring continued for an additional 4 h. Solvent was removed and the residue was extracted with pentane. Column chromatography (pentane) afforded the triflate as a colorless oil (1.3 g).

mixture of bis(pinacolato)diboron (839 А mg. 1.1 equiv). bis(triphenylphosphine)palladium dichloride (63 mg, 3 mol%), triphenylphosphine (47 mg, 6 mol%), potassium phenolate (595 mg, 1.5 equiv), potassium bromide (535 mg, 1.5 equiv), and toluene (20 mL) was degassed, and a solution of the triflate prepared above (727 mg, 1.0 equiv) in toluene (5 mL) was added dropwise by syringe. The reaction mixture was stirred vigorously and heated at 50 °C for 2 h. The crude product was filtered through a short plug of silica (pentane) to afford **S10** (377 mg, 57%), which was essentially pure by ¹H NMR (¹H NMR (300 MHz, CDCl₃) δ 6.81- 6.66 (m, 1H), 6.22 - 6.00 (d, J = 11.7 Hz, 1H), 5.92 - 5.74 (m, 1H), 2.52 -2.37 (m, 2H), 2.35 - 2.24 (m, 2H), 1.92 - 1.74 (m, 2H), 1.27 (s, 12H)).

A mixture of **S10** (470 mg, 1.5 equiv), SPhos (58 mg, 0.10 equiv), 2-iodobenzamide (460 mg, 1.0 equiv), and potassium phosphate (1.2 g, 4 equiv), dioxane (25 mL), and water (5 mL) was degassed. Palladium acetate (16 mg, 0.05 equiv) was added. The reaction mixture was again degassed and stirred vigorously at 90 °C for 14 h. The reaction mixture was then filtered through a short plug of silica (EtOAc). Solvent was removed, and the residue was purified by column chromatography (10:1 to 6:1 hexanes/EtOAc) to afford **3k** as a yellow oil (270 mg, 66%).

31




1-Bromo-1,5-cyclooctadiene was prepared by heating a mixture of 5,6-dibromo-1-cyclooctene (16.3 g), DMSO (36 g), and morpholine (26 g) in benzene (40 mL) at reflux for 18 h. The crude reaction mixture was taken up in DCM (100 mL) and washed twice with water (200 mL). Concentration followed by short-path vacuum distillation afforded the diene (1.5 g).

A mixture of the diene prepared above (660 mg), bis(pinacolato)diboron (985 mg), potassium phenolate (700 mg), triphenylphosphine (55 mg) and potassium bromide (628 mg) in toluene was briefly degassed. Bis(triphenylphosphine)palladium dichloride (125 mg) was added.


The reaction mixture was again degassed and stirred vigorously at 60 °C for 7 h. The reaction mixture was then concentrated and subjected directly to column chromatography (pentane to 10:1 pentane:Et₂O) to afford **S11** (ca. 90% pure, 414 mg) as a colorless oil (¹H NMR (300 MHz, CDCl₃) δ 6.60 - 6.40 (m, 1H), 5.66 - 5.44 (m, 2H), 2.59 - 2.51 (m, 2H), 2.51 - 2.27 (m, 6H), 1.25 (s, 12H)).

A mixture of **S11** from above (414 mg, ca. 90% pure, 1.35 equiv), SPhos (32 mg, 0.06 equiv), 2-iodobenzamide (420 mg, 1.0 equiv), and potassium phosphate (1.10 g, 4.0 equiv), dioxane (5 mL), and water (0.5 mL) was degassed. Palladium acetate (9 mg, 0.03 equiv) was added. The reaction mixture was again degassed and stirred vigorously at 90 °C for 13 h. The reaction mixture was then filtered through a short plug of silica (EtOAc). Solvent was removed, and the residue was purified by column chromatography (10:1 to 8:1 hexanes/EtOAc) to afford **31** as a yellow oil (237 mg, 60%).



A mixture of 2-bromobenzothiophene (426 mg, 2.0 equiv), 2-benzamidophenylboronic acid pinacol ester (323 mg, 1.0 equiv), SPhos (41 mg, 10 mol%), potassium phosphate (849 mg, 4.0 equiv), dioxane (5 mL), and water (0.5 mL) was degassed. Palladium acetate (11 mg, 5 mol%) was added, and the reaction mixture was degassed again and heated at 90 °C with vigorous stirring. After 0.5 h, the reaction mixture was allowed to cool and was filtered through a short plug of Celite. Column chromatography (10:1 hexanes/EtOAc) afforded **3m** (242 mg, 73%) as a yellow oil.

3n




To a stirred solution of 4-aminopyridine (3.00 g, 31.8 mmol) in acetonitrile (150 mL) was added freshly recrystallized NBS (5.67 g, 31.8 mmol) in the dark. The reaction mixture was stirred in the dark for 36h, whereupon solvent was removed, and the resultant residue was partitioned between water and EtOAc. Standard aqueous workup (EtOAc), followed by column chromatography (5:1 to 1:1 hexanes/EtOAc) afforded 4-amino-3-bromopyridine as a colorless solid (2.0 g).

To a stirred solution of 4-amino-3-bromopyridine (1.00 g) in DCM (50 mL) was added sequentially triethylamine (2 mL), benzoyl chloride (812 mg, 1.00 equiv), and DMAP (71 mg, 10 mol%). After 15 min, water was added. Standard aqueous workup (DCM), recrystallization (hexanes/toluene), and column chromatography (2:1 to 1:2 hexanes/EtOAc) afforded the benzoylated product as a white solid (400 mg), which was still slightly impure and used without in the next step without further purification.

A mixture of the amide from above (400 mg), isopropenylboronic acid pinacol ester (364 mg, 1.5 equiv), SPhos (60 mg, 10 mol%), potassium phosphate (1.22 g, 4.0 equiv), dioxane (10 mL) and water (1 mL) was degassed. Palladium acetate (16 mg, 5 mol%) was added, and the

reaction mixture was again degassed and heated at 90 °C with vigorous stirring for 16 h. The reaction mixture was then allowed to cool, and filtered through a short plug of silica (EtOAc eluent). Removal of solvent, followed by column chromatography (1:1 to 4:7 hexanes/EtOAc) afforded **3n** (216 mg) as a yellow solid.




To a stirred solution of 5-phthalimidopent-1-yne (0.778 g, 1.00 equiv) in DCM (10 mL) at -78 °C was added boron tribromide (0.34 mL, 1.00 equiv) over 5 min. The reaction mixture was allowed to warm to room temperature, with stirring continued for 1 h, after which water (3 mL) was added. The reaction mixture was stirred for a further 5 min. Standard aqueous workup (DCM) afforded the crude boronic acid as a yellow-orange oil, which was suspended in hexanes (20 mL) and heated with acetic acid (1 mL) with vigorous stirring at 50 °C overnight. Removal of solvent, followed by column chromatography (20:1 hexanes/EtOAc) afforded the vinyl bromide as a colorless oil.

The vinyl bromide from above and hydrazine hydrate (1.0 mL) were heated at 50 °C in THF (5 mL) with vigorous stirring for 4 h. Gravity filtration with additional THF to remove the hydrazide byproduct and removal of solvent afforded the primary amine as a yellow oil which was used directly in the next step.

A stirred solution of the primary amine from above, formic acid (1.0 mL), and formalin (1.0 mL) in water (5.0 mL) was heated at 90 °C overnight. The reaction mixture was carefully neutralized with saturated NaHCO₃ (5.0 mL). Standard aqueous workup (EtOAc) afforded tertiary amine **S12** as a yellow oil (250 mg, 36% over 3 steps), which was essentially pure by ¹H NMR (¹H NMR (300 MHz, CDCl₃) δ 5.73 - 5.50 (m, 1H), 5.45 - 5.34 (m, 1H), 2.46 (t, *J* = 7.5 Hz, 2H), 2.34 - 2.10 (m, 8H), 1.80 - 1.61 (m, 2H)).

A mixture of **S12** (250 mg, 1.3 equiv), 2-benzamidophenylboronic acid pinacol ester (323 mg, 1.0 equiv), SPhos (41 mg, 10 mol%), potassium phosphate (849 mg, 4.0 equiv), dioxane (10 mL), and water (1.0 mL) was degassed. Palladium acetate (11 mg, 5 mol%) was added, and the reaction mixture was degassed again and heated at 90 °C with vigorous stirring. After 6 h, the reaction mixture was allowed to cool and was filtered through a short plug of Celite. Column chromatography (EtOAc to MeOH gradient) afforded the crude product as a black oil containing only trace impurities (likely palladium). Further purification was achieved by filtration through a short plug of NH silica gel (~3 g, EtOAc eluent) to afford **30** (200 mg) as a yellow oil.



Substrates **3p-3s** were prepared by acylation with the appropriate acyl chloride as outlined in the syntheses for substrates **3a-3c**.

3a NHBz ¹H NMR (500 MHz, CDCl₃) δ 8.53 - 8.44 (m, 2H), 7.84 (d, *J* = 5.0 Hz, 2H), 7.58-7.53 (m, 1H), 7.52 - 7.47 (m, 2H), 7.36 - 7.31 (m, 1H), 7.21 - 7.16 (m, 1H), 7.15 - 7.10 (m, 1H), 5.49 (s, 1H), 5.13 (s, 1H), 2.12 (s, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 165.2, 143.5, 135.3, 134.2, 133.6, 132.0, 129.0, 128.2, 127.8, 127.1, 124.0, 120.8, 117.0, 24.9. HRMS (ESI+): calcd. for [C₁₆H₁₅ON+H]⁺: 238.1226, found: 238.1223.



4a N Ph ¹H NMR (500 MHz, CDCl₃) δ 8.26 - 2.19 (m, 2H), 7.54 - 7.49 (m, 1H), 7.49 - 7.44 (m, 2H), 7.40 - 7.34 (m, 2H), 7.28 - 7.22 (m, 1H), 7.20 - 7.16 (m, 1H), 3.78 (d, *J* = 11.5 Hz, 1H), 3.56 (d, *J* = 11.5 Hz, 1H), 1.94 (s, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 156.4, 139.2, 132.4, 131.8, 129.8, 128.4, 127.2, 127.0, 125.7, 123.4, 78.2, 39.9, 25.0 (1 resonance missing). HRMS (ESI+): calcd. for [C₁₆H₁₄ONBr+H]⁺: 316.0332, found: 316.0327.




3b NHBz ¹H NMR (500 MHz, CDCl₃) δ 8.55 - 8.49 (m, 1H), 8.44 (s, 1H), 7.84 - 7.76 (m, 2H), 7.58 - 7.43 (m, 3H), 7.36 - 7.30 (m, 1H), 7.17 - 7.08 (m, 2H), 5.48 - 5.45 (m, 1H), 5.13 (s, 1H), 2.45 - 2.36 (m, 2H), 1.10 - 1.00 (m, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 165.1, 149.4, 135.2, 134.6, 133.1, 131.9, 129.0, 128.2, 128.1, 127.0, 123.9, 120.5, 115.1, 31.3, 12.7. HRMS (ESI+): calcd. for [C₁₇H₁₇ON+H]⁺: 252.1383, found: 252.1380.




4b N Ph ¹H NMR (300 MHz, CDCl₃) δ 8.23 - 8.15 (m, 2H), 7.55 - 7.41 (m, 3H), 7.37 - 7.30 (m, 2H), 7.27 - 7.19 (m, 1H), 7.12 - 7.07 (m, 1H), 3.79 (d, *J* = 11.0 Hz, 1H), 3.65 (d, *J* = 11.0 Hz, 1H), 2.45 - 2.28 (m, 1H), 2.19 - 2.02 (m, 1H), 0.95 (t, *J* = 7.5 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 156.3, 140.0, 132.5, 131.6, 129.5, 128.4, 128.2, 126.8, 125.9, 124.9, 123.7, 81.6, 40.3, 31.0, 8.3. HRMS (ESI+): calcd. for [C₁₇H₁₆ONBr+H]⁺: 330.0488, found: 330.0483.



6b N Ph ¹H NMR (600 MHz, CDCl₃) δ 8.22 (d, J = 8.0 Hz, 2H), 7.51 (t, J = 7.0 Hz, 1H), 7.47 (t, J = 7.5 Hz, 2H), 7.40 - 7.30 (m, 2H), 7.25 - 7.18 (m, 1H), 7.08 (d, J = 7.5 Hz, 1H), 3.67 (d, J = 11.0 Hz, 1H), 3.57 (d, J = 11.0 Hz, 1H), 2.35 (dq, J = 14.5, 7.5 Hz, 1H), 2.11 (dq, J = 14.5, 7.5 Hz, 1H), 0.94 (t, J = 7.5 Hz, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 156.2, 139.8, 132.5, 131.6, 129.4, 128.4, 128.3, 126.8, 125.9, 125.3, 123.6, 81.1, 32.6, 16.4, 8.7.



3c NHBz ¹H NMR (300 MHz, CDCl₃) δ 8.52 (d, J = 9.0 Hz, 1H), 8.40 (s, 1H), 7.85-7.78 (m, 2H), 7.60-7.45 (m, 3H), 7.38-7.31 (m, 1H), 7.15-7.09 (m, 2H), 5.48-5.44 (m, 1H), 5.14-5.07 (m, 1H), 2.61 (sept, J = 7.0 Hz, 1H), 1.10 (d, J = 6 Hz, 6H). ¹³C NMR (151 MHz, CDCl₃) δ 165.0, 153.9, 135.2, 134.9, 133.3, 131.9, 129.0, 128.4, 128.1, 127.0, 123.7, 120.5, 113.8, 35.6, 21.6. HRMS (ESI+): calcd. for [C₁₈H₁₉ON+H]⁺: 266.1539, found: 266.1540.




4c N Ph ¹H NMR (300 MHz, CDCl₃) δ 8.20-8.12 (m, 2H), 7.55 - 7.41 (m, 3H), 7.36 - 7.28 (m, 2H), 7.25 - 7.17 (m, 1H), 7.14 - 7.06 (m, 1H), 3.95 (d, J = 9.0 Hz, 1H), 3.80 (d, J = 9.0 Hz, 1H) 2.48 (sept, J = 7.0 Hz, 1H), 1.15 (d, J = 7.0 Hz, 3H), 0.96 (d, J = 7.0 Hz, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 155.9, 139.7, 132.5, 131.5, 129.2, 128.4, 127.9, 126.5, 125.7, 125.1, 123.9, 84.3, 39.7, 37.2, 18.1, 16.1. HRMS (ESI+): calcd. for [C₁₈H₁₈ONBr+H]⁺: 344.0645, found: 344.0640.




3d NHBz ¹H NMR (400 MHz, CDCl₃) δ 8.50 (d, J = 8.0 Hz, 1H), 7.79 (s, 1H), 7.54 - 7.24 (m, 12H), 7.20 (td, J = 7.5, 1.0 Hz, 1H), 5.92 (d, J = 0.5 Hz, 1H), 5.44 (d, J = 0.5 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 165.1, 146.5, 139.1, 135.6, 135.0, 131.8, 131.7, 130.7, 129.2, 129.1, 128.9, 128.7, 126.9, 126.8, 124.4, 121.1, 117.9. HRMS (ESI+): calcd. for [C₂₁H₁₇ON+H]⁺: 300.1383, found: 300.1385.




4d N Ph ¹H NMR (400 MHz, CDCl₃) δ 8.42 - 8.20 (m, 2H), 7.58 - 7.42 (m, 5H), 7.42 - 7.29 (m, 5H), 7.29 - 7.17 (m, 1H), 7.16 - 7.04 (m, 1H), 4.25 - 3.99 (m, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 156.1, 140.3, 139.6, 132.3, 131.8, 129.8, 128.8, 128.7, 128.5, 128.4, 126.7, 126.5, 126.1, 125.8, 125.0, 82.3, 37.3. HRMS (ESI+): calcd. for [C₂₁H₁₆ONBr+H]⁺: 378.0488, found: 378.0489.




3e ¹H NMR (500 MHz, CDCl₃) δ 8.52 (d, J = 10.0 Hz, 1H), 8.44 (s, 1H), 7.82 (d, J = 10.0 Hz, 2H), 7.57 - 7.54 (m, 1H), 7.51 - 7.47 (m, 2H), 7.35 - 7.31 (m, 1H), 7.17 - 7.09 (m, 2H), 5.49 (s, 1H), 5.15 (s, 1H), 3.59 (t, J = 5.0 Hz, 2H), 2.58 - 2.42 (m, 2H), 1.67 - 1.59 (m, 2H), 0.85 (s, 9H), 0.01 (s, 6H). ¹³C NMR (126 MHz, CDCl₃) δ 165.1, 147.6, 135.2, 134.7, 132.8, 131.9, 129.0, 128.2, 128.1, 127.0, 123.9, 120.6, 116.3, 62.5, 34.7, 31.2, 26.0, 18.4, -5.2. HRMS (ESI+): calcd. for [C₂₄H₃₃O₂NSi+Na]⁺: 418.2173, found: 418.2172.



4e N Ph ¹H NMR (500 MHz, CDCl₃) δ 8.20 (d, J = 7.5 Hz, 2H), 7.36 - 7.32 (m, 1H), 7.53 - 7.48 (m, 2H) 7.47 - 7.43 (m, 2H), 7.24 - 7.20 (m, 1H), 7.12 (d, J = 7.5 Hz, 1H), 3.78 (d, J = 11 Hz, 1H), 3.65 - 3.58 (m, 3H), 2.44 - 2.35 (m, 1H), 2.24 - 2.15 (m, 1H), 1.69 - 1.61 (m, 1H), 1.58 - 1.48 (m, 1H), 0.88 (s, 9H), 0.01 (d, J = 4 Hz, 6H). ¹³C NMR (126 MHz, CDCl₃) δ 156.2, 139.9, 132.5, 131.6, 129.6, 128.4, 128.3, 126.9, 125.9, 125.1, 123.8, 81.3, 62.7, 40.6, 34.3, 27.4, 26.1, 18.4, -5.1₈, -5.2₁. HRMS (ESI+): calcd. for $[C_{22}H_{32}O_2NBrSi+H]^+$:474.1458, found: 474.1466.



3f NHBz ¹H NMR (600 MHz, CDCl₃) δ 8.52 (s, 1H), 8.45 (d, J = 8.2 Hz, 1H), 7.84 - 7.80 (m, 2H), 7.54 (t, J = 7.5 Hz, 1H), 7.48 (t, J = 7.5 Hz, 2H), 7.36 - 7.30 (m, 1H), 7.16 (dd, J = 7.5, 1.5 Hz, 1H), 7.12 (td, J = 7.5, 1.0 Hz, 1H), 5.49 (s, 1H), 5.15 (s, 1H), 3.64 (t, J = 6.0 Hz, 2H), 2.61 - 2.42 (m, 2H), 1.74 - 1.59 (m, 2H), 1.45 (s, 1H). ¹³C NMR (151 MHz, CDCl₃) δ 165.3, 147.3, 135.2, 134.7, 133.0, 131.9, 129.0, 128.3, 128.1, 127.1, 124.1, 121.3, 116.4, 62.6, 34.9, 30.8. HRMS(ESI+): calcd. for [C₁₈H₁₉O₂N+Na]⁺: 304.1308, found: 304.1310.



4f N Ph ¹H NMR (600 MHz, CDCl₃) δ 8.19 (d, J = 8.0 Hz, 2H), 7.55 - 7.49 (m, 1H), 7.49 - 7.40 (m, 2H), 7.39 - 7.29 (m, 2H), 7.28 - 7.17 (m, 1H), 7.12 (d, J = 7.5 Hz, 1H), 3.78 (d, J = 11.0 Hz, 1H), 3.70 - 3.57 (m, 2H), 2.49 - 2.36 (m, 1H), 2.26 - 2.14 (m, 1H), 1.76 - 1.64 (m, 1H), 1.64 - 1.37 (m, 2H). ¹³C NMR (151 MHz, CDCl₃) δ 156.1, 139.8, 132.4, 131.7, 129.7, 128.4, 128.3, 127.0, 126.0, 124.9, 123.7, 81.2, 62.6, 40.4, 34.3, 27.3. HRMS (ESI+): calcd. for [C₁₈H₁₈O₂N+H]⁺: 360.0594, found: 360.0597.



3g NHBz ¹H NMR (400 MHz, CDCl₃) δ 8.48 (d, J = 8.0 Hz, 1H), 8.37 (s, 1H), 7.82 (d, J = 7.0 Hz, 2H), 7.58 - 7.46 (m, 3H), 7.35 - 7.27 (m, 1H), 7.18 - 7.07 (m, 2H), 5.55 (q, J = 6.5 Hz, 1H), 2.00 (s, 3H), 1.87 (d, J = 6.5 Hz, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 165.0, 135.7, 135.3, 134.5, 133.9, 131.8, 129.0, 128.4, 127.7, 126.9, 126.5, 124.0, 120.6, 18.0, 14.2. HRMS (ESI+): calcd. for $[C_{17}H_{17}ON+H]^+$: 252.1383, found: 252.1383.



4g N Ph ¹H NMR (300 MHz, CDCl₃) δ 8.25 - 8.20 (m, 2H), 7.55 - 7.43 (m, 3H), 7.37 - 7.30 (m, 2H), 7.24 - 7.18 (m, 1H), 7.18 - 7.11 (m, 1H), 4.44 (q, *J* = 7.0 Hz, 1H), 1.94 (s, 3H), 1.66 (d, *J* = 7.0 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 156.4, 138.9, 132.3, 131.7, 129.4, 128.5, 128.2, 126.8, 126.7, 125.7, 124.1, 81.6, 57.0, 27.7, 21.0. HRMS (ESI+): calcd. for $[C_{17}H_{16}ONBr+H]^+$: 330.0488, found: 330.0484.



3h NHBz ¹H NMR (500 MHz, CDCl₃) δ 8.36 (d, *J* = 8.0 Hz, 1H), 7.95 (s, 1H), 7.82 (d, *J* = 8.0 Hz, 2H), 7.61 - 7.55 (m, 1H), 7.54 - 7.49 (m, 2H), 7.40 - 7.35 (m, 1H), 7.19 - 7.13 (m, 2H), 6.22 (s, 1H), 2.16 (s, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 165.3, 136.7, 134.8, 134.8, 132.2, 131.8, 129.1, 129.1, 128.9, 127.0, 124.7, 121.9, 118.8, 19.0. HRMS (ESI+): calcd. for $[C_{16}H_{14}ONCl+H]^+$: 272.0837, found: 272.0837.



4h N Ph ¹H NMR (600 MHz, CDCl₃) δ 8.22 (d, J = 8.0 Hz, 2H), 7.55 - 7.51 (m, 1H), 7.49 - 7.45 (m, 2H), 7.43 - 7.39 (m, 1H), 7.38 - 7.32 (m, 2H), 7.28 - 7.24 (m, 1H), 5.91 (s, 1H), 2.08 (s, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 155.9, 139.2, 131.9₄, 131.8₉, 130.3, 128.5, 126.8, 125.7₁, 125.6₇, 124.7, 81.7, 65.2, 23.3 (1 resonance missing). HRMS (ESI+): calcd. for [C₁₆H₁₃ONBrCl+H]⁺:349.9942, found:349.9937.



3i NHBz ¹H NMR (600 MHz, CDCl₃) δ 8.50 (d, J = 8.0 Hz, 1H), 8.45 (s, 1H), 7.82 (d, J = 7.5 Hz, 2H), 7.55 - 7.50 (m, 1 H), 7.46 - 7.35 (m, 7H), 7.33 - 7.27 (m, 2H), 7.20 - 7.16 (m, 1H), 6.65 (s, 1H), 2.26 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 165.1, 136.9, 135.9, 135.7, 135.0, 134.3, 131.9, 131.6, 129.0, 128.9, 128.5, 128.3, 128.1, 127.3, 126.9, 124.3, 121.2, 20.1. HRMS (ESI+): calcd. for [C₂₂H₁₉ON+H]⁺: 314.1539, found: 314.1539.



4i N Ph ¹H NMR (500 MHz, CDCl₃) δ 8.09 (d, J = 7.5 Hz, 2H), 7.54 - 7.49 (m, 1H), 7.46 - 7.41 (m, 2H), 7.29 - 7.10 (m, 7H), 7.06 - 7.01 (m, 2H), 5.52 (s, 1H), 2.07 (s, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 155.7, 138.8, 136.8, 132.3, 131.6, 129.9, 129.5, 128.7, 128.3, 128.2,

127.70, 126.4, 125.5, 124.9, 82.0, 61.9, 27.5 (1 resonance missing). HRMS (ESI+): calcd. for $[C_{22}H_{18}ONBr+H]^+$: 392.0645, found: 392.0636.




3j NHBz ¹H NMR (300 MHz, CDCl₃) δ 8.62 - 8.43 (m, 2H), 7.92 - 7.76 (m, 2H), 7.63 - 7.44 (m, 3H), 7.37 - 7.23 (m, 1H), 7.21 - 7.05 (m, 2H), 5.96 - 5.78 (m, 1H), 2.39 - 2.13 (m, 4H), 1.94 - 1.64 (m, 4H). ¹³C NMR (101 MHz, CDCl₃) δ 164.9, 136.2, 135.3, 134.6, 134.4, 131.9, 129.0₀, 128.9₆, 128.3, 127.8, 126.9, 123.9, 120.2, 30.3, 25.6, 23.2, 22.2. HRMS (ESI+): calcd. for [C₁₉H₁₉ON+H]⁺: 278.1539, found: 278.1541.




4j N Ph ¹H NMR (600 MHz, CDCl₃) δ 8.22 (d, J = 7.5 Hz, 2H), 7.56 - 7.44 (m, 3H), 7.40 - 7.28 (m, 3H), 7.24 (t, J = 7.5 Hz, 1H), 4.54 (app. s, 1H), 2.81 (td, J = 13.5, 4.5 Hz, 1H), 2.50 - 2.41 (m, 1H), 2.21 - 2.05 (m, 2H), 2.04 - 1.91 (m, 1H), 1.91 - 1.82 (m, 1H), 1.78 - 1.69 (m, 1H). ¹³C NMR (151 MHz, CDCl₃) δ 155.6, 138.9, 132.6, 131.7, 129.3, 128.6, 127.9, 127.8, 126.5, 126.1, 124.9, 79.3, 53.7, 30.1, 29.7, 20.8, 19.7. HRMS (ESI+): calcd. for [C₁₉H₁₈ONBr+H]⁺: 356.0645, found: 356.0647.




6j N Ph ¹H NMR (500 MHz, CDCl₃) δ 8.22 (d, J = 7.0 Hz, 2H), 7.56 - 7.44 (m, 3H), 7.41 - 7.28 (m, 3H), 7.26 - 7.20 (m, 1H), 4.81 (app. s, 1H), 2.88 (td, J = 13.0, 4.5 Hz, 1H), 2.44 - 2.31 (m, 1H), 2.24 - 2.09 (m, 2H), 2.01 - 1.73 (m, 4H). ¹³C NMR (126 MHz, CDCl₃) δ 155.9, 138.9, 132.6, 131.8, 129.3, 128.8, 128.6, 127.9, 126.7, 125.9, 124.8, 79.3, 37.0, 31.9, 30.3, 21.5, 21.1. HRMS (ESI+): calcd. for $[C_{19}H_{18}ONI+H]^+$: 404.0506, found: 404.0508.



3k NHBz ¹H NMR (500 MHz, CDCl₃) δ 8.49 (d, J = 8.0 Hz, 1H), 8.29 (s, 1H), 7.84 (d, J = 7.5 Hz, 2H), 7.54 (t, J = 7.0 Hz, 1H), 7.47 (t, J = 7.5 Hz, 2H), 7.33 (t, J = 7.5 Hz, 1H), 7.19 (d, J = 7.0 Hz, 1H), 7.10 (t, J = 7.5 Hz, 1H), 6.13-6.02 (m, 2H), 5.88 (d, J = 11.5 Hz, 1H), 2.51 - 2.43 (m, 4H), 2.07 - 1.98 (m, 2H). ¹³C NMR (126 MHz, CDCl₃) δ 165.0, 136.2, 136.0, 135.4, 135.3₇, 135.3₅, 135.0, 131.8, 129.1, 128.9, 128.5, 128.1, 127.0, 124.1, 120.4, 31.8, 30.6, 28.1. HRMS (ESI+): calcd. for $[C_{20}H_{19}ON+H]^+$: 290.1539, found: 290.1539.




4k N Ph ¹H NMR (500 MHz, CDCl₃) δ 8.24 – 8.17 (m, 2H), 7.54 – 7.35 (m, 5H), 7.35 - 7.30 (m, 1H), 7.24 (dd, J = 7.5, 1.5 Hz, 1H), 6.26 - 6.19 (m, 1H), 6.09 (dd, J = 12.0, 2.0 Hz, 1H), 4.57 (dd, J = 6.5, 3.0 Hz, 1H), 2.77 - 2.66 (m, 1H), 2.66 - 2.57 (m, 1H), 2.50 - 2.40 (m, 1H), 2.22 – 2.06 (m, 2H), 1.88 - 1.77 (m, 1H). ¹³C NMR (126 MHz, CDCl₃) δ 155.5, 139.1, 136.3, 132.6, 131.8, 131.7, 129.6, 128.6, 128.0, 127.2, 126.7, 126.1, 125.4, 83.2, 58.4, 33.7, 28.0, 23.3. HRMS (ESI+): calcd. for [C₂₀H₁₈ONBr+H]⁺: 368.0645, found: 368.0638.




31 NHBz ¹H NMR (500 MHz, CDCl₃) δ 8.50 (d, J = 8.0 Hz, 1H), 8.46 (s, 1H), 7.84 (d, J = 8.0 Hz, 2H), 7.54 (t, J = 7.0 Hz, 1H), 7.47 (t, J = 7.5 Hz, 2H), 7.29 (t, J = 7.5 Hz, 1H), 7.16 - 7.03 (m, 2H), 5.71 (t, J = 7.0 Hz, 1H), 5.59 - 5.51 (m, 1H), 5.50 - 5.41 (m, 1H), 2.70 - 2.53 (m, 4H), 2.51 - 2.35 (m, 4H). ¹³C NMR (126 MHz, CDCl₃) δ 165.6, 137.9, 135.9, 135.4, 135.0, 131.8, 130.4, 129.6, 129.2, 128.7, 128.6, 127.7, 127.4, 123.7, 120.3, 34.0, 28.4, 27.6, 27.2. HRMS (ESI+): calcd. for [C₂₁H₂₁ON+H]⁺: 304.1696, found: 304.1695.



4 N Ph ¹H NMR (500 MHz, CDCl₃) δ 8.15 (d, J = 7.5 Hz, 2H), 7.54 - 7.40 (m, 3H), 7.40 - 7.30 (m, 2H), 7.23 (t, J = 7.0 Hz, 1H), 7.15 (d, J = 7.5 Hz, 1H), 5.89 - 5.78 (m, 1H), 5.73 - 5.63 (m, 1H), 4.87 (dd, J = 12.0, 4.5 Hz, 1H), 3.10 - 2.90 (m, 2H), 2.85 - 2.72 (m, 1H), 2.53 - 2.42 (m, 2H), 2.39 - 2.29 (m, 1H), 2.28 - 2.10 (m, 2H). ¹³C NMR (126 MHz, CDCl₃) δ 155.4, 139.9, 132.9, 132.5, 131.4, 129.5, 128.4, 127.9, 126.3, 126.0, 125.1, 124.5, 124.2, 85.2, 61.5, 39.1, 34.8, 25.6, 25.2. HRMS (ESI+): calcd. for $[C_{21}H_{20}ONBr+H]^+$: 382.0788, found: 382.0794.



3m ¹H NMR (500 MHz, CDCl₃) δ 8.55 (d, J = 8.0 Hz, 1H), 8.48 (s, 1H), 7.89 (d, J = 7.5 Hz, 1H), 7.82 (d, J = 8.0 Hz, 1H), 7.76 (d, J = 7.5 Hz, 2H), 7.55 - 7.45 (m, 3H), 7.45 - 7.35 (m, 5H), 7.23 (d, J = 7.5 Hz, 1H). ¹³C NMR (126 MHz, CDCl₃) δ 165.4, 140.5, 140.2, 139.8, 135.7, 134.7, 132.0, 131.1, 129.9, 129.0, 127.2, 125.0, 125.0, 124.9, 124.6, 124.1, 123.9, 122.5, 121.9. HRMS (ESI+): calcd. for [C₂₁H₁₅ONS+H]⁺: 330.0947, found: 330.0947.



4m N Ph ¹H NMR (600 MHz, CDCl₃) δ 7.94 - 7.89 (m, J = 8.3, 2H), 7.71 (dd, J = 7.5, 1.0 Hz, 1H), 7.49 - 7.44 (m, 2H), 7.44 - 7.34 (m, 6H), 7.29 - 7.22 (m, 2H), 5.73 (s, 1H). ¹³C NMR (151 MHz, CDCl₃) δ 155.5, 139.2, 138.4, 137.2, 132.1, 131.7, 131.2, 130.3, 128.6, 128.2, 127.9, 127.0, 126.6, 126.4, 125.4, 123.2, 122.2, 102.6, 58.6. HRMS (ESI+): calcd. for [C₂₁H₁₄ONBrS+H]⁺: 408.0052, found: 408.0050.




3n NHBz ¹H NMR (500 MHz, CDCl₃) δ 8.57 (s, 1H), 8.51 (d, *J* = 5.5 Hz, 1H), 8.48 (d, *J* = 5.5 Hz, 1H), 8.39 (s, 1H), 7.81 (d, *J* = 7.5 Hz, 2H), 7.59 (t, *J* = 7.5 Hz, 1H), 7.51 (t, *J* = 7.5 Hz, 2H), 5.61 (s, 1H), 5.21 (s, 1H), 2.16 (s, 3H). ¹³C NMR (126 MHz, CDCl₃) 165.6, 149.9, 148.8, 141.3, 140.1, 134.3, 132.6, 129.2, 127.7, 127.1, 119.0, 113.6, 24.8. HRMS (ESI+): calcd. for [C₁₅H₁₄ON₂+H]⁺: 239.1179, found: 239.1176.




4n N Ph ¹H NMR (400 MHz, CDCl₃) δ 8.57 (d, J = 5.0 Hz, 1H), 8.43 (s, 1H), 8.22 (d, J = 7.5 Hz, 2H), 7.59 – 7.51 (m, 1H), 7.48 (t, J = 7.5 Hz, 2H), 7.21 (d, J = 5.0 Hz, 1H), 3.77 (d, J = 11.5 Hz, 1H), 3.62 (d, J = 11.5 Hz, 1H), 1.98 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 160.2, 151.7, 146.0, 145.1, 132.8, 131.6, 128.9, 128.6, 122.6, 119.3, 77.8, 39.6, 25.4. HRMS (ESI+): calcd. for [C₁₅H₁₃ON₂Br+H]⁺: 317.0284, found: 317.0286.




6n N Ph ¹H NMR (500 MHz, CDCl₃) δ 8.56 (d, J = 5.0 Hz, 1H), 8.42 (s, 1H), 8.25 (dd, J = 8.5, 1.5 Hz, 2H), 7.64 - 7.54 (m, 1H), 7.48 (t, J = 7.5 Hz, 2H), 7.20 (d, J = 5.0 Hz, 1H), 3.67 (d, J = 11.0 Hz, 1H), 3.54 (d, J = 11.0 Hz, 1H), 1.98 (s, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 160.1, 151.6, 145.8, 145.0, 132.7, 131.5, 129.0, 128.6, 122.7, 119.4, 26.9, 15.0 (1 resonance missing). HRMS (ESI+): calcd. for [C₁₅H₁₃ON₂I+H]⁺: 365.0145, found: 365.0137.




30 NHBz ¹H NMR (500 MHz, CDCl₃) δ 8.47 (s, 1H), 8.11 (d, J = 8.0 Hz, 1H), 7.84 (d, J = 7.5 Hz, 2H), 7.56 - 7.43 (m, J = 27.3, 3H), 7.34 - 7.27 (m, 1H), 7.18 - 7.11 (m, 2H), 5.44 (s, 1H), 5.18 (s, 1H), 2.86 - 2.77 (m, 2H), 2.53 (s, 6H), 2.47 (t, J = 7.3 Hz, 2H), 1.88 - 1.76 (m, 2H). ¹³C NMR (126 MHz, CDCl₃) δ 165.6, 145.2, 134.5, 134.3, 133.8, 132.1, 129.3, 128.5, 128.4, 127.1, 125.0, 123.3, 117.5, 57.4, 43.0, 34.6, 22.8. HRMS (ESI+): calcd. for [C₂₀H₂₄ON₂+H]⁺: 309.1961, found: 309.1956.




¹H NMR (500 MHz, CDCl₃) δ 8.19 (d, J = 7.5 Hz, 1H), 40 7.57 - 7.42 (m, 3H), 7.42 - 7.30 (m, 2H), 7.25 - 7.19 (m, 1H), 7.11 (d, J = 7.5 Hz, 1H), 3.77 (d, J = 11.0 Hz, 1H), 3.64 (d, J = 11.0 Hz, 1H), 2.43 - 2.08 (m, 10H), 1.69 - 1.54 (m, 1H), 1.54 - 1.40 (m, 1H). ¹³C NMR (126 MHz, CDCl₃) δ 156.2, 139.8, 132.4, 131.6, 129.6, 128.4, 128.2, 126.9, 125.9, 125.0, 123.6, 81.3, 59.3, 45.4, 40.6, 35.8, 22.2. HRMS (ESI+): calcd. for $[C_{20}H_{23}ON_2Br+H]^+$: 387.1067, found: 387.1070.




¹H NMR (500 MHz, CDCl₃) δ 10.13 (s, 1H), 8.56 (d, J = 8.0 Hz, **3**p 1H), 8.32 (dd, J = 8.0, 1.5 Hz, 1H), 7.54 - 7.44 (m, 1H), 7.32 (t, J = 7.5 Hz, 1H), 7.20 - 7.06 (m, 3H), 7.02 (d, J = 8.5 Hz, 1H), 5.41 (s, 1H), 5.12 - 5.07 (m, 1H), 4.00 (s, 3H), 2.11 (s, 3H). ^{13}C NMR (126 MHz, CDCl₃) δ 163.3, 157.3, 143.9, 135.2, 134.3, 133.3, 132.8, 128.0, 123.7, 122.0, 121.6, 121.5, 116.7, 111.4, 55.78, 24.41 (1 resonance missing).




¹H NMR (500 MHz, CDCl₃) δ 7.76 (dd, J = 7.5, 1.5 Hz, 1H), 7.45 4p -7.39 (m, 1H), 7.38 - 7.30 (m, 2H), 7.27 - 7.21 (m, 1H), 7.17 (d, J = 7.5 Hz, 1H), 7.02 (t, J = 7.5Hz, 1H), 6.97 (d, J = 8.5 Hz, 1H), 3.90 (s, 3H), 3.84 (d, J = 11.0 Hz, 1H), 3.69 (d, J = 11.0 Hz, 1H), 1.90 (s, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 158.6, 157.1, 139.1, 132.2, 131.2, 129.6, 127.0, 126.8, 125.6, 123.7, 122.8, 120.5, 111.9, 79.0, 66.0, 39.6, 25.4.




OMe ¹H NMR (400 MHz, CDCl₃) δ 8.56 - 8.31 (m, 2H), 7.80 (d, **3**q J = 8.5 Hz, 2H), 7.30 (t, J = 7.5 Hz, 1H), 7.18 (d, J = 7.5 Hz, 1H), 7.10 (t, J = 7.5 Hz, 1H), 6.96 (d, J = 8.5 Hz, 2H), 5.47 (s, 1H), 5.11 (s, 1H), 3.84 (s, 3H), 2.11 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) § 164.6, 162.4, 143.4, 134.2, 133.5, 128.8, 128.0, 127.7, 127.3, 123.7, 120.8, 116.7, 114.0, 55.4, 24.6.



¹H NMR (400 MHz, CDCl₃) δ 8.17 (d, J = 9.0 Hz, 2H), OMe **4**q 7.39 - 7.28 (m, 2H), 7.24 - 7.14 (m, 2H), 6.96 (d, J = 9.0 Hz, 2H), 3.87 (s, 3H), 3.76 (d, J = 11.0 Hz, 1H), 3.53 (d, J = 11.0 Hz, 1H), 1.92 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 162.6, 156.3, 139.5, 130.3, 129.7, 127.1, 126.5, 125.4, 124.8, 123.3, 113.8, 78.0, 55.6, 39.8, 24.8.



¹H NMR (500 MHz, CDCl₃) δ 8.57 - 8.31 (m, 2H), 7.76 (d, J = 8.0 3r Hz, 2H), 7.47 (d, J = 8.0 Hz, 2H), 7.33 (t, J = 8.0 Hz, 1H), 7.20 (d, J = 7.5 Hz, 1H), 7.13 (t, J = 7.5 Hz, 1H), 5.48 (s, 1H), 5.11 (s, 1H), 2.12 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 164.1, 143.4, 138.2, 133.9, 133.6, 133.5, 129.3, 128.5, 128.2, 127.8, 124.3, 120.8, 117.0, 24.8.



4r

¹H NMR (500 MHz, CDCl₃) δ 8.21 - 8.10 (m, 2H), 7.46 -7.41 (m, 2H), 7.41 - 7.31 (m, 2H), 7.29 - 7.21 (m, 1H), 7.17 (d, J = 7.5 Hz, 1H), 3.75 (d, J = 11.5 Hz, 1H), 3.54 (d, J = 11.5 Hz, 1H), 1.93 (s, 2H). ¹³C NMR (126 MHz, CDCl₃) δ 155.4, 139.0, 138.0, 130.9, 129.8, 129.8, 128.7, 127.2, 127.1, 125.7, 123.4, 78.4, 39.9, 24.9.





`*t-*Bu ¹H NMR (400 MHz, CDCl₃) δ 8.34 (d, J = 8.3 Hz, 1H), 7.98 (s, 35 1H), 7.30 - 7.23 (m, 1H), 7.13 (d, J = 7.5 Hz, 1H), 7.06 (t, J = 7.5 Hz, 1H), 5.43 (s, 1H), 5.06 -5.00 (m, 1H), 2.07 (s, 3H), 1.28 (s, 9H). ¹³C NMR (101 MHz, CDCl₃) δ 176.4, 143.4, 134.3, 133.3, 128.0, 127.6, 123.6, 120.5, 116.8, 40.2, 27.7, 24.6.





t-Bu ¹H NMR (400 MHz, CDCl₃) δ 7.36 - 7.25 (m, 1H), 7.24 - 7.14 (m, 4s2H), 7.08 (d, J = 7.5 Hz, 1H), 3.64 (d, J = 11.0 Hz, 1H), 3.51 (d, J = 11.0 Hz, 1H), 1.78 (s, 3H), 1.29 (s, 9H). ¹³C NMR (101 MHz, CDCl₃) δ 167.4, 139.0, 129.4, 126.5₄, 126.5₁, 125.3, 123.3, 39.9, 37.6, 27.8, 25.4 (1 resonance missing).


AVQ-400 QMP Proton starting parameters. 7/16/03. Revised 7/22/03 RN


















1H starting parameters (zg30) DRX-500 TBIC












































AV-600 ZBO proton starting parameters 11/16/08 RN









AV-600 ZBO proton starting parameters 11/16/08 RM




AV-600 ZBO proton starting parameters 11/16/08 RN











AV-600 ZBO proton starting parameters 11/16/08 RN















































































Determination of enantioselectivity:


Enantioselectivity was determined by chiral HPLC using Daicel OD-H, AD-H, OJ-H, IA, IB, and IC and the Regis WHELK-O1 columns (0.46 x 25 cm). With the exception of **4f**, **4k**, **4l**, and **4o**, racemic product was generally prepared by reaction with reagent **1d** in acetonitrile under homogeneous conditions. The racemic products **4f**, **4k**, **4l**, and **4o**, we generated by using *rac*-TRIP in place of (*R*)-TIPS-TRIP using the phase-transfer conditions given in "General procedure for halocyclizations."

Chiral HPLC separation conditions and retention times for products:


4a: OD 99:01 hexanes/isopropanol, 1 ml/min, $t_m = 7.4 \text{ min}$, $t_M = 9.4 \text{ min}$. **4b:** OD 99:01 hexanes/isopropanol, 1 ml/min, $t_m = 8.3 \text{ min}$, $t_M = 9.5 \text{ min}$. **4c:** OD 99:01 hexanes/isopropanol, 1 ml/min, $t_m = 8.5 \text{ min}$, $t_M = 9.7 \text{ min}$. **4d:** Two WHELK columns in series, 99:01 hexanes/isopropanol, 0.5 ml/min, $t_m = 19.6 \text{ min}$, $t_M = 19.6 \text$ 18.0 min. **4e:** OD 99:01 hexanes/isopropanol, 1 ml/min, $t_m = 6.4 \text{ min}$, $t_M = 6.9 \text{ min}$. **4f:** OD 92:08 hexanes/isopropanol, 1 ml/min, $t_m = 13.5$ min, $t_M = 15.3$ min. **4g:** OD 99:01 hexanes/isopropanol, 1 ml/min, $t_m = 14.7 \text{ min}$, $t_M = 16.6 \text{ min}$. **4h:** OD 99:01 hexanes/isopropanol, 1 ml/min, $t_m = 7.1 \text{ min}$, $t_M = 9.6 \text{ min}$. **4i:** OD 99:01 hexanes/isopropanol, 1 ml/min, $t_m = 8.5 \text{ min}$, $t_M = 11.8 \text{ min}$. **4j:** OD 99:01 hexanes/isopropanol, 1 ml/min, $t_m = 7.3 \text{ min}$, $t_M = 6.5 \text{ min}$. **4k:** Two WHELK columns in series, 99:01 hexanes/isopropanol, 0.5 ml/min, $t_m = 14.7 \text{ min}$, $t_M = 14.7 \text$ 15.8 min. **41:** OD 99:01 hexanes/*n*-butanol, 0.5 ml/min, $t_m = 14.8 \text{ min}$, $t_M = 11.8 \text{ min}$. **4m:** OD 99:01 hexanes/isopropanol, 1 ml/min, $t_m = 17.5 \text{ min}$, $t_M = 9.9 \text{ min}$. **4n:** IB 95:05 (80:1 hexanes/*n*-butylamine)/isopropanol, 1 ml/min, $t_m = 12.7$ min, $t_M = 10.8$ min. **40:** OJ 97:03 (80:1 hexanes/*n*-butylamine)/isopropanol, 1 ml/min, $t_m = 7.9$ min, $t_M = 11.8$ min. **4p:** OD 97:03 hexanes/isopropanol, 1 ml/min, $t_m = 6.6 \text{ min}$, $t_M = 18.2 \text{ min}$. **4q:** OD 98:02 hexanes/isopropanol, 1 ml/min, $t_m = 8.9$ min, $t_M = 13.3$ min. **4r:** OD 99:01 hexanes/isopropanol, 1 ml/min, $t_m = 6.2 \text{ min}$, $t_M = 7.1 \text{ min}$. **4s:** OD 99:01 hexanes/isopropanol, 1 ml/min, $t_m = 4.6 \text{ min}$, $t_M = 5.2 \text{ min}$. **6b:** OD 99:01 hexanes/isopropanol, 1 ml/min, $t_m = 7.1 \text{ min}$, $t_M = 8.5 \text{ min}$. 6j: AD 99:01 hexanes/isopropanol, 0.5 ml/min, $t_m = 6.2 \text{ min}$, $t_M = 7.5 \text{ min}$. **6n:** IB 95:05 (80:1 hexanes/*n*-butylamine)/isopropanol, 1 ml/min, $t_m = 12.9$ min, $t_M = 11.6$ min.

HPLC traces:


4a:




4b:




4c:




4d:




4e:




4f:




4g:




4h:




4i




4j:




4k:




4l:




4m:




4n:




4o:




4p:




4q:




4r:




4s:




6b:



6j:




6n:



CHAPTER 4: COMBINATION OF CHIRAL ANION PHASE-TRANSFER CATALYSIS AND DIRECTING GROUPS FOR ALKENE FLUORINATION

Abstract:

The combination of directing groups and chiral anion phase-transfer catalysis allows chiral phosphoric acids to catalyze the direct fluorination of alkenes to generate tertiary and quaternary C(sp3)-F bonds, and β -amino- and β -aryl- allylic fluoride moieties. Essentially, a reactive electrophilic chiral ion pair *interacts* with a hydrogen-bond donor directing group but *fluorinates* a remote alkene. A variety of heterocyclic, carbocyclic, and acyclic allylic fluoride products were provided with good to excellent yields and high enantioselectivity. Further, by using two electrophilic salts of differing reactivity, we were able to perform a one-pot, two-step dihalogenation-cyclization reaction sequence utilizing the same catalytic cycle twice.



electrophilic fluorinating reagent generated in-situ

Introduction

Organocatalysts have largely been developed around the idea that hydrogen-bonding can act as a strong attractive interaction between substrate and catalyst, allowing the creation of a pair of diastereomeric transition states. However, the use of hydrogen-bonding in organocatalysis has not been extended to directing groups (DG). Instead, almost all examples have relied on hydrogen-bonding directly with the reactive functional group. Directing groups (DGs) have been used both in the field of enantioselective transition-metal catalysis and for C-H activation.¹⁻⁶ DGs provide the ability to functionalize non-polar bonds (such as alkenes), while maintaining beneficial polar interactions between the substrate and chiral source, by following a similar reactivity model as that described in previous reports of directed reactions (Figure 1).




Figure 1. Top: Substrate-catalyst interactions in precedented metal-catalyzed and organocatalytic directed enantioselective reactions with alkenes. Bottom: Modes of activation of polar groups in chiral phosphoric acid catalysis, compared to this work - directed interaction with alkenes.

Within organocatalysis, the Miller research group has developed an enantioselective epoxidation reaction of allylic alcohols using amino acid catalysts featuring aspartate, capable of hydrogen-bonding with a remote alcohol DG (Figure 1).⁷ In another mode of catalysis, the Tan group has designed bifunctional *covalent* catalysts which are capable of scaffolding and organizing the transition state to provide enantioselectivity.⁸⁻¹⁰




Figure 2. Modes of enantioinduction in electrophilic fluorination.

Both these modes of activation achieve enantioselectivity with catalysts which organize the reactants in the transition state (Figure 1), rather than LUMO-lowering protonation or hydrogenbonding, which has generally been utilized for substrates containing carbon-heteroatom unsaturated bonds such as carbonyls or imines.¹¹⁻¹³ Generally, chiral phosphoric acids have been predominantly used as Brønsted acids in LUMO-lowering activation of a polar electrophile. It is notable that hydrogen bonding to the incoming nucleophile has also been implicated as a key component of achieving enantioselectivity.¹⁴ Based on the well-established ability of phosphoric acids to hydrogen-bond with substrates, we saw an opportunity to combine transition-state organization catalysis with chiral anion phase-transfer catalysis which was introduced in chapter 3. The hypothesis here is that a remote hydrogen-bonding DG could effectively direct an ion-paired chiral phosphate species for the enantioselective fluorination of alkenes (Figure 1, Bottom).

In-situ for mation of a chiral Electrophilic fluorine source




Figure 3. Both solubility and chirality are provided by the organophosphate, when it is ionpaired with the DABCO-derived electrophilic fluorine moiety. In the presence of base, the phosphate is generated in-situ to act as the active catalyst.

Compared with nucleophilic fluorinating reagents which can be used for stereospecific reactions, electrophilic reagents are easier to handle, have a range of reactivity, and are more commonly used in the development of enantioselective fluorination methods (Figure 2). Our recent enantioselective halocyclization methods utilized chiral anion phase-transfer catalysis, in which ion exchange between an insoluble electrophilic salt (such as Selectfluor) and a soluble chiral lipophilic phosphate anion derived from catalysts such as TRIP generates in-situ a chiral electrophilic salt (Figure 3).^{15,16} In addition, our reports of enantioselective fluorinations demonstrated that activated alkenes such as enamides react with high enantioselectivity and yield using the same phase-transfer system.^{17,18} In both examples, hydrogen-bonding between the reacting functional group (amide) and the phosphate catalyst is hypothesized to facilitate the reaction. The enantioselective synthesis of allylic fluorides has been recently achieved by a few research groups - allylic chlorides undergo palladium-catalyzed nucleophilic fluorination in the presence of silver fluoride, while allylsilanes undergo electrophilic fluorination with NFSI in the presence of cinchona alkaloid catalysts (Figure 4).¹⁹⁻²³ While these are useful advancements in the synthesis of these moieties, they suffer limitations such as the requirement of prefunctionalizing the alkene, as well as the use of transition-metals, and long reaction times - at times requiring up to a week for completion.




Figure 4. Top: Enantioselective transformation of allylic chlorides to allylic fluorides using palladium-catalysts. Bottom: Organocatalytic enantioselective allylic fluorination using cinchona alkaloids.

On the other hand, the desirable direct fluorination of a variety of alkenes was reported in racemic fashion by Loh and co-workers (Figure 5).²⁴ This homogeneous reaction required heating, demonstrating the relatively low reactivity of the unactivated alkene toward Selectfluor. Nevertheless, we envisioned that this reaction could be rendered enantioselective by taking advantage of a DG capable of participating in hydrogen-bonding with the phosphate phase-transfer catalyst.




Figure 5. Racemic direct fluorination of alkeness exiting Selert faces, yielder homogeneous conditions.

Results and Discussion

Based on the previous success with benzamides in our phase-transfer system, we initially investigated their ability to act as DGs for direct alkene fluorination. Furthermore, we saw this as an opportunity to access enantioenriched tertiary β —fluoroamines, which has been an outstanding challenge for synthetic chemists, while being useful for the development of drug candidates.²⁵⁻²⁹ Enantioselective fluorination of substrates with no hydrogen-bond donor containing directing group was attempted with poor results, verifying our initial hypothesis that a directing group with hydrogen-bonding capabilities would be required and beneficial.²⁴




Table 1. Optimization of product distribution and enantioselectivity by catalyst and solvent screening.

Specifically, enantioselectivies no higher than 10% ee were obtained. After the installation of a pendant amide group, fluorination proceeded to provide product **1b** in 82% yield and 85% ee (Table 1, entry 1). Also in accord with our hypothesis that a remote hydrogen-bond donor may be essential to direct fluorination, *N*-methylated amide analog of **1a** gave less than 10% conversion under identical conditions (Figure 6). Interestingly, this is evidence of the amide N-H participating in increasing reactivity as well as selectivity. This is in-line with such observations from covalent catalysis, often referred to as induced-intramolecularity. In principle, the transition-state organization provided by attractive and stabilizing interactions increases reactivity (Figure 6). In other words, it seems like the hydrogen-bonding DG improves both enantioselectivity and reactivity. When the phase-transfer catalyst was left out of the reaction

mixture, the fluorination did not proceed, thus verifying that a phase-transfer process is indeed essential, and that there is no background reaction with Selectfluor.




Figure 6. The amide N-H participates in lowering the activation barrier, inducing intramolecularity by hydrogen-bonding. The amide also directs the chiral reagent and is essential for enantioselectivity.

A solvent screen revealed that changing the solvent to toluene helped increase selectivity for the desired allylic fluoride product at the expense of side product 1c (resulting from nucleophilic attack by the amide) (entry 2). Allylic fluorination and cyclization products could be produced from a common fluorinated carbocationic intermediate as a result of deprotonation or nucleophilic attack. As formation of the C-F bond is presumably enantiodetermining for both, the significantly lower enantioselectivity observed for the cyclization product 1c (48% ee; Table 1, entry 1) suggest that there is no shared cationic intermediate and that the two reaction pathways are divergent at an earlier stage. In addition we showed that the allylic fluoride could not be produced in greater enantioselectivity through a kinetic resolution (by an elimination reaction of 1c) in an experiment where we resubjected 2b to reaction conditions with no observed conversion (Figure 7).





Figure 7. Product does not ring-open to form 2a, and the two pathways are distinct (no common benzylic carbocation exists).

A catalyst screen revealed that STRIP provided improvements over the commercially available TRIP.³⁰ The role of the phosphate-directing group interaction is further confirmed by the observation that the undesired cyclization pathway predominates when the reaction was run in acetonitrile under homogeneous conditions (Table 1, entries 5-6). The reactivity under phase-transfer conditions differs greatly from under homogeneous conditions.




a) ee (%) determined by chiral HPLC. b) Conversion determined by NMR >90% for all entries c) With (S)-TRIP rather than (R)-STRIP

Table 2. Studies on electronic and steric factors using amide DGs. Enantioselectivity generally increased with steric bulk on the amide.

While we were exploring substrate scope with the tetralone core and other modifications, we undertook a study to determine whether steric and electronic factors were at play in the

preferential reactivity of benzamides. In addition, we hoped that the understanding would also help in finding a cleavable directing group rather than being solely able to use benzamides. The ability to use non-benzamide DG would be a step forward for chiral anion phase-transfer catalysis in the Toste group, as well as for this particular method. Various substrates were synthesized with electronic and steric variations (Table 2). Chlorinated and fluorinated acetyl derivatives provided insight into the influence of electronegativity, while increasingly bulky alkyl derivatives revealed the effect of changes in steric bulk. Predictably, increased enantioselectivity tracked well with increased steric bulk (t-Bu > i-Pr > Me; entries 1-3). Identical enantioselectivities were achieved with CH₃ and CHF₂ substituents (entries 1 and 5), but one additional fluorine increased enantioselectivity from 30% to 82% ee (entry 5 vs. 6). We postulate that the rotation of the CHF₂ group can minimize steric interactions which are not possible with the symmetrically bulky CF₃. A further increase in size to CCl₃ (TCA), while decreasing the electron-withdrawing ability, improved enantioselectivity to a synthetically useful 93% ee. In addition, comparison of entries 3 and 4 indicate that a phenyl group, due to either electon-withdrawing or pi-stacking interactions, improves enantioselectivity. We found this to be beneficial also in the development of alcohol derived DGs. Unfortunately, more substantial changes such as the use of p-toluenesulfonamide as the directing group provided product with 67% conversion by NMR analysis and only 18% ee - hence we decided not to investigate any other classes of DG. In addition to being highly efficient for the desired transformation, the TCA group was readily hydrolyzed with potassium hydroxide to provide free amine in 90% yield with no racemization of the fluorinated stereocenter (determined by derivatization of the amine), thus allowing access to primary β-fluoroamines and ability to access a number of amine derivatives not necessarily containing the DGs we have optimized (Figure 10).

Table 3 sums up the various changes we made to the core and amide DG. Good yields and high enantioselectivities were maintained with medium-sized rings (entries 3 and 4). The method tolerates electron-withdrawing and electron-donating groups on the fused benzene ring, even when in an electronically significant (by resonance donation/activation) position (entry 8). Chromanone-derived heterocyclic substrates **9a** and **14a** were fluorinated with good yield and high enantioselectivity (96% ee and 97% ee, respectively) to generate heterocyclic fluorinated products.




a) Reaction run at room temperature. b) Product isolated with cyclized by-product in 10:1 ratio. c) Reaction run for 36 h. d) All stereochemistry defined in analogy to compound **14b** (see Supporting information for

crystallography details)

 Table 3. Scope of amide DG substrates.

As seen in the amide DGs, pi-stacking or some other electronic effects from an aromatic ring does have an effect. We had recently observed that phenol acts as a competent hydrogenbond donor in enantioselective fluorination and dearomatization reactions.³¹ Specifically, compound **18a** was found to direct fluorination with high enantioselectivity by Robert Phipps, who was exploring dearomatization. Thus, in addition to amides, 2-hydroxyphenyl was serendipitously discovered to be a DG which promotes enantioselective fluorination of a variety of alkenes under identical reaction conditions (Table 4). In the examples shown here, we observe that the presence of more highly substituted double bonds changes the chemoselectivity, and fluorination of the alkene is seen exclusively rather than fluorination of the phenol. Both β -phenolic tertiary and quaternary fluorides with alkyl, aryl, or heteroaryl substituents were

obtained with good to high enantioselectivity and yield. Compound **23a**, which contains both an allyl and 3,3-dimethylallyl group ortho- to the hydroxyl, reacts specifically to provide the allylic fluoride in 53% ee, which is a surprising result due to the relatively similar steric bulk of the two faces of the compound. Further, fluorinated piperidine **19b** was obtained in moderate yield and enantioselectivity - a facile synthesis of a scaffold which has been explored in therapeutic agents.³² This was achieved with a change in catalyst to one previously reported by Du and coworkers – use of TRIP or STRIP with this substrate provided no reactivity. Interestingly, when the hydroxyl group was shifted to be meta- to the alkene, no reaction was seen. In addition, the use of benzamides in the place of the hydroxyl did not provide desired product. The ideal location of the hydroxyl donor is specific, and different from the ideal location of the benzamide donor. In agreement with previous results, conversion was severely diminished (< 10%) when the phenoxy group was methylated, presumably due to the inability of the methyl ether moiety to effectively participate in hydrogen-bonding with the catalysts. Even with these requirements in DG position and identity, we anticipate that the enantioselective construction of β -amino and β -aryl sp3-C-F bonds will still be valuable in drug discovery.³³



a) Selectfluor (1.35 equiv), Na_2CO_3 (1.45 equiv), (*R*)-STRIP (0.1 equiv), toluene, rt, 18 h. b) Reaction run 36 h. c) Du catalyst (Ref 34) used instead of (*R*)-STRIP. d) All stereochemistry defined in analogy to compound **17b** (see Supporting information for crystallography details).

 Table 4. 2-Hydroxylphenyl DG effective for various alkenes.




Figure 8. Various hydroxyl-DGs explored. Reaction conditions identical to Table 3. Conversion was followed by NMR, and reactions were run for 24-48 h or until starting material had been completely consumed.





Figure 9. Substrate with similar ortho-substituents reacted regioselectively and with moderate enantioselectivity. Shift of the hydroxyl-DG, or replacement with benzamide, are both detrimental to reactivity.


Some effort and serendipity was required to identify a suitable DG which was not aminederived. In the Toste group at this point all of the phase-transfer fluorinations required benzamides. Efforts in expanding this focused on hydroxyl (O-H) based DGs. However, initial results indicated that simple alcohols did not provide high enantioselectivity, maybe due to its small steric parameters or lack of rigidity. First, a bulkier alcohol DG on substrate 15 was found to be ineffective for providing enantioselectivity. Next, benzoylated hydroxylamines were explored in order to mask an alcohol (which would be revealed by deprotection by hydrogenation) as a functional group with the previously successful amide moiety. However, the extended tether length in these cases was detrimental and enantioselectivity was not improved. The incorporation of phenol was investigated with substrate 22 (Figure 8). We explored whether alcohols and amide DG could be interchangeable in analogous substrates 19 and 24; where a hydroxyl group promoted the reaction, a benzamide with the acidic hydrogen in the exact same position did not promote the reaction. When the hydroxyl-DG was moved from ortho- to meta-, the reaction also did not proceed. Thus, there is specificity regarding hydrogen-bond donor location (Figure 9). Another observation of the difference in reactivity between directing groups was that acyclic substrates were not amenable to amide-directed fluorination - with the benzamide DG, exclusively cyclized product was observed, while with TCA no reaction was observed. Thus, only phenol DG was capable of creating tertiary fluorine-containing carbon centers with these types of substrates.

A tandem reaction was achieved using our previously reported electrophilic bromination reagent **28** to further functionalize the product from the fluorination reaction.¹⁶ This reaction proceeds in two steps, using the same catalytic cycle and phase-transfer process. The important factor is the orthogonal reactivity of the two reagents – Selectfluor does not do the halocyclization, while reagent **28** does. The experiment consisted of subjecting **8a** to the standard fluorination conditions for 18 h ("F+") described above, followed by addition of **28** ("Br+") and an equivalent of base, under air.

Deprotection of TCA directing group



One-pot dihalogenation: electrophilic fluorination and bromination



45% yield (one pot), **92% ee**

Figure 10. Reactions with enantioenriched allylic fluoride products.


Complex heterocyclic framework of **20** formed in good yield and high diastereo- and enantioselectivity, including two adjacent stereocenters and the incorporation of two different halogen atoms (Figure 10).

An enantioselective allylic fluorination has been achieved through the combination of DG and phase-transfer catalysis. The phosphoric acid catalyst acts both as a phase-transfer catalyst and a hydrogen-bonding catalyst, and allows the chiral electrophilic fluorine source to react with an unactivated alkene. The attractive hydrogen-bonding interaction requires a hydrogen-bond donor DG on the substrate, which we identified as either an amide or phenol. Various substrates were subjected to these reaction conditions with good results – tertiary, quaternary, cyclic and acyclic substrates were successful. Finally, the application of two electrophilic salts in two sequential reactions was achieved in one-pot to generate highly functionalized compounds in high diastereoselectivity and enantioselectivity.

References

- 1. Hoveyda A. H., Evans D. A., Fu G. C. Chem. Rev. 1993, 93, 1307-1370.
- 2. Engle K. M., Mei T.-S., Wasa M., Yu J.-Q. Acc. Chem. Res. 2012, 45, 788-802.
- 3. Colby D. A., Tsai A. S., Bergman R. G., Ellman J. A. Acc. Chem. Res. 2012, 45, 814-825.
- 4. Zhang X.-G., Dai H.-X., Wasa M., Yu J.-Q. J. Am. Chem. Soc. 2012, 134, 11948-11951.
- 5. Neufeldt S. R., Sanford M. S. Acc. Chem. Res. 2012, 45, 936-946.
- 6. Zhu C., Wang R., Falck J. R. Chem. Asian. J. 2012, 7, 1502-1514.
- 7. Peris G., Jakobsche C. E., Miller S. J. J. Am. Chem. Soc. 2007, 129, 8710-8711.
- 8. Tan K. L. ACS Catalysis, 2011, 1, 877-886.
- 9. Lightburn T. E., Dombrowski, M. T., Tan K. L. J. Am. Chem. Soc. 2008, 130, 9210-9211.
- 10. Tan K. L., Sun X., Worthy A. D. Synlett, 2012, 23, 321-325.
- 11. Phipps R. J., Hamilton G. L., Toste F. D. Nat. Chem. 2012, 4, 603-614.
- 12. Mahlau M., List B. Angew. Chem. Int. Ed. 2013, 52, 518-533.
- 13. Brak K., Jacobsen E. N. Angew. Chem. Int. Ed. 2013, 52, 534-561.
- 14. Simon L., Goodman J. M. J. Org. Chem. 2011, 76, 1775-1788.
- 15. Rauniyar V., Lackner A. D., Hamilton G. L., Toste F. D. Science, 2011, 334, 1681-1684.
- 16. Wang Y.-M., Wu J., Hoong C., Rauniyar V., Toste F. D. J. Am. Chem. Soc. 2012, 134, 12928-12931.
- 17. Honjo T., Phipps R. J., Rauniyar V., Toste F. D. Angew. Chem. Int. Ed. 2012, 51, 9684-9688.
- 18. Phipps R. J., Hiramatsu K., Toste F. D. J. Am. Chem. Soc. 2012, 134, 8376-8379.
- 19. Katcher M. H., Sha A., Doyle A. G. J. Am. Chem. Soc. 2011, 133, 15902-15905.
- 20. Ishimaru T., Shibata N., Horikawa T., Yasuda N., Nakamura S., Toru T., Shiro M. Angew. Chem. Int. Ed. 2008, 47, 4157-4161.
- 21. Tredwell M., Tenza K., Pacheco M. C., Gouverneur V. Org Lett. 2005, 7, 4495-4497.
- 22. Katcher M. H., Doyle A. G. J. Am. Chem. Soc. 2010, 132, 17402-17404.
- 23. For a review: Pacheco M. H., Purser S., Gouverneur V. Chem. Rev. 2008, 108, 1943-1981.
- 24. Luo H.-Q., Loh T.-P. Tetrahedron Lett. 2009, 50, 1554-1556.
- 25. Brunet V. A., O'Hagan D. Angew. Chem. Int. Ed. 2008, 47, 1179-1182.
- 26. Lectard S., Hamashima Y., Sodeoka M. Adv. Synth. Catal. 2010, 352, 2708-2732.
- 27. Duthion B., Pardo D. G., Cossy J. Org. Lett. 2010, 12, 4620-4623.
- 28. Kalow J. A., Schmitt D. E., Doyle A. G. J. Org. Chem. 2012, 77, 4177-4183.
- 29. Fadeyi O. O., Lindsley C. W. Org. Lett. 2009, 11, 943-946.
- 30. Coric I., Mueller S., List B. J. Am. Chem. Soc. 2010, 132, 17370-17373.
- 31. Phipps R. J., Toste F. D. J. Am. Chem. Soc. 2013, 135, 1268-1271.
- 32. Chang M.-Y., Lee N.-C., Lee M.-F., Huang Y.-P., Lin C.-H. *Tetrahedron Lett.* **2010**, *51*, 5900-5903.
- 33. Hagman W. K. J. Med. Chem. 2008, 51, 4359-4369.
- 34. Guo Q.-S., Du D.-M., Xu J. Angew. Chem. Int. Ed. 2008, 47, 759-762; Catalyst 1d.

Supporting Information



Representative synthesis of substrates


PBr₃ (8mL, 2.5 equiv) was added to DMF (7.8mL, 3.0 equiv) in DCM (150 mL) at 0 °C then warmed to room temperature for 1.5 h. Starting material tetralone (5g, 33.7mmol) was added as a solution in DCM (15mL), then the mixture was refluxed. The reaction was quenched with water at 0 °C followed by 20 min of stirring and extraction with DCM. The organic phase was washed with brine and dried with magnesium sulfate. NaBH₄ (0.19g, 1 equiv) was added to **S2** (4.94mmol) in MeOH (30mL) at 0 °C and stirred for one hour. The reaction was warmed up to room temperature and stirred another hour before evaporation of the solvent. The crude mixture was partitioned between methylene chloride and water, and the organic layer separated, dried with magnesium sulfate, and chromatographed (EtOAc: Hex; 3:1) to provide white solid **S3** (88% yield).

S3 was combined with PPh₃ (1.3 equiv) and phthalimide (1.3 equiv) in THF and cooled to 0 $^{\circ}$ C, followed by slow addition (over 30 min.) of DIAD (1.3 equiv). The reaction was warmed up to room temperature and stirred another 2 h, followed by direct silica-gel chromatography (EtOAc: Hex, 4:1) to provide solid S4 (57%).

Hydrazine hydrate (7 equiv) was added to S4 in THF and heated to 60 °C for 16 h. The reaction mixture was diluted with methylene chloride and filtered with Celite. The organic layer was washed with water, then brine, and dried with magnesium sulfate to provide amine S5 (95%).

Triethylamine and benzoyl chloride were added to **S5** in THF at 0 $^{\circ}$ C, and warmed up to room temperature immediately. The reaction was stirred for 8 h followed by filtration with Celite. The filtrate was partitioned between ethyl acetate and water, and the organic layer was separated, washed with brine, and dried with magnesium sulfate. Silica gel chromatography (EtOAc: Hex, 4:1) provided **S6** (85%).

 $Pd(OAc)_2$ (0.05 equiv), SPhos (0.1 equiv), K_3PO_4 (5 equiv), and trimethylboroxine (3 equiv) were added to **S6** in dioxane:H₂O (10:1, 0.2M) at room temperature, then heated to 70 °C for 18 h. The reaction mixture was filtered with Celite, followed by extraction with ethyl acetate. The organic layer was washed with ammonium chloride (sat. aq.), followed by water, then brine, and then dried with magnesium sulfate. Chromatography (EtOAc: Hex, 4:1) provided **S7** (80%).




S9 was prepared from **S8** by a precedented method. Dropwise DIBAL-H addition to a THF solution of **S9** at -78° C followed by stirring for 2 h, the reaction was warmed up to 0 °C and quenched with sodium sulfate decahydrate. Vigorous stirring followed by filtration with Celite provided **S10** as an oil. Purification was done with silica gel column chromatography (0-30% EtOAc in Hexanes); fractions visualized by iodine stain.

Thionyl chloride was added dropwise to S10 in ether at 0 °C and the reaction was stirred for 3 h. The reaction was quenched with sodium bicarbonate (saturated aqueous solution) and extracted with ether. The organic layer was washed with brine, dried with magnesium sulfate and used without further purification.

Phenol and sodium hydride were combined at 0 °C in benzene as a slurry. After 15 minutes of stirring, allylic chloride **S11** was added as a solution in benzene. The reaction stirred at rt for 18 h followed by evaporation of solvent, followed by aqueous workup as described in reference X. **S12** was subjected to Pd(PPh₃)₄, K₃PO₄, and ArBr in dioxane under nitrogen at 85°C for 18 h, followed by filtration with Celite. Silica gel column chromatography (0-25% EtOAC in Hexanes) provided substrates.


 $SOCl_2$ was added as a solution in DCM to S13 (which was prepared with procedures described on the previous page) in diethyl ether at 0 °C. The reaction was quenched after 3 h at room temperature, with sodium bicarbonate (saturated aqueous solution), then extracted with ether. The organic layer was washed with brine, dried with magnesium sulfate, concentrated and used without further purification.

S14b were prepared following the procedure used with intermediate S11.



¹H-NMR (500 MHz, CDCl₃) δ (ppm) 7.73 (d, J = 8.5 **1a** Hz, 2H), 7.47 (d, J = 8.5 Hz, 2H), 7.34-7.14 (m, 4H), 6.06 (s, 1H), 4.35 (d, J = 5 Hz, 2H), 2.77 (t, 1) J = 7.5 Hz, 2H), 2.37-2.34 (m, 2H), 2.18 (s, 3H), 1.35 (s, 9H).¹³C NMR (125 MHz, CDCl₃) δ (ppm) 167.7, 155.0, 136.4, 135.8, 131.9, 131.7, 129.2, 127.2, 126.9, 126.7, 126.5, 125.5, 123.3, 42.2, 35.0, 31.2, 28.5, 26.9, 14.3.

HRMS (ESI) Calcd. [M+H] C23H28ON: 334.2165; found: 334.2170.




¹H-NMR (500 MHz, CDCl₃) δ (ppm) 7.75 (d, J = 8.5 1bHz, 2H), 7.63 (d, J = 7 Hz, 1H), 7.49 (d, J = 8.5 Hz, 2H), 7.28-7.21 (m, 2H), 7.16-7.15 (m, 1H), 6.47 (s, 1H), 5.75 (s,1H), 5.50 (s, 1H), 4.24-4.13 (m, 1H), 3.48-3.42 (m, 1H), 3.16-3.12 (m, 1H), 2.99-2.94 (m, 1H), 2.26-2.14 (m, 2H), 1.36 (s, 9H). ¹³C NMR (125 MHz, CDCl₃) δ (ppm) 167.3, 155.2, 143.9, 143.8, 134.9, 132.5, 131.3, 128.9, 128.4, 128.0, 126.8, 126.5, 125.6, 125.1, 124.8, 109.0, 108.9, 97.4, 95.6, 44.8, 44.6, 34.92, 31.1, 30.4, 30.2, 27.0, 26.9. ¹⁹F-NMR (376.4 MHz) δ (ppm) - 161.0 - -161.2 (m).

HRMS (ESI) Calcd. for [M+H] C23H27ONF: 352.2071; found: 352.2074.


HPLC (ChiralPak IC column) 92:08 (hexane:iPrOH) 1mL/min; Tmajor (22.172 min), Tminor (25.260 min)

Catalysts 2-4 are either commercially available or previously reported.



¹H-NMR (500 MHz, CDCl₃) δ (ppm) 7.79 (d, J = 7.0 Hz, 2H), 5a 7.54-7.44 (m, 3H), 7.34-7.32 (m, 1H), 7.26-7.19 (m, 1H), 7.18-7.14 (m, 2H), 6.10 (brs, 1H), 4.36 (d, J = 5.5 Hz, 2H), 2.78 (t, J = 7.5 Hz, 2H), 2.37 (t, J = 7 Hz, 2H), 2.18 (s, 3H). ¹³C NMR (125) MHz, CDCl₃) δ (ppm) 167.7, 136.3, 135.8, 134.6, 131.6, 131.5, 129.5, 128.7, 127.2, 126.9, 126.8, 126.5, 123.3, 42.4, 28.5, 27.0, 14.3.


HRMS (ESI) Calcd. for [M+H]C₁₉H20ON 278.1539, found: 278.1547.



¹H-NMR (500 MHz, CDCl₃) δ (ppm) 7.81 (d, J = 7.5 Hz, **5**b 2H), 7.63 (d, J = 7.5 Hz, 1H), 7.56-7.53 (m, 1H), 7.49-7.46 (m, 2H), 7.26-7.21 (m, 2H), 7.16-7.15 (m, 1H), 6.49 (brs, 1H), 5.75 (s, 1H), 5.51 (s, 1H), 4.23-4.13 (m, 1H), 3.50-3.43 (m, 1H), 3.19-3.12 (m, 1H), 2.99-2.96 (m, 1H), 2.27-2.12 (m, 2H). ¹³C NMR (125 MHz, CDCl₃) δ (ppm) 167.5, 143.9 (d, JC-F = 16.3 Hz), 134.9, 134.3, 132.5, 131.7, 129.0, 128.7, 128.5, 128.1, 127.1 (d, JC-F = 19.0 Hz), 126.6, 124.9, 109.0 (d, JC-F = 11.3 Hz), 97.2, 95.8, 44.8 (d, JC-F = 25.0 Hz), 30.4 (d, JC-F = 21.3 Hz), 27.0 (d, JC-F = 11.3 Hz).¹⁹F-NMR (376.5 MHz) δ (ppm) – 150.03 - -150.06 (m).


HRMS (ESI) Calcd. for [M+H] C₁₉H20ON 296.1445; found: 296.1452.

HPLC (ChiralPak IC column) 92:08(hexane:*i*PrOH) 1mL/min; Tmajor (18.224 min), Tminor (19.572 min)




6a ¹H-NMR (500MHz, CDCl₃) δ (ppm) 7.34-7.24 (m, 2H), 7.21-7.15 (m, 2H), 6.67 (brs, 1H), 4.27 (d, J = 5.5 Hz, 2H), 2.79 (t, J = 7.5 Hz, 2H), 2.32 (t, J = 7.5Hz, 2H), 2.17 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 162.1, 136.0, 135.7, 130.6, 129.7, 127.3, 127.1, 126.6, 123.5, 92.7, 43.8, 28.4, 26.8, 14.3.

Elemental analysis (CHN) est: 52.77% C, 4.43% H, 4.4% N; found: 52.49% C, 4.53% H, 4.51% N.




6b ¹H-NMR (400 MHz, CDCl₃) δ (ppm) 7.64 (d, J = 7.6 Hz, 1H), 7.30-7.24 (m, 2H), 7.19-7.17 (m, 1H), 7.03 (brs, 1H), 5.78 (d, J = 3.2 Hz, 1H), 5.52 (s, 1H), 4.01-3.89 (m, 1H), 3.56-3.47 (m, 1H), 3.10-3.02 (m, 2H), 2.28-2.16 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 162.2, 143.2, 143.0, 134.5, 132.2, 132.2, 128.9, 128.6, 126.8, 125.0, 124.9, 109.6, 109.5, 96.7, 94.9, 92.5, 46.2, 46.0, 30.6, 30.4, 26.9, 26.8. ¹⁹F-NMR (376.5 MHz) δ (ppm) – 150.59 (m). Elemental analysis (CHN) est: 49.95% C, 3.89% H, 4.16% N; found: 48.96% C, 4.11% H, 3.81% N.

HPLC (ChiralPak IC column) 98:02 (hexane/*i*PrOH) 1mL/min; Tmajor (9.50 min), Tminor (10.90 min).



7a (¹H-NMR (500 MHz, CDCl₃) δ (ppm) 7.73 (d, J = 8.2 Hz, 2H), 7.46 (d, J = 8.2 Hz, 2H), 7.28-7.24 (m, 2H, overlaps CDCl₃) 7.17 (d, J = 2.4 Hz, 2H), 6.11 (s, 1H), 4.33 (d, J = 5.3 Hz, 2H), 2.55 (t, J = 7.1 Hz, 2H), 2.17 (s, 3H), 2.13 – 2.02 (m, 2H), 1.93 – 1.86 (m, 2H), 1.34 (s, 9H). ¹³C NMR (125 MHz, CDCl₃) δ (ppm) 167, 155.0, 143.2, 140.0, 133.5, 132.6, 131.8, 128.5, 126.7, 126.7, 126.5, 126.1, 125.6, 42.2, 35.0, 34.6, 32.1, 31.2, 28.6, 18.3.

HRMS (ESI) Calcd. for [M+H] C24H30ON: 348.2322; found: 348.2330.



¹H-NMR (400 MHz, CDCl₃) δ (ppm) 7.93 (d, *J* = 8.0 Hz,


7b

2H), 7.70 (d, J = 8.0 Hz, 2H), 7.22-7.09 (m, 4H), 6.29 (brs, 1H), 5.64 (s, 1H), 5.22-5.21 (m, 1H), 3.81-3.70 (m, 1H), 3.58-3.45 (m, 1H), 2.82-2.76 (m, 2H), 2.22-1.63 (overlapping multiplets, 4H), 1.35 (s, 9H). ¹³C NMR (125 MHz, CDCl₃) δ (ppm) 167.13, 155.11, 151.40, 151.21, 139.54, 139.54, 138.83, 138.78, 131.55, 129.28, 128.88, 128.34, 128.02, 126.76, 126.73, 125.60, 125.30, 114.71, 114.59, 99.07, 97.30, 45.098, 44.89, 38.70, 38.47, 34.96, 31.19, 23.60, 23.49.


¹⁹F-NMR (376.5 MHz) δ (ppm) -147.2 (broad multiplet), -149.2 (m), -151.36-151.42 (m); possibly rotamers.

HRMS (ESI) Calcd. for [M+H] C24H29ONF: 366.2228; found: 366.2229.

HPLC (ChiralPak IB column) 95:05 (hexane: iPrOH) 1mL/min; Tmajor (9.540 min), Tminor (8.808 min).



¹H-NMR (300 MHz, CDCl₃) δ (ppm) 7.72-7.69 (m, 2H), 8a 7.45-7.38 (m, 3H), 7.31-7.30 (m, 2H), 7.20-7.18 (m, 1H), 4.51 (d, J = 5.4 Hz, 2H), 3.42 (s, 2H), 2.17 (s, 3H),1.32 (s, 9H). ¹³C NMR (125 MHz, CDCl₃) δ (ppm) 167.3, 155.0, 146.4, 142.5, 137.3, 136.2, 131.5, 126.7, 126.3, 125.5, 124.8, 123.4, 118.9, 39.6, 37.5, 34.9, 31.1, 10.4. HRMS (ESI) Calcd. For C22H26ON: 320.201; found: 320.2015.




8b

¹H-NMR (400 MHz, CDCl₃) δ (ppm) 7.71 (d, J = 8.0 Hz, 2H), 7.53-7.46 (m, 3H), 7.27-7.24 (3H), 6.48 (brs, 1H), 5.78 (d, J = 4.0 Hz, 1H), 5.44 (s, 1H), 4.16-4.04 (m, 1H), 3.79-3.72 (m, 1H), 3.42-3.21 (m, 2H), 1.35 (s, 9H). ¹³C NMR (125 MHz, CDCl₃) δ (ppm) 167.6, 155.3, 149.2, 149.1, 140.7, 137.9, 137.8, 131.3, 129.7, 127.4, 126.9, 125.6, 125.5, 121.1, 107.7, 107.6, 102.7, 100.8, 46.1, 45.8, 40.8, 40.6, 35.0, 31.2. ¹⁹F-NMR $(376.4 \text{ MHz}) \delta (\text{ppm}) - 144.78 - -144.81 \text{ (m)}.$


HRMS (ESI) Calcd. for C22H25ONF: 338.1915; found: 352.1923.

HPLC (ChiralPak IC column) (90:10 hexane: iPrOH) 1mL/min; Tmajor (22.436 min), Tminor (20.620 min).



¹H-NMR (400 MHz, CDCl₃) δ (ppm) 7.72 (d, 8.4Hz, 9a 2H), 7.45 (d, 8.4Hz, 2H), 7.27-7.13 (m, 2H), 6.97-6.93 (m, 1H), 6.83 (d, 7.6Hz, 1H), 6.18 (s, 1H), 4.71 (s, 2H), 4.25 (d, 5.6Hz, 2H), 2.11 (s, 3H), 1.33 (s, 9H). ¹³C NMR (125 MHz, CDCl₃) δ (ppm) 167.8, 155.2, 153.8, 131.2, 128.9, 127.4, 126.9, 125.6, 125.4, 124.7, 123.9, 121.4, 115.8, 67.0, 38.7, 35.0, 31.2, 12.9.

HRMS (ESI) Calcd. for [M+H] C22H26O2N: 336.1958; found: 336.1963.




¹H-NMR (400 MHz, CDCl₃) δ (ppm) 7.75 (d, J = 8.4 Hz,

9b 2H), 7.62-7.60 (m, 1H), 7.50 (d, J = 8.4 Hz, 2H), 7.30-7.25 (m, 1H), 7.04-6.96 (m, 2H), 6.43 (brs, 1H), 5.811 (s, 1H), 5.50 (s, 1H), 4.37-4.33 (m, 1H), 4.24-4.12 (m, 2H), 3.82-3.72 (m, 1H), 1.38 (s, 9H). ¹³C NMR (125 MHz, CDCl₃) δ (ppm) 167.4, 155.3, 152.9, 138.6, 138.4, 131.2, 130.2, 126.9, 125.6, 124.7, 122.0, 119.3, 117.6, 107.4, 107.3, 68.1, 67.8, 43.4, 43.2, 35.0, 31.2, ¹⁹F-NMR (376.4 MHz) δ (ppm) –166.28 - –166.40 (m).

HRMS (ESI) Calcd. for [M+H] C22H25O2NF: 354.1864; found: 354.1874.


HPLC (ChiralPak IC column) 90:10 (hexane/iPrOH) 1mL/min; Tmajor (28.140 min), Tminor (31.536 min)



10a

¹H-NMR (400 MHz, CDCl₃) δ (ppm) 8.24 (s, 2H), 8.032 CF3 (s, 1H), 7.66 -7.64 (m, 1H), 7.25-7.20 (m, 1H), 7.13-7.11 (m, 1H), 6.51 (brs, 1H), 4.56-4.55 (m, 2H), 2.86 (t, J = 8.0 Hz, 2H), 2.57 (ts, J = 8.0 Hz, 2H), 1.57 (s, 3H).


¹³C NMR (125 MHz, CDCl₃) δ (ppm) 164.8, 136.5, 136.0, 135.7, 132.7, 132.4, 132.1, 131.8, 130.5, 130.2, 127.3, 127.0, 126.6, 125.1, 125.1, 125.0, 125.0, 124.0, 123.4, 121.8, 42.8, 28.4, 27.1, 14.4. HRMS (ESI) Calcd. For C21H18ONF₆: 414.1287, found: 414.1303.



ĊF₃ ¹H-NMR (400 MHz, CDCl₃) δ (ppm) 8.23 (s, 2H), 8.04 10b (s, 1H), 7.63-7.61 (m, 1H), 7.26-7.15 (m, 4H), 6.58 (brs, 1H), 5.76 (s, 1H), 5.50 (s, 1H), 4.21 -4.08 (m, 1H), 3.59-3.51 (m, 1H), 3.13-2.89 (m, 2H), 2.23-2.21 (m, 2H). ¹³C NMR (125 MHz, CDCl₃) δ (ppm) 164.6, 143.7, 143.5, 136.3, 134.6, 132.5, 132.3, 132.2, 129.0, 128.6, 127.4, 126.7, 125.3, 124.9, 109.3, 109.2, 96.93, 95.50, 45.2, 45.0, 30.6, 30.4, 26.9, 26.85. ¹⁹F-NMR $(376.5 \text{ MHz}) \delta (\text{ppm}) - 62.1 \text{ (s)}, -150.0 \text{ (m)}.$

HRMS (ESI) Calcd. for [M+H] C21H17ONF₇: 432.119; found: 432.121.

HPLC (ChiralPak IB column) 99:01 (hexane/iPrOH) 1mL/min; Tmajor (21.40 min), Tminor (24.99min).




11a

 NO_2^{-1} H-NMR (500 MHz, CDCl₃) δ (ppm) 8.33-8.29 (m. 2H). 8.00-7.94 (m, 2H), 7.34-7.28 (m, 1H), 7.26-7.14 (m, 3H), 6.23 (brs, 1H), 4.38-4.37 (m, 2H), 2.87 (t, J = 8.0 Hz, 2H), 2.38-2.35 (m, 2H), 2.19 (s, 3H).¹³C NMR (100 MHz, CDCl₃) δ (ppm) 165.7,

149.6, 140.1, 136.1, 135.7, 130.7, 130.0, 128.2, 127.3, 127.0, 126.6, 123.8, 123.4; 42.7, 28.4, 27.1, 14.3.


HRMS (ESI) Calcd. for [M+H] C19H19O3N2: 323.139; found: 323.1402.



11b


NO₂ ¹H-NMR (400 MHz, CDCl₃) δ (ppm) 8.32 (d, J = 8.8Hz, 2H), 7.95 (d, J = 8.4 Hz, 2H), 7.62-7.60 (m, 1H), 7.25-7.15 (m, 4H), 6.50 (brs, 1H), 5.74 (m, 1H), 5.49 (s, 1H), 4.19-4.07 (m, 1H), 3.58-3.48 (m, 1H), 3.19-2.97 (m, 2H), 2.23-2.16 (m, 2H). ¹³C NMR (125 MHz, CDCl₃) δ (ppm) 165.5, 149.7, 143.6 (d, *J*C–F = 16.3 Hz), 139.8, 134.6, 132.3 (d, JC-F = 16.3 Hz), 128.97-128.61, 128.2, 126.7, 124.9, 124.0, 109.2 (11.3), 96.9, 95.5, 45.1, 44.9, 30.7, 30.5, 27.0, 26.9. ¹⁹F-NMR (376.5 MHz) δ (ppm) –150.31 (m). HRMS (ESI) Calcd. for [M+H] C19H18O3N2F: 341.1296; found: 341.1307.

HPLC (ChiralPak IA column) 90:10 (hexane/iPrOH) 1mL/min; Tmajor (15.868 min), Tminor (18.700 min).



12a

¹H-NMR (400 MHz, CDCl₃) δ (ppm) 7.74 (d, J = 8Hz, 2H), 7.44-7.42 (m, 2H), 7.27 -7.21 (m, 1H), 6.75-6.70 (m, 2H), 6.33 (brs, 1H), 4.41-4.29 (m, 2H), 3.93 (s, 3H), 2.74-2.7 (t, J = 8 Hz, 2H), 2.33-2.31 (m, 2H), 2.12 (s, 3H), 1.33 (s, 9H). ¹³C NMR (125 MHz, CDCl₃) δ (ppm) 167.6, 158.3, 154.8, 137.6, 131.7, 129.4, 129.3, 128.8, 126.8, 125.4, 124.5, 113.3, 111.0, 55.2, 42.2, 34.9, 31.1, 28.9, 26.8, 14.2. HRMS (ESI) Calcd. For C24H30O2N: 364.227, found: 364.228.




12b

¹H-NMR (400 MHz, CDCl₃) δ (ppm) 7.77 (d, J = 8.4 Hz, 2H), 7.58 (d, J = 8.8 Hz, 1H), 7.52-7.50 (m, 2H), 6.83-6.81 (m, 1H), 6.67 (s, 1H), 6.48-6.47 (m, 1H), 5.63-5.62 (m, 1H), 5.40 (s, 1H), 4.27-4.14 (m, 1H), 3.84 (s, 3H), 3.50-3.41 (m, 1H), 3.21-3.14 (m, 1H), 2.96-2.92 (m,1H), 2.27-2.13 (m, 2H), 1.39 (s, 9H). ¹³C NMR (125 MHz, CDCl₃) δ (ppm) 167.4, 159.7, 155.3, 143.5, 136.4, 131.4, 126.8, 126.3, 125.6, 125.4, 113.6, 112.7, 106.7, 106.6, 55.3, 44.8, 44.6, 35.0, 31.2, 30.3, 30.2, 27.3, 27.2. ¹⁹F-NMR (376.5 MHz) δ (ppm) - 150.3 (m).

HRMS (ESI) Calcd. for [M+H] C24H29O2NF: 383.2177; found: 382.2187.


HPLC (ChiralPak IC column) 96:04 (hexane/iPrOH) 1mL/min; Tmajor (60.28 min), Tminor (64.92 min).



13a

¹H-NMR (400 MHz, CDCl₃) δ (ppm) 7.72 (d, J = 8.4Hz, 2H), 7.44 (d, J = 8.4 Hz, 2H), 7.27 (s, 1H), 7.13 (s, 1H), 7.02-7.01 (m, 1H), 6.26 (brs, 1H), 4.51 (d, J = 5.6 Hz, 2H), 3.38 (s, 2H), 2.42 (s, 3H), 2.15 (s, 3H), 1.33 (s, 9H). ¹³C NMR (125) MHz, CDCl₃) δ (ppm) 167.3, 155.0, 146.6, 139.5, 137.5, 136.2, 135.9, 131.5, 126.7, 125.6, 125.5, 123.1, 119.7, 39.18, 37.6, 34.9, 31.1, 21.5, 10.4.


HRMS (ESI) Calcd. For C23H28ON: 334.2165, found: 334.2176.



¹H-NMR (400 MHz, CDCl₃) δ (ppm) 7.72 (d, J = 8.0 13b Hz, 2H), 7.47 (J = 8.0 Hz, 2H), 7.33 (s, 1H), 7.11 (s, 2H), 5.75 (d, J = 4 Hz, 1H), 5.40 (d, J = 4 Hz, 1H), 4.14-4.02 (m, 1H), 3.77-3.7- (m, 1H), 3.36-3.16 (m, 2H), 2.37 (s, 3H), 1.35 (s, 9H). ¹³C NMR (125 MHz, CDCl₃) δ (ppm) 167.5, 155.2, 149.2, 149.0, 137.8, 137.7, 137.1, 131.3, 130.7, 126.8, 125.6, 125.1, 121.5, 107.2, 107.1, 102.9, 46.0, 45.8, 40.4, 40.2, 34.9, 31.1, 21.3. ¹⁹F-NMR $(376.5 \text{ MHz}) \delta (\text{ppm}) -144.83 - -145.01(\text{m}).$

HRMS (ESI) Calcd. for [M+H] C23H27ONF:352.2071; found: 352.2084.


HPLC (ChiralPak IC column) 96:04 (hexane/iPrOH) 1mL/min; Tmajor (33.86 min), Tminor (37.06 min).



14a

¹H-NMR (300 MHz, CDCl₃) δ (ppm) 7.70 (d, J = 6.0 Hz, 2H), 7.43 (d, J = 8.1 Hz), 7.14 (s, 1H), 7.08-7.05 (m, 1H), 6.75-6.72 (m, 1H), 6.21 (brs, 1H), 6.21 1H), 4.68 (s, 2H), 4.23 (d, J = 5.7 Hz), 2H), 2.06 (s, 3H), 1.32 (s, 9H). ¹³C NMR (75 MHz, CDCl₃) δ (ppm) 168.0, 155.6, 152.6, 131.3, 128.7, 127.1, 127.0, 126.8, 126.5, 126.4, 125.9, 124.1, 117.3, 67.4, 38.9, 35.2, 31.4, 13.1.

HRMS (ESI) Calcd. For [M+H]C22H24O2NCI: 370.1587; found: 370.1580.




14b

¹H-NMR (300 MHz, CDCl₃) δ (ppm) 7.71 (d, J = 9Hz, 2H), 7.51-7.44 (m, 3H), 7.18-7.14 (m, 1H), 6.38 (brs, 1H), 5.75 (s, 1H), 5.48 (s, 1H), 4.31-25 (m, 1H), 4.19-4.03 (m, 2H), 3.77-3.64 (m, 1H), 1.33 (s, 9H). ¹³C NMR (125 MHz, CDCl₃) δ (ppm) 167.38, 155.45, 151.53, 137.58, 137.4, 131.1, 130.1, 127.2, 126.9, 125.6, 124.3, 120.8, 119.1, 108.8, 108.66, 68.13, 67.82, 43.2, 43.0, 35.0, 31.2. ¹⁹F-NMR (376.5 MHz) δ (ppm) – 166.27 - -166.39 (m).


HRMS (ESI) Calcd. for [M+H] C22H24O2NCIF: 388.1493; found: 388.1488.

HPLC (ChiralPak IC column) 90:10 (hexane/*i*PrOH) 1mL/min; Tmajor (20.832 min), Tminor (23.336 min).



15a (m, 1H), 7.27-7.15 (m, 4H), 6.95-6.93 (m, 1H), 6.88-6.83 (m, 1H), 5.31 (s, 1H), 3.73 (s, 2H), 2.81 (t, J = 7.6 Hz, 2H), 2.26-2.23 (t and s overlap, 5H). ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 154.4, 136.7, 135.8, 133.8, 130.2, 127.9, 127.6, 127.2, 126.5, 126.3, 125.6, 123.1, 120.9, 116.0, 115.5, 34.4, 28.6, 28.1, 14.5.


HRMS (ESI) Calcd. for [M] C18H18O: 250.1352; found: 250.1351.



15b ¹H-NMR (400 MHz, CDCl₃) δ (ppm) 7.63-7.61 (m, 1H), 7.29-7.13 (m, 4H), 6.97-6.94 (m, 2H), 6.87-6.84 (m, 1H), 5.93 (d, J = 21 Hz, 1H), 5.62 (d, J = 4.0 Hz, 1H), 5.35 (s, 1H), 3.23-2.99 (m, 4H), 2.22-2.11 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 155.0, 144.9, 144.8, 134.5, 133.1, 133.1, 132.6, 128.8, 128.77, 128.3, 125.13, 125.11, 121.9, 120.6, 117.0, 108.9, 108.8, 100.2, 98.8, 39.0, 38.8, 32.2, 32.0, 27.0, 26.9. ¹⁹F-NMR (376.5 MHz) δ (ppm) –137.1 – 137.3 (m).


HRMS (ESI) Calcd. for [M] C18H16OF: 267.1191; found: 267.1192.

HPLC (ChiralPak IC column) 98:02 (hexane/*i*PrOH) 1mL/min; Tmajor (7.72 min), Tminor (8.80 min).



16a N¹H-NMR (500 MHz, CDCl₃) δ (ppm) 8.22 (s, 1H), 7.66 (d, J = 2.5 Hz, 1H), 7.19-7.11 (m, 2H), 6.90-6.81 (m, 2H), 6.71 (d, J = 8.5 Hz, 1H), 5.93 (t, J = 3.5 Hz, 1H), 5.60 (s, 1H), 3.93 (s, 3H), 3.57 (d, J = 7.5 Hz, 2H), 2.13 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 163.1, 153.9, 143.6, 135.3, 133.0, 132.2, 130.0, 127.5, 126.7, 125.4, 120.8, 115.4, 110.1, 53.5, 29.6, 15.7.

HRMS (ESI) Calcd. for [M+H] C16H18O2N: 256.1332; found: 256.1325.




16b O N ¹H-NMR (400 MHz, CDCl₃) δ (ppm) 8.26 (s, 1H), 7.70 (d, J = 8.4 Hz, 1H), 7.14-7.04 (m, 2H), 6.87-6.75 (m, 3H), 5.79 (s, 1H), 5.73-5.58 (m, 1H), 5.40 (s, 2H), 3.96 (s, 3H), 3.16-2.84 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 163.8, 154.1, 144.8, 143.7, 143.5, 137.4, 131.7, 128.3, 127.2, 123.2, 120.7, 115.6, 114.7, 114.6, 110.6, 95.0, 93.3, 53.6, 36.4, 36.2.

¹⁹F-NMR (376.5 MHz) δ (ppm) –174.3 - –174.6 (m).

HRMS (ESI) Calcd. for [M+H] C16H17O2NF: 274.1230; found: 274.1238.

HPLC (ChiralPak IC) 98:02 (hexane/iPrOH) 1mL/min; Tmajor (9.228 min), Tminor (10.452


min)



17a 1 H-NMR (400 MHz, CDCl₃) δ (ppm) 7.43-7.10 (m, 7H), 6.90 (t, J = 9.8 Hz, 1H), 6.80 (d, J = 10.4 Hz, 1H), 5.96(t, J = 8.4 Hz, 1H), 3.57 (d, J = 9.6 Hz, 2H), 2.19 (s, 3H);

¹³C NMR (100 MHz, CDCl₃) δ (ppm) 154.0, 143.4, 136.9, 130.1, 128.3, 127.6, 127.0, 126.8, 125.8, 125.5, 121.0, 115.6, 29.9, 16.1.


HRMS (EI) Calcd. for [M] C16H16O: 224.1201; found: 224.1204.



17b F ¹H-NMR (400 MHz, CDCl₃) δ (ppm) 7.45-7.35 (m, 5H), 7.15 (t, J = 7.8 Hz, 1H), 7.03 (d, J = 7.2 Hz, 1H), 6.89-6.82 (m, 2H), 5.77-5.66 (m, 1H), 5.44 (d, J = 12 Hz, 2H), 5.21 (d, J = 8 Hz, 1H), 3.15-2.93 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 154.1, 146.7, 146.5, 138.2, 131.7, 128.5, 128.3, 128.1, 126.8, 123.4, 120.8, 115.9, 114.6, 114.5, 95.6 93.9, 36.4, 36.2, 29.7. ¹⁹F-NMR (376.5 MHz) δ (ppm) –173.9 – –174.2 (m).

HRMS (EI) Calcd. for [M] C16H15OF: 242.1107; found: 242.1110.


HPLC (ChiralPak IC) 94:06 (hexane/iPrOH) 1mL/min; Tmajor (4.384 min), Tminor (4.612 min).



18a ¹H-NMR (500 MHz, CDCl₃) δ (ppm) 7.15-7.12 (m, 2H), 6.84-6.82 (m, 1H), 6.76 (d, J = 8 Hz, 1H), 5.37-5.34 (m, 1H), 5.16 (s, 1H), 3.39 (d, J = 7 Hz, 2H), 1.81-1.80 (m, 6H).

¹³C NMR (100 MHz, CDCl₃) δ (ppm) 154.2, 134.5, 130.1, 127.6, 127.3, 122.1, 120.9, 115.8, 29.6, 25.9, 17.9.

HRMS (EI) Calcd. for [M] C11H14O: 162.1045; found: 162.1048.



18b F ¹H-NMR (400 MHz, CDCl₃) δ (ppm) 7.17-7.13 (m, 2H), 6.91-6.82 (m, 2H), 5.32 (d, J = 8.4 Hz, 1H), 5.2 (m, 1H), 4.99 (d, J = 21.6 Hz, 2H), 3.09-2.96 (m, 2H), 2.19 (s, 1H), 1.83 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 154.1, 142.8, 142.7, 131.5, 128.3, 123.6, 120.9, 116.0, 113.1, 113.0, 97.5, 95.8, 35.6, 35.4, 17.5, 17.5. ¹⁹F-NMR (376.5 MHz) δ (ppm) – 173.2 - -173.5 (m).


HRMS (EI) Calcd. for [M] C11H13OF: 180.0950; found: 180.0949.

HPLC (ChiralPak IC) 99:01 (hexane/*i*PrOH) 1mL/min; Tmajor (19.892 min), Tminor (24.844 min).

TsN OH

19a = 8.4 Hz, 2H), 7.19 (t, J = 6.4 Hz, 1H), 7.04-7.02 (m, 1H), 6.93-6.89 (m, 2H), 5.83 (s, 1H), 5.19 (s, 1H), 3.82-3.81 (m, 2H), 3.40 (t, J = 5.6 Hz, 2H), 2.58 (s, 2H), 2.22 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 152.2, 143.9, 134.0, 133.1, 129.8, 128.9, 128.3, 127.8, 122.5, 121.1, 120.6, 115.8, 115.5, 45.0, 43.2, 29.4, 21.6.

HRMS (ESI) Calcd. for [M-1] C18H18O3NS: 328.1013; found: 328.1009.




19b ¹H-NMR (400 MHz, CDCl₃) δ (ppm) 7.77 (d, J = 8.0 Hz, 2H), 7.40 (d, J = 8.4 Hz, 2H), 7.26-7.21 (m, 1H), 7.11-7.09 (m, 1H), 6.95-6.88 (m, 2H), 6.15-6.14 (m, 1H), 5.46-5.34 (m/brs overlap, 2H), 4.16-4.08 (m, 1H), 3.99-3.92 (m, 1H), 3.66-3.53 (m, 1H), 3.31-3.21 (m, 1H), 2.49 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 153.1, 144.2, 133.2, 132.7, 132.5, 129.9, 129.8, 129.7, 129.6, 129.56, 127.8, 125.0, 120.8, 116.1, 85.85, 84.14, 65.9, 47.7, 47.4, 44.9, 21.6.


¹⁹F-NMR (376.5 MHz) δ (ppm) –168.97 (m)

HRMS (ESI) Calcd. for [M-1] C18H17O3NSF: 346.0919; found: 346.0913.

HPLC (ChiralPak IA) 80:20 (hexane/iPrOH) 1mL/min; Tmajor (12.38 min), Tminor (14.87 min).




20a OH ¹H-NMR (500 MHz, CDCl₃) δ (ppm) 7.33-7.22 (m, 2H), 7.16-7.14 (m, 2H), 2.76-2.73 (m, 2H), 2.56 (s, 2H), 2.35 (brm, 2H), 2.11-2.107 (m, 3H), 1.33 (s, 6H).




20b ⁽ⁱ⁾ ⁽ⁱ⁾

HPLC (ChiralPak IA column) 96:04 (hexane/*i*PrOH) 1mL/min; Tmajor (7.22 min), Tminor (8.77 min).




21a O ¹H-NMR (500 MHz, CDCl₃) δ (ppm) 8.37 (s, 1H), 7.45 (d, J = 7.5 Hz, 1H), 7.36-7.23 (m, 4H), 6.81 (s, 2H), 5.00 (s, 2H), 3.55 (s, 2H), 2.25 (s, 6H), 2.20 (s, 3H).




21b ¹H-NMR (400 MHz, CDCl₃) δ (ppm) 8.60 (s, 1H), 7.53 (d, J = 7.2 Hz, 1H), 7.34-7.30 (m, 4H), 6.89 (brs, 2H), 5.82-5.81 (m, 1H), 5.47-5.46 (m, 1H), 1000 (m, 2H), 10000 (m, 2H), 1000 (m, 2H), 10000 (m, 2H),4.44-4.23 (m, 2H), 3.75-3.70 (m, 1H), 3.42-3.31 (m, 1H), 2.36 (s, 6H), 2.32 (s, 3H). ¹⁹F-NMR $(376.5 \text{ MHz}) \delta (\text{ppm}) - 168.45 - -168.53 \text{ (m)}.$

HPLC (ChiralPak OD column) 96:04 (hexane/iPrOH) 0.5mL/min; Tmajor (44.7min), Tminor (40.5 min).




22a ¹H-NMR (400 MHz, CDCl₃) δ (ppm) 7.40-7.37 (m, 1H), 7.30-7.20 (m, 4H), 7.11-7.10 (m, 1H), 7.00-6.93 (m, 2H), 5.14 (s, 1H), 2.96-2.91 (m, 2H), 2.59-2.46 (m, 2H), 1.98 (s, 3H).




22b

¹H-NMR (400 MHz, CDCl₃) δ (ppm) 7.72-7.70 (m, 1H), 7.59-7.55 (m, 2H), 7.45-7.19 (m, 5H), 5.85-5.84 (m, 1H), 5.11-5.10 (m, 1H), 4.71-4.67 (m, s overlap, 3H total), 3.19-3.11 (m, 1H), 2.96-2.90 (m, 1H), 2.77-2.72 (m, 1H), ¹⁹F-NMR (376.5 MHz) δ (ppm) -134.9-135.0 (m).

HPLC (ChiralPak IB column) 90:10 (hexane/iPrOH) 1mL/min; Tmajor (6.78 min), Tminor (6.28 min).




¹H-NMR (400 MHz, CDCl₃) δ (ppm) 7.02-7.00 (m, 2H), 6.85-23a 6.81 (m, 1H), 6.07-6.02 (m, 1H), 5.33-5.30 (m, 2H), 5.18-5.13 (m, 2H), 3.42-3.36 (m, 4H), 1.79 (s, 6H).




¹H-NMR (400 MHz, CDCl₃) δ (ppm) 7.06-7.03 (m, 2H), 6.87-23b 6.83 (m, 1H), 6.08-5.98 (m, 1H), 5.44-5.42 (m, 1H), 5.20-5.17 (m, 3H), 5.02 (s, 1H), 4.95 (s, 1H), 3.44 (d, J = 7.6 Hz, 2H), 3.07-2.96 (m, 2H), 1.83 (s, 3H). ¹⁹F-NMR (376.5 MHz) δ (ppm) – 173.62-173.86 (m).


HPLC (ChiralPak IA column) 99:01 (hexane/iPrOH) 1mL/min; Tmajor (8.66 min), Tminor (9.02 min).



24 ¹H-NMR (400 MHz, CDCl₃) δ (ppm) 8.33 (d, J = 8.4 Hz, 1H), 8.19 (s, 1H), Ts 7.82-7.80 (m, 2H), 7.72-7.70 (m, 2H), 7.59-49 (m, 3H), 7.35-7.31 (m, 3H), 7.14-7.04 (m, 2H), 5.80 (s, 1H), 3.77 (d, J = 3.2 Hz, 2H), 3.34 (t, J = 5.6 Hz, 2H), 2.52 (brs, 2H), 2.45 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 165.1, 143.9, 134.9, 134.6, 134.4, 133.1, 132.4, 132.0, 129.8, 129.0, 128.5, 128.0, 127.7, 126.9, 124.4, 123.8, 121.6, 45.0, 43.1, 30.2, 24.8, 21.5.




¹H-NMR (400 MHz, CDCl₃) δ (ppm) 7.72 (d, J = 8.4 Hz, 2H), 7.34 (d, J = 8.0 25 Ts Hz, 2H), 7.18 (t, J = 7.6 Hz, 1H), 6.88-6.86 (m, 1H), 6.79 (s, 1H), 6.78-6.72 (m, 1H), 5.96 (brs, 1H), 5.01 (s, 1H), 3.76-3.74 (m, 2H), 3.32-3.29 (m, 2H), 2.60-2.57 (m, 2H), 2.44 (s, 3H).



¹H-NMR (400 MHz, CDCl₃) δ (ppm) 8.02 (d, J = 8.4 Hz, 2H), 26 7.63 (d, J = 8.0 Hz, 1H), 7.47-7.45 (m, 2H), 7.41-7.32 (m, 2H), 7.29 (s, 1H), 4.12 (t, J = 16 Hz, 1H), 4.00-3.83 (m, 2H), 3.60-3.46 (m, 2H), 3.28-3.22 (m, 1H), 1.34 (s, 9H). ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 156.4, 154.5, 141.1, 137.1, 137.06, 130.3, 129.7, 127.6, 127.3, 125.5, 125.4, 125.2, 94.49, 85.25, 85.05, 49.97, 49.71, 40.94, 40.70, 35.19, 35.08, 34.85, 31.16, 30.97. ¹⁹F-NMR (376.5 MHz) δ (ppm) –168.45 - -168.53 (m).


HRMS (ESI) Calcd. for [M+H] C22H24ONFBr: 416.1013; found: 416.1020.


HPLC (ChiralPak IB column) 99:01 (hexane/iPrOH) 1mL/min; Tmajor (11.26 min), Tminor (9.252 min).





27 ¹H-NMR (400 MHz, CDCl₃) δ (ppm) 8.02(d, J = 8.0 Hz, 2H), 7.53-7.48 (m, 3H), 7.26-7.25 (m, 1H), 6.84 (d, J = 8.8 Hz, 1H), 4.63-4.58 (m, 1H), 4.27-4.25 (m, 1H), 4.21-4.10 (m, 1H), 3.95-3.70 (m, 3H), 1.36 (s, 9H). ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 154.9, 153.0, 150.5, 131.2, 129.5, 127.5, 127.2, 126.7, 125.5, 123.4, 118.5, 85.8, 84.6, 48.7, 48.6, 36.0, 35.9, 35.1, 31.3. ¹⁹F-NMR (376.5 MHz) δ (ppm) –175.20- -175.33 (m). HRMS (ESI) Calcd. for [M+H] C22H24O2NFBrCl: 466.0575; found: 466.0579. HPLC (ChiralPak IC column) 98:02 (hexane/*i*PrOH) 1mL/min; Tmajor (6.28 min), Tminor (5.66

min).



































JW-08-42-rac (ad)




JW-08-124 IB9505_15
















	Pk #	Retention Time	Area Percent	Lambda Max
6000 - E. B. T. C.	1	20.620	2.671	205
	2	22.436	97.329	204














JW-08-35p







JW-07-174p1 AVQ-400 QNP Proton starting parameters. 7/16/03. Revised












Results	Pk #	Retention Time	Area Percent	Lambda Max
	1	21.960	48.546	213
	2	24.780	51.454	213


JW-08-80rep-IB9901-30min







JW-AD 67 AVQ-400 QNP Carbon Starting parameters 7/16







AD-2-68rac-ic9604-70min








J₩-08-76























201p1 AVQ-400 QNP Proton starting parameters. 7/16/03. Revised 7/22/




































JW-08-41rt





















JW-08-121 IC9802_30min









JW-08-207rac- IB9901_15





JW-08-202B IB9901







JW-08-194rac IC9802_30min

















JW-09-102strip ic9901-45










AVQ-400 PROCNO Date_ Time Time PROBHD PULPROG TD SOLVENT NS DS	QNP Probe 19F 1 shlft9s1158[ati 20120909 9.58 AVQ-400 5 mm QNP 1H/13 zgflqn 131072 CDC13 24 0	starting parame ve to CFC13 at	ters. (re 0 ppm (08	vised P 2103 Hv			173.8 173.8 173.9 173.9	-174.02 -174.08 -174.10 -174.14		
SWH FIDRES AQ RG DW DE TE D1 TD0	90090.094 Hz 0.687333 Hz 0.7275051 sec 4096 5.550 use 6.00 use 292.9 K 1.00000000 sec 3	2								
NUC1 Pl PL1 SF01 SI SF WDW SSB LB GB GB PC	CHANNEL 11 197 16.00 USE -3.00 dB 20.04748917 W 376.4607042 MHz 65536 376.4980736 MHz 0 2.00 Hz 0 4.00									
interest page 1							generation for the state of the	-		Hitsia
		-40 -60	-80	-100	-120	-140	-160	-180	-200	


JW-09-115rac- IC9406















JW-09-176rac





JW-09-176ent





























JW-10-41






09-46ent ia9604



Sample ID:JW-09-41racFilename:C:\EZStart\Projects\Default\Data\JWu\JW-09-41rac_OD9604_60halfflow.met6-22-2012 1-17-59 PM.datMethod:C:\EZStart\Projects\Default\Method\Yiming\OD9604IP_pt5flow_60min.metInjection volume:5 uL


Description: {Data Description}



2: 250 nm, 4 nm	Results		
Rete	ention Time	Area	Area Percent
	40.757	1973761	48.733
	45.189	2076433	51.267


Sample ID: JW-09-41ent Filename: C:\EZStart\Projects\Default\Data\JWu\JW-09-41ent_OD9604_60halfflow.met6-22-2 012 2-35-51 PM.dat Method: C:\EZStart\Projects\Default\Method\Yiming\OD9604IP_pt5flow_60min.met Injection volume: 5 uL


Description: {Data Description}




2: 250 nm, 4 nm Results


Retention Time	Area	Area Percent
40.448	3814523	32.696
44.688	7852100	67.304






ppm -126 -127 -128 -129 -130 -131 -132 -133 -134 -135 -136 -137 -138 -139









AVQ-400 QNP Probe 19F starting parameters. (revised P1, 2/12/04 RN) chemical shifts relative to CFC13 at 0 ppm (082103 HvH) sw 239.28 ppm; o1p 0 ppm


09-110-IA9901





314














A colorless plate 0.10 x 0.06 x 0.03 mm in size was mounted on a Cryoloop with Paratone oil. Data were collected in a nitrogen gas stream at 100(2) K using phi and omega scans. Crystal-to-detector distance was 60 mm and exposure time was 10 seconds per frame using a scan width of 1.0°. Data collection was 98.3% complete to 67.00° in . A total of 22020 reflections were collected covering the indices, -8 <= h <= 9, -14 <= k <= 14, -23 <= l <= 23. 6821 reflections were found to be symmetry independent, with an R_{int} of 0.0431. Indexing and unit cell refinement indicated a primitive, monoclinic lattice. The space group was found to be P2(1) (No. 4). The data were integrated using the Bruker SAINT software program and scaled using the SADABS software program. Solution by direct methods (SIR-2008) produced a complete heavy-atom phasing model consistent with the proposed structure. All non-hydrogen atoms were refined anisotropically by full-matrix least-squares (SHELXL-97). All hydrogen atoms were placed using the FIX command in SHELXL-97. Absolute stereochemistry was unambiguously determined to be *R* at C1 and C23, respectively.

Table 1. Crystal data and structure refinen X-ray ID Sample/notebook ID Empirical formula Formula weight Temperature Wavelength Crystal system Space group Unit cell dimensions	nent for toste52. toste52 JW-08-41 C22 H23 Cl F N O2 387.86 100(2) K 1.54178 Å Monoclinic P2(1) a = 8.4882(3) Å b = 11.8855(5) Å c = 19.4286(8) Å	= 90°. = 96.216(3)°. = 90°.
Volume Z Density (calculated) Absorption coefficient F(000) Crystal size Crystal color/habit Theta range for data collection Index ranges Reflections collected Independent reflections Completeness to theta = 67.00° Absorption correction Max. and min. transmission Refinement method Data / restraints / parameters Goodness-of-fit on F ² Final R indices [I>2sigma(I)] R indices (all data)	1948.56(13) Å ³ 4 1.322 Mg/m ³ 1.953 mm ⁻¹ 816 0.10 x 0.06 x 0.03 mm ³ colorless plate 4.37 to 67.86°. -8<=h<=9, -14<=k<=14, -2 22020 6821 [R(int) = 0.0431] 98.3 % Semi-empirical from equiv 0.9437 and 0.8287 Full-matrix least-squares o 6821 / 1 / 493 1.044 R1 = 0.0730, wR2 = 0.188 R1 = 0.0832, wR2 = 0.200	ralents n F ² 2
Absolute structure parameter Largest diff. peak and hole	-0.01(3) 0.798 and -0.438 e.Å ⁻³	

Table 2. Atomic coordinates ($x \ 10^4$) and equivalent isotropic displacement parameters	(Å ² x
10 ³)	

	Х	у	Z	U(eq)	
$\overline{\mathrm{C}}(1)$	4214(5)	4439(3)	4535(2)	37(1)	
C(2)	4829(5)	4120(4)	3852(2)	38(1)	
C(3)	4754(5)	5039(4)	3328(2)	39(1)	
C(4)	5340(6)	4891(5)	2687(3)	51(1)	
C(5)	5186(7)	5740(6)	2204(3)	62(1)	
C(6)	4413(7)	6725(5)	2311(3)	56(1)	
C(7)	3870(6)	6904(4)	2953(2)	47(1)	
C(8)	4050(5)	6071(4)	3456(2)	40(1)	
C(9)	4262(5)	5694(3)	4652(2)	35(1)	
C(10)	5316(6)	3090(4)	3738(3)	50(1)	
C(11)	5087(6)	3825(4)	5147(2)	43(1)	
C(12)	5296(5)	4865(3)	6234(2)	37(1)	
C(13)	4874(5)	4903(4)	6955(2)	40(1)	
C(14)	5710(6)	5647(5)	7422(3)	51(1)	
C(15)	5458(7)	5665(6)	8101(3)	63(1)	
C(16)	4361(6)	4971(5)	8368(3)	57(1)	
C(17)	3520(6)	4244(5)	7900(3)	54(1)	
C(18)	3750(6)	4219(4)	7214(3)	48(1)	
C(19)	4109(9)	4941(7)	9146(3)	80(2)	
C(20)	5199(19)	4005(11)	9475(4)	166(6)	
C(21)	2355(11)	4761(9)	9229(4)	102(3)	
C(22)	4550(10)	6092(8)	9482(3)	91(2)	
C(23)	-804(5)	6703(3)	4348(2)	38(1)	
C(24)	-615(5)	6248(4)	3630(2)	39(1)	
C(25)	-157(5)	7111(4)	3131(2)	43(1)	
C(26)	-32(6)	6841(5)	2436(3)	52(1)	
C(27)	451(7)	7658(6)	1998(3)	62(1)	
C(28)	776(7)	8751(5)	2218(3)	60(1)	
C(29)	658(6)	9025(4)	2896(3)	54(1)	
C(30)	180(5)	8219(4)	3351(3)	45(1)	
C(31)	247(5)	7702(3)	4524(2)	41(1)	
C(32)	-856(6)	5180(4)	3472(2)	49(1)	
C(33)	-581(5)	5820(3)	4927(2)	38(1)	
C(34)	586(5)	6545(3)	6039(2)	38(1)	
C(35)	264(5)	7014(3)	6729(2)	38(1)	
C(36)	-1125(5)	7571(4)	6829(2)	40(1)	
C(37)	-1360(5)	7994(4)	7466(3)	45(1)	
C(38)	-229(6)	7874(4)	8035(3)	51(1)	

for toste52. U(eo) is defined as one third of the trace of the orthogonalized U ¹ tensor.	

C(39)	1176(6)	7332(4)	7931(2)	49(1)
C(40)	1433(5)	6907(4)	7288(2)	43(1)
C(41)	-506(7)	8293(6)	8763(3)	65(2)
C(42)	-837(15)	7315(12)	9203(4)	141(5)
C(43)	-2152(13)	8927(12)	8735(5)	134(5)
C(44)	778(11)	8987(12)	9071(5)	131(4)
N(1)	4551(4)	4093(3)	5807(2)	41(1)
N(2)	-712(4)	6278(3)	5599(2)	39(1)
O(1)	3480(3)	6295(2)	4071(2)	38(1)
O(2)	6346(3)	5460(3)	6043(2)	45(1)
O(3)	39(4)	8557(2)	4013(2)	48(1)
O(4)	1930(3)	6439(3)	5883(2)	44(1)
F(1)	2601(3)	4115(2)	4492(1)	44(1)
F(2)	-2405(3)	7101(2)	4316(1)	46(1)
Cl(1)	5951(3)	5539(2)	1412(1)	94(1)
Cl(2)	678(3)	7284(2)	1137(1)	92(1)

C(1)-F(1)	1.416(5)	C(20)-H(20C)	0.9800
C(1)-C(9)	1.509(5)	C(21)-H(21A)	0.9800
C(1)-C(11)	1.519(6)	C(21)-H(21B)	0.9800
C(1)-C(2)	1.526(6)	C(21)-H(21C)	0.9800
C(2)-C(10)	1.318(6)	C(22)-H(22A)	0.9800
C(2)-C(3)	1.490(6)	C(22)-H(22B)	0.9800
C(3)-C(8)	1.399(6)	C(22)-H(22C)	0.9800
C(3)-C(4)	1.400(6)	C(23)-F(2)	1.434(5)
C(4)-C(5)	1.374(8)	C(23)-C(31)	1.502(6)
C(4)-H(4)	0.9500	C(23)-C(24)	1.521(6)
C(5)-C(6)	1.369(8)	C(23)-C(33)	1.535(6)
C(5)-Cl(1)	1.751(5)	C(24)-C(32)	1.317(7)
C(6)-C(7)	1.394(7)	C(24)-C(25)	1.492(6)
C(6)-H(6)	0.9500	C(25)-C(26)	1.403(7)
C(7)-C(8)	1.388(6)	C(25)-C(30)	1.404(7)
C(7)-H(7)	0.9500	C(26)-C(27)	1.383(8)
C(8)-O(1)	1.364(5)	C(26)-H(26)	0.9500
C(9)-O(1)	1.435(5)	C(27)-C(28)	1.385(9)
C(9)-H(9A)	0.9900	C(27)-Cl(2)	1.763(6)
C(9)-H(9B)	0.9900	C(28)-C(29)	1.370(8)
C(10)-H(10A)	0.9500	C(28)-H(28)	0.9500
C(10)-H(10B)	0.9500	C(29)-C(30)	1.394(7)
C(11)-N(1)	1.441(6)	C(29)-H(29)	0.9500
C(11)-H(11A)	0.9900	C(30)-O(3)	1.364(6)
C(11)-H(11B)	0.9900	C(31)-O(3)	1.419(5)
C(12)-O(2)	1.226(5)	C(31)-H(31A)	0.9900
C(12)-N(1)	1.347(6)	C(31)-H(31B)	0.9900
C(12)-C(13)	1.485(6)	C(32)-H(32A)	0.9500
C(13)-C(18)	1.389(7)	C(32)-H(32B)	0.9500
C(13)-C(14)	1.403(7)	C(33)-N(2)	1.429(6)
C(14)-C(15)	1.358(8)	C(33)-H(33A)	0.9900
C(14)-H(14)	0.9500	C(33)-H(33B)	0.9900
C(15)-C(16)	1.387(8)	C(34)-O(4)	1.218(5)
C(15)-H(15)	0.9500	C(34)-N(2)	1.358(6)
C(16)-C(17)	1.394(8)	C(34)-C(35)	1.504(6)
C(16)-C(19)	1.550(8)	C(35)-C(36)	1.384(6)
C(17)-C(18)	1.368(7)	C(35)-C(40)	1.395(6)
C(17)-H(17)	0.9500	C(36)-C(37)	1.370(7)
C(18)-H(18)	0.9500	C(36)-H(36)	0.9500
C(19)-C(21)	1.529(11)	C(37)-C(38)	1.391(7)
C(19)-C(20)	1.541(11)	C(37)-H(37)	0.9500
C(19)-C(22)	1.545(12)	C(38)-C(39)	1.390(7)
C(20)-H(20A)	0.9800	C(38)-C(41)	1.541(7)
C(20)-H(20B)	0.9800	C(39)-C(40)	1.388(7)
- (()			

Table 3. Bond lengths [Å] and angles $[\circ]$ for toste52.

C(20) $H(20)$	0.0500	C(A2) $H(A2A)$	0.0000
C(39)-H(39)	0.9500	C(43)-H(43A)	0.9800
C(40)-H(40)	0.9500	C(43)-H(43B)	0.9800
C(41)-C(44)	1.444(11)	C(43)-H(43C)	0.9800
C(41)- $C(42)$	1.487(13)	C(44)-H(44A)	0.9800
C(41)-C(43)	1.583(11)	C(44)-H(44B)	0.9800
C(42)-H(42A)	0.9800	C(44)-H(44C)	0.9800
C(42)-H(42B)	0.9800	N(1)-H(1)	0.8800
C(42)-H(42C)	0.9800	N(2)-H(2)	0.8800
F(1)-C(1)-C(9)	106.7(3)	N(1)-C(11)-H(11A)	108.6
F(1)-C(1)-C(11)	107.6(3)	C(1)-C(11)-H(11A)	108.6
C(9)-C(1)-C(11)	110.7(3)	N(1)-C(11)-H(11B)	108.6
F(1)-C(1)-C(2)	107.5(3)	C(1)-C(11)-H(11B)	108.6
C(9)-C(1)-C(2)	111.8(4)	H(11A)-C(11)-H(11B)	100.0
	112.2(3)	O(2)-C(12)-N(1)	120.9(4)
C(11)-C(1)-C(2) C(10)-C(2)-C(3)			
C(10)-C(2)-C(3)	123.9(4)	O(2)-C(12)-C(13)	121.7(4)
C(10)-C(2)-C(1)	121.3(4)	N(1)-C(12)-C(13)	117.2(4)
C(3)-C(2)-C(1)	114.8(4)	C(18)-C(13)-C(14)	117.0(4)
C(8)-C(3)-C(4)	117.9(4)	C(18)-C(13)-C(12)	124.7(4)
C(8)-C(3)-C(2)	120.6(4)	C(14)-C(13)-C(12)	118.2(4)
C(4)-C(3)-C(2)	121.5(4)	C(15)-C(14)-C(13)	121.1(5)
C(5)-C(4)-C(3)	119.9(5)	C(15)-C(14)-H(14)	119.5
C(5)-C(4)-H(4)	120.1	C(13)-C(14)-H(14)	119.5
C(3)-C(4)-H(4)	120.1	C(14)-C(15)-C(16)	122.4(5)
C(6)-C(5)-C(4)	122.4(5)	C(14)-C(15)-H(15)	118.8
C(6)-C(5)-Cl(1)	118.6(4)	C(16)-C(15)-H(15)	118.8
C(4)-C(5)-Cl(1)	118.9(5)	C(15)-C(16)-C(17)	116.2(5)
C(5)-C(6)-C(7)	118.5(5)	C(15)-C(16)-C(19)	123.2(6)
C(5)-C(6)-H(6)	120.8	C(17)-C(16)-C(19)	120.5(5)
C(7)-C(6)-H(6)	120.8	C(18)-C(17)-C(16)	122.1(5)
C(8)-C(7)-C(6)	119.9(5)	C(18)-C(17)-H(17)	118.9
C(8)-C(7)-H(7)	120.0	C(16)-C(17)-H(17)	118.9
C(6)-C(7)-H(7)	120.0	C(17)-C(18)-C(13)	121.1(5)
O(1)-C(8)-C(7)	117.1(4)	C(17)-C(18)-H(18)	119.5
O(1)-C(8)-C(3)	121.8(4)	C(13)-C(18)-H(18)	119.5
C(7)-C(8)-C(3)		C(13)-C(13)-T(13) C(21)-C(19)-C(20)	
	121.2(4)		113.8(9) 105.0(7)
O(1)-C(9)-C(1)	111.8(3)	C(21)-C(19)-C(22)	105.9(7)
O(1)-C(9)-H(9A)	109.3	C(20)-C(19)-C(22)	110.9(7)
C(1)-C(9)-H(9A)	109.3	C(21)-C(19)-C(16)	110.2(5)
O(1)-C(9)-H(9B)	109.3	C(20)-C(19)-C(16)	106.3(6)
C(1)-C(9)-H(9B)	109.3	C(22)-C(19)-C(16)	109.8(6)
H(9A)-C(9)-H(9B)	107.9	C(19)-C(20)-H(20A)	109.5
C(2)-C(10)-H(10A)	120.0	C(19)-C(20)-H(20B)	109.5
C(2)-C(10)-H(10B)	120.0	H(20A)-C(20)-H(20B)	109.5
H(10A)-C(10)-H(10B)	120.0	C(19)-C(20)-H(20C)	109.5
N(1)-C(11)-C(1)	114.6(4)	H(20A)-C(20)-H(20C)	109.5

H(20B)-C(20)-H(20C)	109.5	C(24)-C(32)-H(32A)	120.0
C(19)-C(21)-H(21A)	109.5	C(24)-C(32)-H(32B)	120.0
C(19)-C(21)-H(21B)	109.5	H(32A)-C(32)-H(32B)	120.0
H(21A)-C(21)-H(21B)	109.5	N(2)-C(33)-C(23)	113.1(3)
C(19)-C(21)-H(21C)	109.5	N(2)-C(33)-H(33A)	109.0
H(21A)-C(21)-H(21C)	109.5	C(23)-C(33)-H(33A)	109.0
H(21B)-C(21)-H(21C)	109.5	N(2)-C(33)-H(33B)	109.0
C(19)-C(22)-H(22A)	109.5	C(23)-C(33)-H(33B)	109.0
C(19)-C(22)-H(22B)	109.5	H(33A)-C(33)-H(33B)	107.8
H(22A)-C(22)-H(22B)	109.5	O(4)-C(34)-N(2)	122.5(4)
C(19)-C(22)-H(22C)	109.5	O(4)-C(34)-C(35)	122.3(4)
	109.5		
H(22A)-C(22)-H(22C)		N(2)-C(34)-C(35)	115.8(4)
H(22B)-C(22)-H(22C)	109.5	C(36)-C(35)-C(40)	118.7(4)
F(2)-C(23)-C(31)	106.6(3)	C(36)-C(35)-C(34)	122.8(4)
F(2)-C(23)-C(24)	105.7(3)	C(40)-C(35)-C(34)	118.5(4)
C(31)-C(23)-C(24)	111.8(4)	C(37)-C(36)-C(35)	120.8(4)
F(2)-C(23)-C(33)	107.3(3)	C(37)-C(36)-H(36)	119.6
C(31)-C(23)-C(33)	110.5(4)	C(35)-C(36)-H(36)	119.6
C(24)-C(23)-C(33)	114.4(3)	C(36)-C(37)-C(38)	121.7(4)
C(32)-C(24)-C(25)	123.8(4)	C(36)-C(37)-H(37)	119.2
C(32)-C(24)-C(23)	121.8(4)	C(38)-C(37)-H(37)	119.2
C(25)-C(24)-C(23)	114.4(4)	C(39)-C(38)-C(37)	117.4(4)
C(26)-C(25)-C(30)	118.3(4)	C(39)-C(38)-C(41)	120.2(5)
C(26)-C(25)-C(24)	121.3(4)	C(37)-C(38)-C(41)	122.4(5)
C(30)-C(25)-C(24)	120.3(4)	C(40)-C(39)-C(38)	121.4(4)
C(27)-C(26)-C(25)	119.3(5)	C(40)-C(39)-H(39)	119.3
C(27)-C(26)-H(26)	120.4	C(38)-C(39)-H(39)	119.3
C(25)-C(26)-H(26)	120.4	C(39)-C(40)-C(35)	120.0(4)
C(26)-C(27)-C(28)	120.1(5)	C(39)-C(40)-H(40)	120.0(1)
C(26)-C(27)-Cl(2)	118.4(5)	C(35)-C(40)-H(40)	120.0
C(28)-C(27)-Cl(2) C(28)-C(27)-Cl(2)	119.4(4)	C(44)-C(41)-C(42)	112.9(8)
C(28)-C(27)-C(27) C(29)-C(28)-C(27)	119.1(5)	C(44)-C(41)-C(42) C(44)-C(41)-C(38)	112.9(8)
C(29)-C(28)-H(28)	120.5	C(42)-C(41)-C(38)	109.4(6)
C(27)-C(28)-H(28)	120.5	C(44)-C(41)-C(43)	111.5(8)
C(28)-C(29)-C(30)	120.2(5)	C(42)-C(41)-C(43)	99.8(8)
C(28)-C(29)-H(29)	119.9	C(38)-C(41)-C(43)	110.2(5)
C(30)-C(29)-H(29)	119.9	C(41)-C(42)-H(42A)	109.5
O(3)-C(30)-C(29)	117.2(4)	C(41)-C(42)-H(42B)	109.5
O(3)-C(30)-C(25)	121.9(4)	H(42A)-C(42)-H(42B)	109.5
C(29)-C(30)-C(25)	120.9(5)	C(41)-C(42)-H(42C)	109.5
O(3)-C(31)-C(23)	112.4(4)	H(42A)-C(42)-H(42C)	109.5
O(3)-C(31)-H(31A)	109.1	H(42B)-C(42)-H(42C)	109.5
C(23)-C(31)-H(31A)	109.1	C(41)-C(43)-H(43A)	109.5
O(3)-C(31)-H(31B)	109.1	C(41)-C(43)-H(43B)	109.5
C(23)-C(31)-H(31B)	109.1	H(43A)-C(43)-H(43B)	109.5
H(31A)-C(31)-H(31B)	107.9	C(41)-C(43)-H(43C)	109.5
· · · · · · · · · · · · · · · · · · ·			

H(43A)-C(43)-H(43C)	109.5
H(43B)-C(43)-H(43C)	109.5
C(41)-C(44)-H(44A)	109.5
C(41)-C(44)-H(44B)	109.5
H(44A)-C(44)-H(44B)	109.5
C(41)-C(44)-H(44C)	109.5
H(44A)-C(44)-H(44C)	109.5
H(44B)-C(44)-H(44C)	109.5
C(12)-N(1)-C(11)	121.7(4)
C(12)-N(1)-H(1)	119.1
C(11)-N(1)-H(1)	119.1
C(34)-N(2)-C(33)	121.8(3)
C(34)-N(2)-H(2)	119.1
C(33)-N(2)-H(2)	119.1
C(8)-O(1)-C(9)	114.5(3)
C(30)-O(3)-C(31)	115.6(3)

Symmetry transformations used to generate equivalent atoms:

	U11	U ²²	U33	U23	U13	U ¹²
C(1)	36(2)	32(2)	42(2)	-3(2)	4(2)	0(2)
C(1)	31(2)	42(2)	40(2)	-4(2)	5(2)	3(2)
C(2) C(3)	38(2)	42(2)	37(2)	-1(2)	5(2)	0(2)
C(4)	60(3)	56(3)	40(2)	-2(2)	14(2)	6(2) $6(2)$
C(5)	78(4)	75(4)	33(2)	2(2) $2(2)$	14(2)	3(3)
C(6)	67(3)	63(3)	39(2)	11(2)	7(2)	-6(2)
C(7)	51(3)	46(2)	44(2)	9(2)	2(2)	0(2) $0(2)$
C(8)	41(2)	45(2)	35(2)	0(2)	6(2)	-2(2)
C(9)	31(2)	36(2)	40(2)	1(2)	7(2)	5(2)
C(10)	56(3)	44(2)	53(3)	-2(2)	14(2)	11(2)
C(10) $C(11)$	51(2)	33(2)	46(2)	-2(2)	5(2)	6(2)
C(12)	29(2)	37(2)	44(2)	5(2)	-2(2)	1(2)
C(12)	32(2)	43(2)	42(2)	2(2)	0(2)	4(2)
C(13)	48(3)	61(3)	44(2)	-2(2)	4(2)	-13(2)
C(15)	60(3)	80(4)	45(3)	-10(3)	-8(2)	-9(3)
C(16)	56(3)	72(3)	44(3)	13(2)	9(2)	8(2)
C(10)	52(3)	61(3)	48(3)	6(2)	12(2)	-2(2)
C(18)	48(3)	50(3)	48(3)	-1(2)	8(2)	-3(2)
C(19)	98(5)	103(5)	36(3)	3(3)	-3(3)	21(4)
C(20)	286(16)	170(10)	42(4)	25(5)	12(6)	136(11)
C(21)	126(7)	131(7)	54(4)	-3(4)	40(4)	-34(6)
C(22)	93(5)	138(7)	41(3)	-9(4)	10(3)	1(5)
C(23)	34(2)	38(2)	43(2)	-2(2)	10(2)	3(2)
C(24)	38(2)	40(2)	41(2)	0(2)	6(2)	6(2)
C(25)	38(2)	47(2)	43(2)	2(2)	2(2)	6(2)
C(26)	56(3)	57(3)	41(2)	-1(2)	1(2)	-9(2)
C(27)	62(3)	84(4)	40(3)	9(3)	1(2)	-9(3)
C(28)	62(3)	65(3)	52(3)	21(2)	1(2)	-5(2)
C(29)	59(3)	47(2)	55(3)	9(2)	5(2)	8(2)
C(30)	43(2)	44(2)	48(3)	0(2)	3(2)	6(2)
C(31)	47(2)	34(2)	42(2)	-4(2)	9(2)	-1(2)
C(32)	58(3)	49(3)	39(2)	-6(2)	11(2)	1(2)
C(33)	35(2)	39(2)	42(2)	-4(2)	10(2)	-1(2)
C(34)	36(2)	33(2)	46(2)	5(2)	11(2)	0(2)
C(35)	41(2)	36(2)	39(2)	1(2)	9(2)	-7(2)
C(36)	36(2)	39(2)	45(2)	0(2)	7(2)	-4(2)
C(37)	38(2)	48(2)	51(3)	-3(2)	13(2)	-2(2)
C(38)	64(3)	48(2)	44(3)	3(2)	19(2)	-1(2)
C(39)	53(3)	59(3)	35(2)	3(2)	5(2)	4(2)
C(40)	37(2)	46(2)	46(2)	2(2)	5(2)	0(2)
C(41)	75(4)	85(4)	35(3)	-5(2)	12(2)	11(3)

Table 4. Anisotropic displacement parameters (Å²x 10³)for toste52. The anisotropic displacement factor exponent takes the form: -2 2 [h²a*²U¹¹ + ... + 2 h k a* b* U¹²]


C(42)	187(10)	194(12)	49(4)	-25(6)	45(5)	-94(9)
C(43)	121(7)	212(13)	68(5)	-45(7)	2(5)	60(8)
C(44)	99(6)	200(12)	97(6)	-83(7)	22(5)	-26(7)
N(1)	48(2)	39(2)	36(2)	6(2)	6(1)	-7(2)
N(2)	33(2)	41(2)	43(2)	-1(2)	11(1)	-1(1)
O(1)	41(2)	35(1)	40(2)	3(1)	7(1)	2(1)
O(2)	36(2)	54(2)	44(2)	2(1)	6(1)	-8(1)
O(3)	63(2)	31(1)	54(2)	2(1)	19(2)	0(1)
O(4)	33(2)	52(2)	46(2)	-8(1)	6(1)	-2(1)
F(1)	41(1)	43(1)	48(1)	-7(1)	11(1)	-7(1)
F(2)	42(1)	44(1)	53(2)	0(1)	10(1)	7(1)
Cl(1)	120(1)	122(2)	47(1)	4(1)	35(1)	10(1)
Cl(2)	122(2)	117(2)	38(1)	2(1)	12(1)	-22(1)

	Х	У	Z	U(eq)	
H(4)	5842	4205	2586	61	
H(6)	4251	7273	1954	67	
H(7)	3376	7597	3047	57	
H(9A)	3743	5874	5071	42	
H(9B)	5379	5944	4733	42	
H(10A)	5644	2898	3301	60	
H(10B)	5337	2539	4093	60	
H(11A)	4969	3005	5069	52	
H(11B)	6229	4007	5168	52	
H(14)	6464	6145	7261	61	
H(15)	6056	6173	8404	75	
H(17)	2762	3750	8063	64	
H(18)	3130	3725	6910	58	
H(20A)	5012	3310	9207	250	
H(20B)	4972	3876	9952	250	
H(20C)	6308	4233	9473	250	
H(21A)	2057	3986	9103	152	
H(21B)	1712	5283	8926	152	
H(21C)	2173	4899	9711	152	
H(22A)	4014	6182	9901	136	
H(22B)	4217	6695	9154	136	
H(22C)	5700	6131	9605	136	
H(26)	-276	6103	2268	62	
H(28)	1077	9303	1904	72	
H(29)	902	9767	3055	64	
H(31Å)	13	8015	4974	49	
H(31B)	1367	7454	4575	49	
H(32A)	-739	4920	3018	58	
H(32B)	-1146	4669	3813	58	
H(33A)	-1388	5222	4831	46	
H(33B)	475	5468	4925	46	
H(36)	-1925	7660	6451	48	
H(37)	-2319	8379	7520	54	
H(39)	1978	7251	8309	59	
H(40)	2406	6543	7227	52	
H(42A)	-756	7550	9689	211	
H(42B)	-65	6718	9148	211	
H(42C)	-1909	7034	9062	211	

Table 5. Hydrogen coordinates ($x \ 10^4$) and isotropic displacement parameters (Å²x 10^3) for toste52.

H(43A)	-2414	9058	9208	202
H(43B)	-2980	8465	8484	202
H(43C)	-2081	9649	8498	202
H(44A)	415	9431	9448	197
H(44B)	1125	9494	8719	197
H(44C)	1665	8507	9253	197
H(1)	3716	3743	5934	49
H(2)	-1660	6391	5730	46

17b (nosyl-derivative)



A colorless rod 0.060 x 0.040 x 0.040 mm in size was mounted on a Cryoloop with Paratone oil. Data were collected in a nitrogen gas stream at 100(2) K using phi and omega scans. Crystal-todetector distance was 60 mm and exposure time was 5 seconds per frame using a scan width of 1.0°. Data collection was 100.0% complete to 67.000° in . A total of 43179 reflections were collected covering the indices, $-8 \le h \le 8$, $-16 \le k \le 16$, $-26 \le l \le 26$. 3685 reflections were found to be symmetry independent, with an R_{int} of 0.0226. Indexing and unit cell refinement indicated a primitive, orthorhombic lattice. The space group was found to be P 21 21 21 (No. 19). The data were integrated using the Bruker SAINT software program and scaled using the SADABS software program. Solution by direct methods (SIR-2011) produced a complete heavyatom phasing model consistent with the proposed structure. All non-hydrogen atoms were refined anisotropically by full-matrix least-squares (SHELXL-2012). All hydrogen atoms were placed using a riding model. Their positions were constrained relative to their parent atom using appropriate HFIX command in SHELXL-2012. Absolute stereochemistry the was unambiguously determined to be R at C9.

Table 1. Crystal data and structure refinen X-ray ID Sample/notebook ID Empirical formula Formula weight Temperature Wavelength Crystal system Space group Unit cell dimensions	nent for toste72. toste72 JW-10-NS C22 H18 F N O5 S 427.43 100(2) K 1.54178 Å Orthorhombic P 21 21 21 $a = 6.8101(4)$ Å $= 90^{\circ}$. $b = 13.2958(8)$ Å $= 90^{\circ}$. $c = 22.2494(14)$ Å $= 90^{\circ}$.
Volume	2014.6(2) Å ³
Z	4
Density (calculated)	1.409 Mg/m^3
Absorption coefficient	1.817 mm ⁻¹
F(000)	888
Crystal size	0.060 x 0.040 x 0.040 mm ³
Crystal color/habit	colorless rod
Theta range for data collection	3.873 to 68.334°.
Index ranges Reflections collected	-8<=h<=8, -16<=k<=16, -26<=l<=26
Independent reflections	43179 3685 [R(int) = 0.0226]
Completeness to theta = 67.000°	100.0 %
Absorption correction	Semi-empirical from equivalents
Max. and min. transmission	0.929 and 0.841
Refinement method	Full-matrix least-squares on F^2
Data / restraints / parameters	3685 / 0 / 271
Goodness-of-fit on F ²	1.065
Final R indices [I>2sigma(I)]	R1 = 0.0209, wR2 = 0.0555
R indices (all data)	R1 = 0.0211, wR2 = 0.0557
Absolute structure parameter	-0.002(3)
Extinction coefficient	n/a
Largest diff. peak and hole	0.178 and -0.217 e.Å ⁻³

Table 2. Atomic coordinates	$(x 10^4)$ and equivalent	isotropic displacement parameters (Å ² x
10 ³)		

	х	у	Z	U(eq)	
$\overline{\mathrm{C}}(1)$	5215(3)	12126(1)	1663(1)	26(1)	
C(2)	7181(3)	11910(1)	1538(1)	32(1)	
C(3)	8374(3)	11480(2)	1974(1)	41(1)	
C(4)	7629(4)	11262(2)	2537(1)	47(1)	
C(5)	5687(4)	11489(2)	2669(1)	45(1)	
C(6)	4491(3)	11913(1)	2238(1)	35(1)	
C(7)	3880(3)	12562(1)	1204(1)	26(1)	
C(8)	2574(4)	13271(2)	1330(1)	40(1)	
C(9)	4009(2)	12090(1)	588(1)	24(1)	
C(10)	2945(2)	11083(1)	574(1)	25(1)	
C(11)	3181(3)	10524(1)	-11(1)	26(1)	
C(12)	1647(3)	10472(1)	-420(1)	33(1)	
C(13)	1859(3)	9973(2)	-964(1)	41(1)	
C(14)	3613(3)	9505(2)	-1105(1)	42(1)	
C(15)	5178(3)	9548(2)	-710(1)	34(1)	
C(16)	4936(3)	10053(1)	-170(1)	27(1)	
C(17)	5427(2)	8871(1)	1041(1)	24(1)	
C(18)	3986(3)	8253(1)	795(1)	26(1)	
C(19)	2288(3)	8086(1)	1122(1)	28(1)	
C(20)	2111(2)	8537(1)	1679(1)	27(1)	
C(21)	3567(3)	9120(1)	1935(1)	28(1)	
C(22)	5266(3)	9288(1)	1610(1)	26(1)	
N(1)	245(2)	8409(1)	2005(1)	36(1)	
O(1)	6555(2)	10168(1)	228(1)	27(1)	
O(2)	7819(2)	8428(1)	168(1)	36(1)	
O(3)	8948(2)	9643(1)	936(1)	33(1)	
O(4)	-903(2)	7769(1)	1825(1)	45(1)	
O(5)	-55(3)	8961(1)	2434(1)	51(1)	
F(1)	3122(2)	12724(1)	160(1)	34(1)	
S(1)	7421(1)	9220(1)	582(1)	26(1)	

for toste72. U(eq) is defined as one third of the trace of the orthogonalized U^{ij} tensor.

C(1)-C(2)	1.397(3)	C(12)-H(12)	0.9500
C(1)-C(6)	1.401(2)	C(13)-C(14)	1.383(3)
C(1)-C(7)	1.484(2)	C(13)-H(13)	0.9500
C(2)-C(3)	1.388(3)	C(14)-C(15)	1.381(3)
C(2)-H(2)	0.9500	C(14)-H(14)	0.9500
C(3)-C(4)	1.383(3)	C(15)-C(16)	1.388(2)
C(3)-H(3)	0.9500	C(15)-H(15)	0.9500
C(4)-C(5)	1.388(4)	C(16)-O(1)	1.422(2)
C(4)-H(4)	0.9500	C(17)-C(22)	1.387(2)
C(5)-C(6)	1.377(3)	C(17)-C(18)	1.391(2)
C(5)-H(5)	0.9500	C(17)-S(1)	1.7613(17)
C(6)-H(6)	0.9500	C(18)-C(19)	1.383(3)
C(7)-C(8)	1.326(3)	C(18)-H(18)	0.9500
C(7)-C(9)	1.512(2)	C(19)-C(20)	1.383(3)
C(8)-H(8A)	0.9500	C(19)-H(19)	0.9500
C(8)-H(8B)	0.9500	C(20)-C(21)	1.381(3)
C(9)-F(1)	1.4080(19)	C(20)-N(1)	1.474(2)
C(9)-C(10)	1.523(2)	C(21)-C(22)	1.383(3)
C(9)-H(9)	1.0000	C(21)-H(21)	0.9500
C(10)-C(11)	1.507(2)	C(22)-H(22)	0.9500
C(10)-H(10A)	0.9900	N(1)-O(5)	1.221(2)
C(10)-H(10B)	0.9900	N(1)-O(4)	1.224(2)
C(11)-C(12)	1.387(3)	O(1)-S(1)	1.6002(12)
C(11)-C(16)	1.395(3)	O(2)-S(1)	1.4237(13)
C(12)-C(13)	1.389(3)	O(3)-S(1)	1.4214(14)
C(2)-C(1)-C(6)	118.51(18)	C(8)-C(7)-C(1)	122.97(17)
C(2)-C(1)-C(7)	122.03(16)	C(8)-C(7)-C(9)	121.68(17)
C(6)-C(1)-C(7)	119.45(17)	C(1)-C(7)-C(9)	115.22(14)
C(3)-C(2)-C(1)	120.44(19)	C(7)-C(8)-H(8A)	120.0
C(3)-C(2)-H(2)	119.8	C(7)-C(8)-H(8B)	120.0
C(1)-C(2)-H(2)	119.8	H(8A)-C(8)-H(8B)	120.0
C(4)-C(3)-C(2)	120.3(2)	F(1)-C(9)-C(7)	109.85(13)
C(4)-C(3)-H(3)	119.8	F(1)-C(9)-C(10)	108.04(13)
C(2)-C(3)-H(3)	119.8	C(7)-C(9)-C(10)	110.80(14)
C(3)-C(4)-C(5)	119.7(2)	F(1)-C(9)-H(9)	109.4
C(3)-C(4)-H(4)	120.2	С(7)-С(9)-Н(9)	109.4
C(5)-C(4)-H(4)	120.2	C(10)-C(9)-H(9)	109.4
C(6)-C(5)-C(4)	120.4(2)	C(11)-C(10)-C(9)	113.52(14)
C(6)-C(5)-H(5)	119.8	C(11)-C(10)-H(10A)	108.9
C(4)-C(5)-H(5)	119.8	C(9)-C(10)-H(10A)	108.9
C(5)-C(6)-C(1)	120.7(2)	C(11)-C(10)-H(10B)	108.9
C(5)-C(6)-H(6)	119.7	C(9)-C(10)-H(10B)	108.9
C(1)-C(6)-H(6)	119.7	H(10A)-C(10)-H(10B)	107.7
() - (*)(*)	*		

Table 3. Bond lengths [Å] and angles $[\circ]$ for toste72.

C(12)-C(11)-C(16)	117.14(16)
C(12)-C(11)-C(10) C(16)-C(11)-C(10)	120.75(16) 122.10(16)
C(11)-C(12)-C(13)	121.20(18)
С(11)-С(12)-Н(12)	119.4
C(13)-C(12)-H(12)	119.4
C(14)-C(13)-C(12) C(14)-C(13)-H(13)	120.12(19) 119.9
C(12)-C(13)-H(13)	119.9
C(15)-C(14)-C(13)	120.30(17)
C(15)-C(14)-H(14)	119.8
C(13)-C(14)-H(14) C(14)-C(15)-C(16)	119.8 118.60(18)
C(14)-C(15)-C(10) C(14)-C(15)-H(15)	120.7
С(16)-С(15)-Н(15)	120.7
C(15)-C(16)-C(11)	122.61(17)
C(15)-C(16)-O(1)	119.96(16)
C(11)-C(16)-O(1) C(22)-C(17)-C(18)	117.27(14) 122.60(16)
C(22)-C(17)-S(1)	119.03(13)
C(18)-C(17)-S(1)	118.13(13)
C(19)-C(18)-C(17)	118.58(16)
C(19)-C(18)-H(18) C(17)-C(18)-H(18)	120.7 120.7
C(20)-C(19)-C(18)	118.27(16)
С(20)-С(19)-Н(19)	120.9
C(18)-C(19)-H(19)	120.9
C(21)-C(20)-C(19) C(21)-C(20)-N(1)	123.46(16) 118.69(16)
C(21)-C(20)-N(1) C(19)-C(20)-N(1)	117.83(16)
C(20)-C(21)-C(22)	118.35(16)
C(20)-C(21)-H(21)	120.8
C(22)-C(21)-H(21)	120.8
C(21)-C(22)-C(17) C(21)-C(22)-H(22)	118.64(16) 120.7
C(17)-C(22)-H(22)	120.7
O(5)-N(1)-O(4)	124.62(17)
O(5)-N(1)-C(20)	117.37(17)
O(4)-N(1)-C(20) C(16)-O(1)-S(1)	118.00(17) 120.46(11)
O(3)-S(1)-O(2)	120.40(11)
O(3)-S(1)-O(1)	103.36(7)
O(2)-S(1)-O(1)	109.54(7)
O(3)-S(1)-C(17) O(2) S(1) C(17)	110.26(8)
O(2)-S(1)-C(17) O(1)-S(1)-C(17)	109.08(8) 102.05(7)

Symmetry transformations used to generate equivalent atoms:

	U11	U ²²	U33	U23	U13	U12
C(1)	32(1)	21(1)	26(1)	-4(1)	-1(1)	-5(1)
C(2)	31(1)	32(1)	33(1)	-2(1)	-6(1)	-4(1)
C(3)	37(1)	35(1)	52(1)	-6(1)	-19(1)	-3(1)
C(4)	68(2)	33(1)	42(1)	1(1)	-32(1)	-9(1)
C(5)	70(2)	37(1)	27(1)	1(1)	-9(1)	-19(1)
C(6)	46(1)	31(1)	28(1)	-4(1)	2(1)	-12(1)
C(7)	26(1)	25(1)	28(1)	1(1)	4(1)	-2(1)
C(8)	43(1)	38(1)	38(1)	-1(1)	6(1)	10(1)
C(9)	22(1)	27(1)	24(1)	4(1)	-1(1)	2(1)
C(10)	21(1)	27(1)	27(1)	0(1)	4(1)	1(1)
C(11)	27(1)	24(1)	27(1)	1(1)	5(1)	-2(1)
C(12)	30(1)	34(1)	35(1)	-1(1)	-1(1)	2(1)
C(13)	43(1)	47(1)	34(1)	-7(1)	-8(1)	0(1)
C(14)	52(1)	45(1)	29(1)	-10(1)	4(1)	0(1)
C(15)	36(1)	34(1)	33(1)	-3(1)	12(1)	1(1)
C(16)	28(1)	27(1)	27(1)	2(1)	3(1)	-3(1)
C(17)	19(1)	20(1)	32(1)	2(1)	2(1)	1(1)
C(18)	27(1)	21(1)	32(1)	0(1)	-1(1)	0(1)
C(19)	23(1)	23(1)	39(1)	6(1)	-5(1)	-3(1)
C(20)	23(1)	23(1)	36(1)	11(1)	3(1)	1(1)
C(21)	32(1)	24(1)	28(1)	3(1)	3(1)	2(1)
C(22)	26(1)	22(1)	31(1)	0(1)	-2(1)	-2(1)
N(1)	29(1)	35(1)	44(1)	17(1)	7(1)	3(1)
O(1)	23(1)	25(1)	32(1)	0(1)	5(1)	0(1)
O(2)	33(1)	31(1)	44(1)	-4(1)	11(1)	6(1)
O(3)	20(1)	32(1)	46(1)	4(1)	2(1)	-1(1)
O(4)	27(1)	42(1)	66(1)	21(1)	3(1)	-6(1)
O(5)	45(1)	58(1)	49(1)	6(1)	22(1)	2(1)
F(1)	38(1)	29(1)	34(1)	6(1)	-11(1)	1(1)
S(1)	20(1)	24(1)	35(1)	0(1) 0(1)	5(1)	2(1)
~(1)		- ·(1)	22(1)	v(+)		-(1)

Table 4. Anisotropic displacement parameters (Å²x 10³) for toste72. The anisotropic displacement factor exponent takes the form: -2 2 [h² a*²U¹¹ + ... + 2 h k a* b* U¹²]

	х	У	Z	U(eq)	
H(2)	7705	12059	1152	38	
H(3)	9708	11334	1884	50	
H(4)	8443	10958	2833	57	
H(5)	5179	11352	3058	54	
H(6)	3162	12062	2333	42	
H(8A)	2462	13522	1728	48	
H(8B)	1750	13527	1021	48	
H(9)	5420	11986	479	29	
H(10A)	3450	10657	905	30	
H(10B)	1529	11199	648	30	
H(12)	429	10782	-325	40	
H(13)	797	9954	-1241	50	
H(14)	3743	9153	-1474	50	
H(15)	6394	9238	-808	41	
H(18)	4165	7953	412	32	
H(19)	1270	7672	967	34	
H(21)	3405	9397	2326	33	
H(22)	6301	9681	1773	32	

Table 5. Hydrogen coordinates ($x \ 10^4$) and isotropic displacement parameters (Å²x 10³) for toste72.